<SEC-DOCUMENT>0001206774-16-005288.txt : 20160401
<SEC-HEADER>0001206774-16-005288.hdr.sgml : 20160401
<ACCEPTANCE-DATETIME>20160401163049
ACCESSION NUMBER:		0001206774-16-005288
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20160517
FILED AS OF DATE:		20160401
DATE AS OF CHANGE:		20160401
EFFECTIVENESS DATE:		20160401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		161547622

	BUSINESS ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>geron_def14a.htm
<DESCRIPTION>DEFINITIVE PROXY STATEMENT
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor=#ffffff>

<BR>

<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>

<DIV style="TEXT-ALIGN: center"><FONT style="FONT-FAMILY: Times New Roman" size=2><b>UNITED STATES </b></FONT><br><FONT style="FONT-FAMILY: Times New Roman" size=2><b>SECURITIES AND EXCHANGE COMMISSION<BR>

Washington, D.C. 20549</b></FONT></DIV>
<DIV>&nbsp;</DIV>


<DIV style="TEXT-ALIGN: center"><FONT style="FONT-FAMILY: Times New Roman" size=4><b>SCHEDULE 14A</b></FONT><BR>
<br><FONT style="FONT-FAMILY: Times New Roman" size=2>Proxy Statement Pursuant to Section 14(a) of the Securities <BR>Exchange
Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; )</FONT><FONT style="FONT-FAMILY: Times New Roman">
</FONT></DIV>
<DIV>&nbsp;</DIV>
<DIV align=left>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="99%" colSpan=3><FONT style="FONT-FAMILY: times new roman" size=2>Filed by the Registrant
      [X]</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="99%" colSpan=3><FONT style="FONT-FAMILY: times new roman" size=2>Filed by a Party other than
      the Registrant [&nbsp;&nbsp; ]&nbsp; </FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="99%" colSpan=3>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="99%" colSpan=3><FONT style="FONT-FAMILY: times new roman" size=2>Check the appropriate
      box:</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="99%" colSpan=3>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT style="FONT-FAMILY: times new roman" size=2>[&nbsp;&nbsp; ]</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"><FONT style="FONT-FAMILY: times new roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD vAlign=top noWrap align=left width="97%"><FONT style="FONT-FAMILY: times new roman" size=2>Preliminary Proxy
      Statement</FONT></TD></TR>
  <TR style="LINE-HEIGHT: normal" vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT style="FONT-FAMILY: times new roman" size=2>[&nbsp;&nbsp; ]</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD vAlign=top noWrap align=left width="97%"><FONT style="FONT-FAMILY: times new roman" size=2><B>Confidential, for Use of the
      Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT style="FONT-FAMILY: times new roman" size=2>[X]</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD vAlign=top noWrap align=left width="97%"><FONT style="FONT-FAMILY: times new roman" size=2>Definitive Proxy
      Statement</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT style="FONT-FAMILY: times new roman" size=2>[&nbsp;&nbsp; ]</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD vAlign=top noWrap align=left width="97%"><FONT style="FONT-FAMILY: times new roman" size=2>Definitive Additional
      Materials</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="1%" ><FONT size=2>[&nbsp;&nbsp; ]</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%" >&nbsp;</TD>
    <TD vAlign=top noWrap align=left width="97%" ><FONT size=2>Soliciting Material Pursuant to &sect;240.14a-12</FONT></TD></TR></TABLE></DIV><BR>
<DIV>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="3%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="94%"><FONT style="FONT-FAMILY: times new roman" size=2><STRONG>GERON CORPORATION</STRONG></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="3%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" width="3%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" width="94%"><FONT style="FONT-FAMILY: times new roman" size=2>(Name of Registrant as
      Specified In Its Charter)</FONT></TD>
    <TD style="TEXT-ALIGN: center" width="3%">&nbsp;</TD></TR>
  <TR>
    <TD width="3%"></TD>
    <TD width="94%">&nbsp; </TD>
    <TD width="3%"></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="3%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="94%"><FONT style="FONT-FAMILY: times new roman" size=2>&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="3%">&nbsp;</TD></TR>
  <TR>
    <TD style="TEXT-ALIGN: center" noWrap width="3%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="94%">
      <DIV align=center><FONT style="FONT-FAMILY: times new roman" size=2>(Name
      of Person(s) Filing Proxy Statement, if other than the
      Registrant)</FONT></DIV></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%">&nbsp;</TD></TR></TABLE></DIV><BR>
<DIV>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="100%" colSpan=5><FONT style="FONT-FAMILY: times new roman" size=2>Payment of Filing Fee (Check
      the appropriate box):</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=right width="1%"><FONT style="FONT-FAMILY: times new roman" size=2>[X]</FONT></TD>
    <TD vAlign=top noWrap align=right width="1%"><FONT style="FONT-FAMILY: times new roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD vAlign=top noWrap align=left width="98%" colSpan=3><FONT style="FONT-FAMILY: times new roman" size=2>No fee required.</FONT></TD></TR>
  <TR>
    <TD vAlign=top align=right width="1%">
      <DIV><FONT style="FONT-FAMILY: times new roman" size=2><FONT style="FONT-FAMILY: times new roman" size=2>[&nbsp;&nbsp;
      ]</FONT></FONT></DIV></TD>
    <TD vAlign=top align=right width="1%"><FONT style="FONT-FAMILY: times new roman" size=2>&nbsp;</FONT></TD>
    <TD vAlign=top align=left width="98%" colSpan=3>
      <DIV><FONT style="FONT-FAMILY: times new roman" size=2>Fee computed on
      table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</FONT></DIV></TD></TR>
  <TR>
    <TD vAlign=top align=right width="1%" ></TD>
    <TD vAlign=top align=right width="1%" ></TD>
    <TD vAlign=top align=right width="1%" ></TD>
    <TD vAlign=top align=left width="1%" ></TD>
    <TD vAlign=top align=left width="96%" >&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-BOTTOM: 1pt" vAlign=top align=right width="1%">&nbsp;</TD>
    <TD style="PADDING-BOTTOM: 1pt" vAlign=top align=right width="1%">&nbsp;</TD>
    <TD style="PADDING-BOTTOM: 1pt" vAlign=top align=right width="1%"><FONT size=2>1)</FONT></TD>
    <TD style="PADDING-BOTTOM: 1pt" vAlign=top align=left width="1%">&nbsp;<FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT></TD>
    <TD vAlign=top align=left width="96%"><FONT size=2>Title of each class of
      securities to which transaction applies:</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=right width="1%"><FONT style="FONT-FAMILY: times new roman" size=2>&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=right width="1%"><FONT style="FONT-FAMILY: times new roman" size=2>&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=right width="1%"><FONT style="FONT-FAMILY: times new roman" size=2>&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left" vAlign=top width="96%"><FONT style="FONT-FAMILY: times new roman" size=2>&nbsp;
      </FONT></TD></TR>
  <TR>
    <TD vAlign=top align=right width="1%"></TD>
    <TD vAlign=top align=right width="1%"></TD>
    <TD vAlign=top align=right width="1%"><FONT size=2>2)</FONT></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top width="96%"><FONT size=2>Aggregate number of securities to
      which transaction applies:</FONT></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="96%">&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top align=right width="1%"></TD>
    <TD vAlign=top align=right width="1%"></TD>
    <TD vAlign=top align=right width="1%"><FONT size=2>3)</FONT></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top width="96%" align=justify><FONT size=2>Per unit price or other underlying
      value of transaction computed pursuant to Exchange Act Rule 0-11 (set
      forth the amount on which the filing fee is calculated and state how it
      was determined):</FONT></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="96%">&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top align=right width="1%"></TD>
    <TD vAlign=top align=right width="1%"></TD>
    <TD vAlign=top align=right width="1%"><FONT size=2>4)</FONT></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top width="96%"><FONT size=2>Proposed maximum aggregate value of transaction:</FONT></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="96%">&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top align=right width="1%"></TD>
    <TD vAlign=top align=right width="1%"></TD>
    <TD vAlign=top align=right width="1%"><FONT size=2>5)</FONT></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top width="96%"><FONT size=2>Total fee paid:</FONT></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="96%">&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top align=right width="1%">
      <DIV><FONT style="FONT-FAMILY: times new roman" size=2><FONT style="FONT-FAMILY: times new roman" size=2>[&nbsp;&nbsp;
      ]</FONT></FONT></DIV></TD>
    <TD vAlign=top align=right width="1%"><FONT style="FONT-FAMILY: times new roman" size=2>&nbsp;</FONT></TD>
    <TD vAlign=top align=left width="98%" colSpan=3>
      <DIV><FONT style="FONT-FAMILY: times new roman" size=2>Fee paid previously
      with preliminary materials.</FONT></DIV></TD></TR>
  <TR>
    <TD vAlign=top align=right width="1%" ></TD>
    <TD vAlign=top align=right width="1%" ></TD>
    <TD vAlign=top align=left width="98%"  colSpan=3>&nbsp;</TD></TR>
  <TR style="LINE-HEIGHT: normal">
    <TD vAlign=top align=right width="1%">
      <DIV><FONT style="FONT-FAMILY: times new roman" size=2><FONT style="FONT-FAMILY: times new roman" size=2>[&nbsp;&nbsp;
      ]</FONT></FONT></DIV></TD>
    <TD vAlign=top align=right width="1%"><FONT style="FONT-FAMILY: times new roman" size=2>&nbsp;</FONT></TD>
    <TD style="TEXT-ALIGN: left" vAlign=top width="98%" colSpan=3>
      <DIV style="TEXT-ALIGN: justify"><FONT style="FONT-FAMILY: times new roman" size=2>Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for
which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or
Schedule and the date of its filing.</FONT></DIV></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="1%" ></TD>
    <TD vAlign=top noWrap align=left width="1%" ></TD>
    <TD vAlign=top noWrap align=left width="1%" ></TD>
    <TD vAlign=top noWrap align=left width="1%" ></TD>
    <TD vAlign=top noWrap align=left width="96%" >&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD style="PADDING-TOP: 4pt" vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD vAlign=top noWrap align=left width="1%"><FONT size=2>&nbsp;</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"><FONT size=2>1)</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD vAlign=top noWrap align=left width="96%"><FONT style="FONT-FAMILY: times new roman" size=2>Amount Previously
    Paid:</FONT></TD></TR>
  <TR>
    <TD style="PADDING-BOTTOM: 1pt; BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD style="PADDING-BOTTOM: 1pt; BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD style="PADDING-BOTTOM: 1pt; BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD style="PADDING-BOTTOM: 1pt; BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="96%">&nbsp;</TD></TR>
  <TR style="PADDING-TOP: 4pt" vAlign=bottom>
    <TD style="PADDING-TOP: 4pt" vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="1%"><FONT size=2>&nbsp;</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"><FONT size=2>2)</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD vAlign=top noWrap align=left width="96%"><FONT style="FONT-FAMILY: times new roman" size=2>Form, Schedule or Registration
      Statement No.:</FONT></TD></TR>
  <TR>
    <TD style="PADDING-BOTTOM: 1pt; BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD style="PADDING-BOTTOM: 1pt; BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD style="PADDING-BOTTOM: 1pt; BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD style="PADDING-BOTTOM: 1pt; BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="96%">&nbsp;</TD></TR>
  <TR style="PADDING-TOP: 4pt" vAlign=bottom>
    <TD style="PADDING-TOP: 4pt" vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="1%"><FONT size=2>&nbsp;</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"><FONT size=2>3)</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD vAlign=top noWrap align=left width="96%"><FONT style="FONT-FAMILY: times new roman" size=2>Filing Party:</FONT></TD></TR>
  <TR>
    <TD style="PADDING-BOTTOM: 1pt; BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD style="PADDING-BOTTOM: 1pt; BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD style="PADDING-BOTTOM: 1pt; BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD style="PADDING-BOTTOM: 1pt; BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="96%">&nbsp;</TD></TR>
  <TR style="PADDING-TOP: 4pt" vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="1%"><FONT size=2>&nbsp;</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"><FONT size=2>4)</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%">&nbsp;</TD>
    <TD vAlign=top noWrap align=left width="96%"><FONT style="FONT-FAMILY: times new roman" size=2>Date Filed:</FONT></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="96%">&nbsp;</TD></TR></TABLE></DIV><BR>

	<HR align=center width="100%" noshade SIZE=2>


<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>


<P align=center><IMG src="geron_def14a1x1x1.jpg" border=0></P>
<P align=center><B><FONT face="Times New Roman" size=4>GERON
CORPORATION<BR></FONT></B><B><FONT face="Times New Roman" size=2>149
Commonwealth Drive, Suite 2070<BR>Menlo Park, CA 94025</FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2>April 1, 2016</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2>Dear Geron
Stockholder:</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>You are cordially invited
to attend the 2016 Annual Meeting of Stockholders of Geron Corporation, which
will be held on May 17, 2016 at 4:00 p.m., Pacific Daylight Time, at the Westin
San Francisco Airport, One Old Bayshore Highway, Millbrae, California 94030. In
addition, we will be hosting the meeting via conference call which can be
accessed via telephone by dialing 877-303-9139 (U.S.); 760-536-5195
(international). The passcode is 72479234. A live audio-only webcast will also
be available at http://edge.media-server.com/m/p/idtu8fhu.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>As permitted by the rules
of the Securities and Exchange Commission, we are also pleased to furnish our
proxy materials to stockholders primarily over the Internet. We believe this
process will expedite stockholders&#146; receipt of materials, lower the costs of our
annual meeting and reduce the environmental impact of printing and mailing hard
copies. Stockholders who continue to receive hard copies of proxy materials may
help us reduce costs by opting to receive future proxy materials by
e-mail.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>On or about April 4, 2016,
we will distribute to our stockholders a notice containing instructions on how
to access our 2016 Proxy Statement and our 2015 Annual Report on Form 10-K, and
how to vote online. This notice also will include instructions on how you can
receive a paper copy of the proxy materials, including the notice of the Annual
Meeting, 2016 Proxy Statement, 2015 Annual Report on Form 10-K and proxy card.
If you received your proxy materials by mail, the notice of Annual Meeting, 2016
Proxy Statement, 2015 Annual Report on Form 10-K and proxy card from our Board
of Directors were enclosed. If you received your proxy materials via e-mail, the
e-mail contained voting instructions and links to the 2016 Proxy Statement and
2015 Annual Report on Form 10-K.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>At this year&#146;s Annual
Meeting, the agenda includes the following items:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">election of Directors; <BR>&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">advisory vote to approve named executive
      officer compensation; and <BR>&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">ratification of Ernst &amp; Young LLP as our
      independent registered public accounting firm.</TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2><U>Your vote is important
to us</U>. Whether or not you plan to attend the meeting, please vote
electronically via the Internet or by telephone, or, if you requested paper
copies of the proxy materials, please complete, sign, date and return the
accompanying proxy card in the enclosed postage-paid envelope.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Thank you for your ongoing
support of, and continued interest in, Geron Corporation.</FONT></P>
<DIV align=right>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="50%" border=0>

  <TR>
    <TD noWrap align=left width="100%"><FONT size=2 face="Times New Roman">Sincerely,</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="100%"><IMG src="geron_def14a1x1x2.jpg" border=0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%"><FONT face="Times New Roman" size=2>John
      A. Scarlett, M.D.</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%"><FONT face="Times New Roman" size=2>President and Chief Executive
  Officer</FONT></TD></TR></TABLE></DIV><BR>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=center><IMG src="geron_def14a1x2x1.jpg" border=0></P>
<P align=center><B><FONT face="Times New Roman" size=4>GERON
CORPORATION<BR></FONT></B><B><FONT face="Times New Roman" size=2>149
Commonwealth Drive, Suite 2070<BR>Menlo Park, CA 94025</FONT></B></P>
<P align=center><B><FONT face="Times New Roman">______________________<BR><BR>NOTICE OF ANNUAL MEETING OF
STOCKHOLDERS<BR></FONT></B><B><FONT face="Times New Roman" size=2>To Be Held on
May 17, 2016</FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2>To the Stockholders of
Geron Corporation:</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>NOTICE IS HEREBY GIVEN that
the Annual Meeting of Stockholders of GERON CORPORATION, a Delaware corporation
(the &#147;Company&#148;), will be held on May 17, 2016, at 4:00 p.m., Pacific Daylight
Time, at the Westin San Francisco Airport, One Old Bayshore Highway, Millbrae,
California 94030. Stockholders may also access the meeting via telephone by
dialing 877-303-9139 (U.S.); 760-536-5195 (international). The passcode is
72479234. A live audio-only webcast will also be available at
http://edge.media-server.com/m/p/idtu8fhu. The meeting will be held for the
following purposes:</FONT></P>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD VALIGN="TOP" NOWRAP STYLE="text-align: justify"><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD VALIGN="TOP" NOWRAP STYLE="text-align: justify"><FONT face="Times New Roman" size=2>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD VALIGN="TOP" WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>To elect
      the two nominees for director named in the accompanying proxy statement,
      or the Proxy Statement, to hold office as Class II members of the Board of
      Directors until the 2019 annual meeting of stockholders;</FONT></TD></TR>
  <TR>
    <TD NOWRAP STYLE="text-align: justify"></TD>
    <TD VALIGN="TOP" WIDTH="100%" COLSPAN="2" STYLE="text-align: justify">&nbsp; </TD></TR>
  <TR>
    <TD VALIGN="TOP" NOWRAP STYLE="text-align: justify"></TD>
    <TD VALIGN="TOP" NOWRAP STYLE="text-align: justify"><FONT face="Times New Roman" size=2>2.</FONT></TD>
    <TD VALIGN="TOP" WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>To
      approve, on an advisory basis, the compensation of the Company&#146;s named
      executive officers, as disclosed in the Proxy Statement;</FONT></TD></TR>
  <TR>
    <TD NOWRAP STYLE="text-align: justify"></TD>
    <TD VALIGN="TOP" WIDTH="100%" COLSPAN="2" STYLE="text-align: justify">&nbsp; </TD></TR>
  <TR>
    <TD VALIGN="TOP" NOWRAP STYLE="text-align: justify"></TD>
    <TD VALIGN="TOP" NOWRAP STYLE="text-align: justify"><FONT face="Times New Roman" size=2>3.</FONT></TD>
    <TD VALIGN="TOP" WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>To ratify
      the selection by the Audit Committee of the Board of Directors of Ernst
      &amp; Young LLP as the Company&#146;s independent registered public accounting
      firm for the fiscal year ending December 31, 2016; and</FONT></TD></TR>
  <TR>
    <TD NOWRAP STYLE="text-align: justify"></TD>
    <TD VALIGN="TOP" WIDTH="100%" COLSPAN="2" STYLE="text-align: justify">&nbsp; </TD></TR>
  <TR>
    <TD VALIGN="TOP" NOWRAP STYLE="text-align: justify"></TD>
    <TD VALIGN="TOP" NOWRAP STYLE="text-align: justify"><FONT face="Times New Roman" size=2>4.</FONT></TD>
    <TD VALIGN="TOP" WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>To
      transact such other business as may properly come before the Annual
      Meeting or any postponement or adjournment
thereof.</FONT></TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The foregoing items of
business are more fully described in the Proxy Statement accompanying this
Notice.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board of Directors has fixed the close of business on March 21,
2016, as the record date for the determination of stockholders entitled to
notice of and to vote at the Annual Meeting and at any adjournment or
postponement thereof. Each stockholder is entitled to one vote for each share of
common stock held at that time.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><B><FONT face="Times New Roman" size=2><U>Your Vote Is Important
To Us.</U></FONT></B><FONT face="Times New Roman" size=2> Whether or not you plan to
attend the meeting, please vote electronically via the Internet or by telephone,
or, if you requested paper copies of the proxy materials, please complete, sign,
date and return the accompanying proxy card in the enclosed postage-paid
envelope. Please note, however, that if your shares are held of record by a
broker, bank or other nominee and you wish to vote at the meeting, you must
obtain from the record holder a proxy issued in your name.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%"><FONT size=2 face="Times New Roman">By Order of the Board of Directors,</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%"><IMG src="geron_def14a1x2x2.jpg" border=0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%"><FONT face="Times New Roman" size=2>Stephen N. Rosenfield</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%"><I><FONT face="Times New Roman" size=2>Executive Vice President, General Counsel</FONT></I></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%"><I><FONT face="Times New Roman" size=2>and Corporate Secretary</FONT></I></TD></TR></TABLE><BR>
<P align=justify><FONT face="Times New Roman" size=2>Menlo Park,
California<BR>April 1, 2016</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>Important Notice
Regarding the Availability of Proxy Materials for the Annual
Meeting:<BR></FONT></B><FONT face="Times New Roman" size=2>Letter to
Stockholders, Notice and 2016 Proxy Statement, and 2015 Annual Report on Form
10-K are available at<BR>www.proxyvote.com.</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>YOUR VOTE IS VERY
IMPORTANT, REGARDLESS OF THE NUMBER OF SHARES YOU OWN.<BR>WHETHER OR NOT YOU
EXPECT TO ATTEND THE MEETING, WE URGE YOU TO SUBMIT<BR></FONT></B><B><FONT face="Times New Roman" size=2>YOUR PROXY PROMPTLY IN ORDER TO ASSURE THAT A
QUORUM IS PRESENT.</FONT></B></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>

<P align=center><B><FONT face="Times New Roman" size=2><A NAME="toc"></A>Table of
Contents</FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%"><B><FONT face="Times New Roman" size=1>Description</FONT></B></TD>
    <TD noWrap align=left width="93%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Page</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=2><A HREF="#QuestionsandAnswersabou"><FONT face="Times New Roman" size=2>Questions and Answers about These Proxy Materials and Voting</FONT></A></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff>&nbsp;&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><A HREF="#QuestionsandAnswersabou">1</A></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff>&nbsp;&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=2>&nbsp;&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" colSpan=2><FONT face="Times New Roman" size=2><A HREF="#proposal1">Proposal 1: Election of Directors</A></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2><A HREF="#proposal1">8</A></FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR>
    <TD noWrap align=left width="95%" colSpan=2>&nbsp; </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=2><A HREF="#CorporateGovernanceMatters"><FONT face="Times New Roman" size=2>Corporate Governance Matters</FONT></A></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><A HREF="#CorporateGovernanceMatters">12</A></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=2>&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" colSpan=2><A HREF="#CompensationofDirectors"><FONT face="Times New Roman" size=2>Compensation of Directors</FONT></A></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2><A HREF="#CompensationofDirectors">17</A></FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR>
    <TD noWrap align=left width="95%" colSpan=2>&nbsp; </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2><A HREF="#proposal2">Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation</A>&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><A HREF="#proposal2">20</A></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=2>&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" colSpan=2><A HREF="#CompensationDiscussionandAnalysis"><FONT face="Times New Roman" size=2>Compensation Discussion and Analysis</FONT></A></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2><A HREF="#CompensationDiscussionandAnalysis">21</A></FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR>
    <TD noWrap align=left width="95%" colSpan=2>&nbsp; </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=2><A HREF="#CompensationCommitteeReport"><FONT face="Times New Roman" size=2>Compensation Committee Report</FONT></A></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><A HREF="#CompensationCommitteeReport">41</A></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=2>&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" colSpan=2><A HREF="#ExecutiveCompensationTables"><FONT face="Times New Roman" size=2>Executive Compensation Tables</FONT></A></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2><A HREF="#ExecutiveCompensationTables">41</A></FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR>
    <TD noWrap align=left width="95%" colSpan=2>&nbsp; </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=2><A HREF="#EquityCompensationPlans"><FONT face="Times New Roman" size=2>Equity Compensation Plans</FONT></A></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><A HREF="#EquityCompensationPlans">48</A></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff>&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=2>&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" colSpan=2><FONT face="Times New Roman" size=2><A HREF="#proposal3">Proposal 3: Ratification of Selection of Independent Registered Public Accounting Firm</A></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2><A HREF="#proposal3">48</A></FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR>
    <TD noWrap align=left width="95%" colSpan=2>&nbsp;&nbsp; </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=2><A HREF="#PrincipalAccountantFees"><FONT face="Times New Roman" size=2>Principal Accountant Fees and Services</FONT></A></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><A HREF="#PrincipalAccountantFees">49</A></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=2>&nbsp;&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" colSpan=2><A HREF="#AuditCommitteeReport"><FONT face="Times New Roman" size=2>Audit Committee Report</FONT></A></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2><A HREF="#AuditCommitteeReport">50</A></FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR>
    <TD noWrap align=left width="95%" colSpan=2>&nbsp;&nbsp; </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=2><A HREF="#SecurityOwnershipofCertain"><FONT face="Times New Roman" size=2>Security Ownership of Certain Beneficial Owners and Management</FONT></A></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><A HREF="#SecurityOwnershipofCertain">51</A></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=2>&nbsp;&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" colSpan=2><A HREF="#CertainTransactions"><FONT face="Times New Roman" size=2>Certain Transactions</FONT></A></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2><A HREF="#CertainTransactions">53</A></FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR>
    <TD noWrap align=left width="95%" colSpan=2>&nbsp;&nbsp; </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=2><A HREF="#OtherMatters"><FONT face="Times New Roman" size=2>Other Matters</FONT></A></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><A HREF="#OtherMatters">54</A></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>

<P align=center><B><FONT face="Times New Roman" size=2>GERON CORPORATION<BR>149
Commonwealth Drive, Suite 2070<BR>Menlo Park, CA 94025</FONT></B></P>
<P align=center><STRONG><FONT size=2 face="Times New Roman">____________________</FONT></STRONG></P>
<P align=center><B><FONT face="Times New Roman">PROXY
STATEMENT<BR></FONT></B><B><FONT face="Times New Roman">FOR THE ANNUAL MEETING
OF STOCKHOLDERS<BR>TO BE HELD ON MAY 17, 2016<BR><FONT size=2 face="Times New Roman">____________________</FONT></FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="QuestionsandAnswersabou"></A>QUESTIONS AND ANSWERS
ABOUT THESE PROXY MATERIALS AND VOTING</FONT></B></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Why am I receiving these
materials?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We have sent you a Notice
of Availability of Proxy Materials (the &#147;Notice&#148;) or our proxy materials, as
applicable, because the Board of Directors (the &#147;Board&#148;) of Geron Corporation, a
Delaware corporation (&#147;Geron&#148;, the &#147;Company&#148;, &#147;we&#148; or &#147;us&#148;), is soliciting your
proxy to vote at our 2016 Annual Meeting of Stockholders (the &#147;Annual Meeting&#148;),
to be held on May 17, 2016, at 4:00 p.m., Pacific Daylight Time, at the Westin
San Francisco Airport, One Old Bayshore Highway, Millbrae, California 94030 or
at any adjournment or postponement thereof. You may vote by proxy over the
Internet or by phone, or by mail if you requested printed copies of the proxy
materials.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We intend to distribute the
Notice and the proxy materials on or about April 4, 2016 to all stockholders of
record entitled to vote at the Annual Meeting.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>What is the purpose of
the Annual Meeting?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>At our Annual Meeting,
stockholders will act upon the matters described in this Proxy Statement. In
addition, following the meeting, management will report on current events at
Geron and respond to questions from stockholders.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>How can I attend the
Annual Meeting?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>All stockholders are
cordially invited to attend the Annual Meeting in person at the Westin San
Francisco Airport, One Old Bayshore Highway, Millbrae, California 94030. For
directions to attend the Annual Meeting, please contact our Investor Relations
department at (650) 473-7765 or by email at investor@geron. com. Stockholders
may also access the meeting via telephone by dialing 877-303-9139 (U.S.);
760-536-5195 (international). The passcode is 72479234. A live audio-only
webcast will also be available at http://edge.media-server.com/m/p/idtu8fhu via
the Internet. The Annual Meeting will start at 4:00 p.m., Pacific Daylight Time,
on May 17, 2016.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>How can I participate in
the Annual Meeting if I cannot attend in person?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>If you cannot attend the
meeting in person, stockholders may participate via telephone by dialing
877-303-9139 (U.S.); 760-536-5195 (international). The passcode is 72479234. We
recommend that you dial in at least 10 minutes early to minimize any delay in
joining the meeting. Participants via telephone will also have an opportunity to
ask questions during the meeting.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Annual Meeting will
also be available via the Internet in a live audio-only webcast available at
http://edge.media-server.com/m/p/idtu8fhu. The audio webcast of the Annual
Meeting will be available for replay approximately one hour following the live
meeting through June 17, 2016. Since the webcast is audio-only, participants
will be unable to ask questions in this forum.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>1</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><B><FONT face="Times New Roman" size=2>Why did I receive a
Notice in the mail regarding the Internet availability of proxy materials
instead of a full set of proxy materials?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We are pleased to continue
to apply the rules from the United States Securities and Exchange Commission
(the &#147;SEC&#148;) that allow companies to furnish their proxy materials over the
Internet. If you received the Notice by mail, you will not receive a printed
copy of the proxy materials unless you request one. Instead, the Notice will
instruct you as to how you may access and review the proxy materials and cast
your vote via the Internet. If you received a Notice by mail and would like to
receive a printed copy of our proxy materials, please follow the instructions
included in the Notice. A stockholder&#146;s election to receive proxy materials by
mail or electronically by email will remain in effect until the stockholder
terminates such election.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Why did I receive a full
set of proxy materials instead of a Notice regarding the Internet availability
of proxy materials?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We are providing paper
copies of the proxy materials to stockholders who previously requested to
receive them. If you would like to reduce the environmental impact and costs
incurred by us in mailing proxy materials, you may elect to receive all future
proxy materials electronically via email or the Internet. To sign up for
electronic delivery, please follow the instructions provided with your proxy
materials and on your proxy card or voting instruction card, to vote using the
Internet and, when prompted, indicate that you agree to receive or access future
stockholder communications electronically. Alternatively, you can go to
www.proxyvote.com and enroll for online delivery of proxy materials.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>How can I access the
proxy materials over the Internet?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>You may view and also
download our proxy materials, including the 2015 Annual Report on Form 10-K, at
www.proxyvote.com.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>How do I order proxy
materials if I have not received them?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>This Proxy Statement and
Geron&#146;s 2015 Annual Report on Form 10-K are available at www.proxyvote.com.
Internet distribution of proxy materials is designed to expedite receipt by
stockholders, lower the cost of the Annual Meeting and conserve natural
resources. However, if you have not received a copy of our proxy materials and
would like to receive one for the Annual Meeting or for future stockholder
meetings, you may request printed copies as follows:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><FONT face="Times New Roman">by telephone: call
      1-800-579-1639 free of charge and follow the
      instructions;&nbsp;<BR>&nbsp;&nbsp; </FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">by Internet: go to www.proxyvote.com and follow the
      instructions; or&nbsp;<BR>&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">by e-mail: send an e-mail message to
      sendmaterial@proxyvote.com. Please send a blank e-mail and put the
      12-Digit Control Number located in your Notice in the subject
  line.</TD></TR></TABLE>
<P align=justify><B><FONT face="Times New Roman" size=2>Who can vote at the
Annual Meeting?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Only holders of record at
the close of business on March 21, 2016 (the &#147;Record Date&#148;) will be entitled to
notice of and to vote at the Annual Meeting or any adjournment or postponement
thereof. At the close of business on the Record Date, we had 158,916,775 shares
of common stock, par value $0.001 per share (&#147;Common Stock&#148;), outstanding. Each
holder of record of Common Stock on the Record Date will be entitled to one vote
for each share held on all matters to be voted upon at the Annual Meeting. The
stock transfer books will not be closed between the Record Date and the Annual
Meeting date. A list of stockholders entitled to vote at the Annual Meeting will
be available for examination at our principal executive offices at the address
listed above for a period of ten days prior to the Annual Meeting and during the
Annual Meeting.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>2</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>

<P align=justify><B><FONT face="Times New Roman" size=2>What am I voting on at
the Annual Meeting?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>You are being asked to vote
on three proposals, as follows:</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD NOWRAP ALIGN="LEFT" WIDTH="1%" STYLE="text-align: justify"><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT></TD>
    <TD VALIGN="TOP" NOWRAP ALIGN="LEFT" WIDTH="2%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Proposal 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT></TD>
    <TD VALIGN="TOP" ALIGN="LEFT" WIDTH="96%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>To
      elect the two nominees for director named in this Proxy Statement to hold
      office as Class II members of our Board of Directors until the 2019 annual
      meeting of stockholders;</FONT></TD></TR>
  <TR>
    <TD WIDTH="1%" STYLE="text-align: justify"></TD>
    <TD VALIGN="TOP" WIDTH="98%" COLSPAN="2" STYLE="text-align: justify">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD NOWRAP ALIGN="LEFT" WIDTH="1%" STYLE="text-align: justify"></TD>
    <TD VALIGN="TOP" NOWRAP ALIGN="LEFT" WIDTH="2%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Proposal 2</FONT></TD>
    <TD VALIGN="TOP" ALIGN="LEFT" WIDTH="96%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>To
      approve, on an advisory basis, the compensation of our named executive
      officers, as disclosed in this Proxy Statement; and</FONT></TD></TR>
  <TR>
    <TD WIDTH="1%" STYLE="text-align: justify"></TD>
    <TD VALIGN="TOP" WIDTH="98%" COLSPAN="2" STYLE="text-align: justify">&nbsp;&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD NOWRAP ALIGN="LEFT" WIDTH="1%" STYLE="text-align: justify"></TD>
    <TD VALIGN="TOP" NOWRAP ALIGN="LEFT" WIDTH="2%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Proposal 3</FONT></TD>
    <TD VALIGN="TOP" ALIGN="LEFT" WIDTH="96%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>To
      ratify the selection by the Audit Committee of the Board of Directors of
      Ernst &amp; Young LLP as our independent registered public accounting firm
      for the fiscal year ending December 31,
2016.</FONT></TD></TR></TABLE><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>What are the choices in
voting?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>For Proposal 1, you may
either vote &#147;For&#148; all nominees to the Board of Directors or you may &#147;Withhold&#148;
your vote for any nominee you specify. For Proposals 2 and 3, you may vote &#147;For&#148;
the proposal or &#147;Against&#148; the proposal or &#147;Abstain&#148; from voting on the
proposal.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>What is the
recommendation of the Board on each of the matters scheduled to be voted on at
the Annual Meeting?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board of Directors
recommends that you vote:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><FONT face="Times New Roman" size=2>FOR the
      nominees to the Board of Directors (Proposal 1);<BR>&nbsp;&nbsp;
  </FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><FONT face="Times New Roman" size=2>FOR the
      approval, on an advisory basis, of the compensation of our named executive
      officers as disclosed in this Proxy Statement (Proposal 2); and</FONT>
      <BR>&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><FONT face="Times New Roman" size=2>FOR the
      ratification of the selection of Ernst &amp; Young LLP as our independent
      registered public accounting firm for the fiscal year ending December 31,
      2016 (Proposal 3).</FONT></TD></TR></TABLE>
<P align=justify><B><FONT face="Times New Roman" size=2>Could other matters be
decided at the Annual Meeting?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our Bylaws require that we
receive advance notice of any proposal to be brought before the Annual Meeting
by our stockholders, and we have not received notice of any such proposals. If
any other matter were to be properly submitted for a vote at the Annual Meeting,
the proxy holders appointed by the Board will have the discretion to vote on
those matters for you as they see fit. This includes, among other things,
considering any motion to adjourn the Annual Meeting to another time and/or
place, including for the purpose of soliciting additional proxies for or against
a given proposal.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>What is the difference
between holding shares as a stockholder of record or as a beneficial
owner?</FONT></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Stockholder of Record: Shares
Registered in Your Name</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>You are a stockholder of
record if at the close of business on March 21, 2016, your shares were
registered directly in your name with our transfer agent, Computershare Trust
Company, N.A. As a stockholder of record, you may vote during the Annual Meeting
or vote by proxy.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Beneficial Owner: Shares
Registered in the Name of a Broker or Bank</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>You are a beneficial owner,
if at the close of business on March 21, 2016, your shares were held in an
account at a brokerage firm, bank, dealer, or other similar organization and not
in your name. The organization holding your account is considered to be the
stockholder of record for purposes of voting at the Annual Meeting. Being a
beneficial owner means that, like most stockholders, your shares are held in
&#147;street name&#148; and these proxy materials are being forwarded to you by that
organization. As a beneficial owner, you have the right to direct your broker or
other agent on how to vote the shares in your account by following the voting
instructions your broker </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>3</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>

<P align=justify><FONT face="Times New Roman" size=2>or other nominee provides.
If you do not provide your broker or nominee with instructions on how to vote
your shares, your broker or nominee will be able to vote your shares with
respect to some of the proposals, but not all. Refer to the section below &#147;What
are broker non-votes?&#148; for more information.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>How do I vote my shares
and what are the voting deadlines?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Please refer to the proxy
card for instructions on, and access information for, voting by telephone, over
the Internet or by mail.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Stockholder of Record: Shares
Registered In Your Name</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>If you are a stockholder of
record, there are several ways for you to vote your shares.</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%" style="text-align: justify"><STRONG><U>Via the Internet</U></STRONG><FONT face="Times New Roman" size=2>. You may vote at www.proxyvote.com, 24
      hours a day, seven days a week. You will need the 12-Digit Control Number
      included on your Notice or your proxy card (if you received a printed copy
      of the proxy materials). Votes submitted through the Internet must be
      received by 11:59 p.m., Eastern Time, on May 16, 2016.<BR>&nbsp;&nbsp;
      </FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%" style="text-align: justify"><B><U>By Telephone</U></B><FONT face="Times New Roman" size=2>.
    You may vote using a touch-tone telephone by calling 1-800-690-6903, 24 hours a day, seven days a week. You will need the
    12-Digit Control Number included on your Notice or your proxy card (if you received a printed copy of the proxy materials).
    Votes submitted by telephone must be received by 11:59 p.m., Eastern Time, on May 16, 2016.</FONT><BR><FONT face="Times New Roman" size=2>&nbsp;&nbsp;
    </FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%" style="text-align: justify"><B><U>By Mail</U></B><FONT face="Times New Roman" size=2>.
    If you received printed proxy materials, you may submit your vote by completing, signing, and dating each proxy card received
    and returning it in the postage-paid envelope. Sign your name exactly as it appears on the proxy card. Proxy cards submitted
    by mail must be received no later than May 16, 2016 to be voted at the Annual Meeting.</FONT><BR><FONT face="Times New Roman" size=2>&nbsp;
    </FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><B><U>During the Annual Meeting</U></B><FONT face="Times New Roman" size=2>.
    Stockholders may also submit their vote if they attend the meeting in person.</FONT></TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Internet and telephone
voting procedures described above, which comply with Delaware law, are designed
to authenticate stockholders&#146; identities, to allow stockholders to vote their
shares, and to confirm that their instructions have been properly recorded.
However, please be aware that you must bear any costs associated with your
Internet access, such as usage charges from Internet access providers and
telephone companies.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Beneficial Owner: Shares
Registered in the Name of a Broker or Bank</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>If you are a beneficial
owner of your shares, you should have received a Notice or voting instructions
from the broker or other nominee holding your shares. You should follow the
instructions in the Notice or voting instructions provided by your broker or
nominee in order to instruct your broker or other nominee on how to vote your
shares. The availability of telephone and Internet voting will depend on the
voting process of the broker or nominee. Please contact your bank, broker or
other agent if you have questions about their instructions on how to vote your
shares. To vote during the 2016 Annual Meeting, you must obtain a valid proxy
from your broker, bank, or other agent, and attend the meeting in person to
submit your vote.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Geron Plan
Participants</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>As trustee of the Geron
401(k) Plan, Prudential Bank and Trust FSB will receive a proxy that
incorporates all the shares owned by the Geron 401(k) Plan and will vote such
proxy as directed by the Geron 401(k) sponsor.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Shares purchased through
the 1996 Employee Stock Purchase Plan and the 2014 Employee Stock Purchase Plan
will follow standard brokerage industry practices. Shares held in the name of
the broker will be voted on behalf of the holder on certain routine matters. To
the extent the brokerage firm votes shares on the behalf of the holder, the
shares will be counted for the purpose of determining a quorum.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>4</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>

<P align=justify><B><FONT face="Times New Roman" size=2>Can I vote my shares by
filling out and returning the Notice?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>No. The Notice will,
however, provide instructions on how to vote by Internet, by telephone, or by
requesting and returning a paper proxy card or voting instruction
card.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>How many votes are
needed to approve a proposal?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>A quorum of stockholders is
necessary to hold a valid meeting. In order to constitute a quorum and to
transact business at the Annual Meeting, a majority of the outstanding shares of
Common Stock on the Record Date must be represented at the Annual Meeting.
Shares represented by proxies that reflect abstentions or &#147;broker non-votes&#148;
will be counted as shares that are present and entitled to vote for purposes of
determining the presence of a quorum.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid" noWrap></TD>
    <TD style="BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 3pt; WIDTH: 1%; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Proposal</FONT></B></TD>
    <TD style="BORDER-TOP: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-TOP: #000000 1pt solid" noWrap align=left width="42%" colSpan=2></TD>
    <TD style="BORDER-TOP: #000000 1pt solid" noWrap align=left width="2%"></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 3pt; BORDER-TOP: #000000 1pt solid; WIDTH: 53%; TEXT-ALIGN: left" noWrap colSpan=2></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-LEFT: #000000 1pt solid" noWrap>&nbsp;&nbsp; </TD>
    <TD style="PADDING-LEFT: 3pt; WIDTH: 1%; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Number</FONT></B></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%"><B><FONT face="Times New Roman" size=1>Proposal</FONT></B></TD>
    <TD noWrap align=left width="40%">&nbsp;</TD>
    <TD noWrap align=left width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Vote
    Required</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 3pt; WIDTH: 52%; TEXT-ALIGN: left" noWrap>&nbsp;</TD></TR>
  <TR style="LINE-HEIGHT: normal" vAlign=bottom>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap bgColor=#cceeff></TD>
    <TD style="PADDING-LEFT: 3pt; PADDING-BOTTOM: 2pt; VERTICAL-ALIGN: top; WIDTH: 1%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap bgColor=#cceeff><FONT face="Times New Roman" size=2>1</FONT></TD>
    <TD style="PADDING-BOTTOM: 2pt; VERTICAL-ALIGN: top; WIDTH: 1%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left" noWrap bgColor=#cceeff></TD>
    <TD style="PADDING-BOTTOM: 2pt; VERTICAL-ALIGN: top; WIDTH: 42%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: justify" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>To elect the
      two nominees for director named in this Proxy Statement to hold office as
      Class II members of our Board of Directors until the 2019 annual meeting
      of stockholders.</FONT></TD>
    <TD style="PADDING-BOTTOM: 2pt; VERTICAL-ALIGN: top; WIDTH: 2%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left" bgColor=#cceeff></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 3pt; PADDING-BOTTOM: 2pt; VERTICAL-ALIGN: top; WIDTH: 53%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: justify" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>The two
      nominees receiving the most &#147;FOR&#148; votes properly cast in person or by
      proxy will be elected. Only votes &#147;FOR&#148; or &#147;WITHHOLD&#148; will affect the
      outcome of the vote.</FONT></TD></TR>
  <TR style="LINE-HEIGHT: normal" vAlign=bottom>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap></TD>
    <TD style="PADDING-LEFT: 3pt; PADDING-BOTTOM: 2pt; VERTICAL-ALIGN: top; WIDTH: 1%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap><FONT face="Times New Roman" size=2>2</FONT></TD>
    <TD style="PADDING-BOTTOM: 2pt; VERTICAL-ALIGN: top; WIDTH: 1%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left" noWrap></TD>
    <TD style="PADDING-BOTTOM: 2pt; VERTICAL-ALIGN: top; WIDTH: 42%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: justify" colSpan=2><FONT face="Times New Roman" size=2>To approve, on an advisory
      basis, the compensation of our named executive officers, as disclosed in
      this Proxy Statement.</FONT></TD>
    <TD style="PADDING-BOTTOM: 2pt; VERTICAL-ALIGN: top; WIDTH: 2%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left"></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 3pt; PADDING-BOTTOM: 2pt; VERTICAL-ALIGN: top; WIDTH: 53%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: justify" colSpan=2><FONT face="Times New Roman" size=2>The affirmative vote of the
      holders of a majority of the shares present or represented, in person or
      by proxy, at this meeting. Abstentions will have the same effect as a vote
      against this proposal, and broker non-votes will have no effect on the
      outcome of this proposal. However, this proposal is advisory and
      non-binding upon us.</FONT></TD></TR>
  <TR style="LINE-HEIGHT: normal" vAlign=bottom>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap bgColor=#cceeff></TD>
    <TD style="PADDING-LEFT: 3pt; PADDING-BOTTOM: 2pt; VERTICAL-ALIGN: top; WIDTH: 1%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap bgColor=#cceeff><FONT face="Times New Roman" size=2>3</FONT></TD>
    <TD style="PADDING-BOTTOM: 2pt; VERTICAL-ALIGN: top; WIDTH: 1%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left" noWrap bgColor=#cceeff></TD>
    <TD style="PADDING-BOTTOM: 2pt; VERTICAL-ALIGN: top; WIDTH: 42%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: justify" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>To ratify
      the selection by the Audit Committee of the Board of Directors of Ernst
      &amp; Young LLP as our independent registered public accounting firm for
      the fiscal year ending December 31, 2016.</FONT></TD>
    <TD style="PADDING-BOTTOM: 2pt; VERTICAL-ALIGN: top; WIDTH: 2%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left" bgColor=#cceeff></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 3pt; PADDING-BOTTOM: 2pt; VERTICAL-ALIGN: top; WIDTH: 53%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: justify" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>The
      affirmative vote of the holders of a majority of the shares present or
      represented, in person or by proxy, at this meeting. Abstentions will have
      the same effect as a vote against this proposal, and broker non-votes will
      have no effect on the outcome of this
proposal.</FONT></TD></TR></TABLE><BR>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Although the election of
directors at the Annual Meeting is uncontested and directors are elected by a
plurality of votes cast, and we therefore expect that each of the named nominees
for director will be elected at the Annual Meeting, under our Corporate
Governance Guidelines, any nominee for director is required to submit an offer
of resignation for consideration by the Nominating and Corporate Governance
Committee if such nominee for director (in an uncontested election) receives a
greater number of &#147;WITHHOLD&#148; votes from his or her election than votes &#147;FOR&#148;
such election. In such case, the Nominating and Corporate Governance Committee
will then consider all of the relevant facts and circumstances and recommend to
the Board the action to be taken with respect to such offer of resignation. For
more information on this policy see the section entitled &#147;Corporate Governance
Matters &#150; Corporate Governance Guidelines&#148;.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>What are &#147;broker
non-votes&#148;?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Broker non-votes occur when
a beneficial owner of shares held in &#147;street name&#148; does not give instructions to
the broker or nominee holding the shares on how to vote on matters deemed
&#147;non-routine.&#148; Generally, if shares are held in street name, the beneficial
owner of the shares is entitled to give voting instructions to the broker or
nominee holding the shares. If the beneficial owner does not provide voting
instructions, the broker or nominee can still vote the shares with respect to
matters that are considered to be &#147;routine,&#148; but not with respect to
&#147;non-routine&#148; matters. In the event that a broker, bank, custodian, nominee or
other record holder of Geron Common Stock indicates on a proxy that it does not
have discretionary authority to vote certain shares on a particular proposal,
then those shares will be treated as broker non-votes with respect to that
proposal. Accordingly, if you own shares through a nominee, such as a broker or
bank, please be sure to instruct your nominee on how to vote to ensure that your
vote is counted on each of the proposals.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>5</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>

<P align=justify><B><FONT face="Times New Roman" size=2>Which ballot measures
are considered &#147;routine&#148; or &#147;non-routine?&#148;</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The ratification of the
selection of Ernst &amp; Young LLP as our independent registered public
accounting firm for the fiscal year ending December 31, 2016 (Proposal 3) is
considered routine under applicable rules. A broker or other nominee may
generally vote on routine matters, and therefore no broker non-votes are
expected to occur in connection with Proposal 3. The election of directors
(Proposal 1) and the advisory vote on the compensation of our named executive
officers (Proposal 2) are considered non-routine matters under applicable rules.
A broker or other nominee cannot vote without instructions on non-routine
matters, and therefore we expect broker non-votes on Proposals 1 and
2.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>What does it mean if I
receive more than one set of proxy materials or more than one Notice, or
combination thereof?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>If you receive more than
one set of proxy materials, or more than one Notice or a combination thereof,
your shares may be registered in more than one name or may be registered in
different accounts. Please follow the voting instructions on </FONT><B><FONT face="Times New Roman" size=2>each</FONT></B><FONT face="Times New Roman" size=2> set of proxy materials or Notices to ensure that all of your shares are
voted.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>How will your proxy be
voted?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Votes will be counted by
the Inspector of Election appointed for the Annual Meeting, who will separately
count &#147;FOR&#148; and (with respect to proposals other than the election of directors)
&#147;AGAINST&#148; votes, abstentions and broker non-votes. In addition, with respect to
the election of directors, the Inspector of Election will count the number of
&#147;WITHHOLD&#148; votes received for the nominees. If your shares are held by your
broker as your nominee (that is, in &#147;street name&#148;), you will need to obtain a
proxy form from the institution that holds your shares and follow the
instructions included on that form regarding how to instruct your broker to vote
your shares. If you do not give instructions to your broker, your broker can
vote your shares with respect to &#147;routine&#148; items, but not with respect to
&#147;non-routine&#148; items. See &#147;What are &#147;broker non-votes?&#148; and &#147;Which ballot
measures are considered &#147;routine&#148; or &#147;non-routine&#148;?&#148; above for more information
regarding &#147;routine&#148; and &#147;non-routine&#148; matters.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Can I revoke or change
my vote after I submit my proxy?</FONT></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Stockholder of Record: Shares
Registered In Your Name</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>If you are a stockholder of
record, you may revoke or change your vote at any time before the final vote at
the Annual Meeting by:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">signing and returning a new proxy card with a
      later date;<BR>&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">submitting a later-dated vote by telephone or
      via the Internet &#151; only your latest Internet or telephone proxy received
      by 11:59 p.m., Eastern Time, on May 16, 2016, will be counted;<BR>&nbsp;
    </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">attending the Annual Meeting in person and
      voting again; or<BR>&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">delivering a written revocation to our
      Corporate Secretary at Geron&#146;s offices, 149 Commonwealth Drive, Suite
      2070, Menlo Park, California 94025, before the Annual
  Meeting.</TD></TR></TABLE>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Beneficial Owner: Shares
Registered in the Name of a Broker or Bank</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>If you are a beneficial
owner of your shares, you must contact the broker or other nominee holding your
shares and follow their instructions for revoking or changing your
vote.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Is my vote
confidential?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Yes. Proxy cards, ballots
and voting tabulations that identify stockholders by name are kept confidential.
There are exceptions for contested proxy solicitations or when necessary to meet
legal requirements. In addition, all comments written on a proxy card or
elsewhere will be forwarded to management, but your identity will be kept
confidential unless you ask that your name be disclosed.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>6</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>

<P align=justify><B><FONT face="Times New Roman" size=2>How can I obtain a copy
of Geron&#146;s Annual Report on Form 10-K?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We will mail to you without
charge, upon written request, a copy of our Annual Report on Form 10-K filed
with the SEC for the fiscal year ended December 31, 2015, as well as a copy of
any exhibit specifically requested. Requests should be sent to: Corporate
Secretary, Geron Corporation, 149 Commonwealth Drive, Suite 2070, Menlo Park,
California 94025. A copy of our Annual Report on Form 10-K has also been filed
with the SEC and may be accessed from the SEC&#146;s homepage (www.sec.gov). You may
also view and download our 2015 Annual Report on Form 10-K on our website at
www.geron.com as well as www.proxyvote.com.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>How can I find out the
results of the voting at the Annual Meeting?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Preliminary voting results
will be announced at the Annual Meeting. Final voting results will be published
by Geron in a Current Report on Form 8-K, filed with the SEC, that we expect to
file within four business days after the Annual Meeting. If final voting results
are not available to us in time to file a Current Report on Form 8-K within four
business days after the Annual Meeting, we intend to file a Current Report on
Form 8-K to publish preliminary results and, within four business days after the
final results are known to us, file an additional Current Report on Form 8-K to
publish the final results.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Who is paying for this
proxy solicitation?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We will pay the entire cost
of solicitation of proxies, including preparation, assembly, printing and
mailing of this Proxy Statement, the proxy card and any additional information
furnished to stockholders. Copies of solicitation materials will be furnished to
banks, brokerage houses, fiduciaries and custodians holding in their names
shares of Common Stock beneficially owned by others to forward to such
beneficial owners. In addition, we may reimburse persons representing beneficial
owners of Common Stock for their costs of forwarding solicitation materials to
such beneficial owners. The original solicitation of proxies by mail may be
supplemented by solicitation by mail, telephone or other electronic means, or in
person, by our directors, officers, or other regular employees, or at our
request, by Alliance Advisors, LLC. No additional compensation will be paid to
directors, officers or other regular employees for such services, but Alliance
Advisors will be paid its customary fee, estimated to be $6,000, to render
solicitation services.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>When are stockholder
proposals due for next year&#146;s Annual Meeting?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>To be considered for
inclusion in next year&#146;s proxy materials, your proposal must be submitted in
writing by December 5, 2016, to our Corporate Secretary at Geron Corporation,
149 Commonwealth Drive, Suite 2070, Menlo Park, California, 94025, and must
comply with all applicable requirements of Rule 14a-8 promulgated under the
Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). However, if
our 2017 Annual Meeting of Stockholders is not held between April 17, 2017 and
June 16, 2017, then the deadline will be a reasonable time prior to the time we
begin to print and send our proxy materials.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>If you wish to bring a
proposal before the stockholders or nominate a director at the 2017 Annual
Meeting of Stockholders, but you are not requesting that your proposal or
nomination be included in next year&#146;s proxy materials, you must notify our
Corporate Secretary, in writing, not earlier than the close of business on
January 17, 2017 and not later than the close of business on February 16, 2017.
However, if our 2017 Annual Meeting of Stockholders is not held between April
17, 2017 and July 16, 2017, then the deadline will be the 90<SUP>th</SUP> day
prior to the 2017 Annual Meeting or, if later, the 10<SUP>th</SUP> day following
the day on which public disclosure of the date of the 2017 Annual Meeting of
Stockholders was first made. We also advise you to review Geron&#146;s Bylaws, which
contain additional requirements about advance notice of stockholder proposals
and director nominations. The chairman of the 2017 Annual Meeting of
Stockholders may determine, if the facts warrant, that a matter has not been
properly brought before the meeting and, therefore, may not be considered at the
meeting. Stockholders interested in submitting a proposal are advised to contact
knowledgeable counsel with regard to the detailed requirements of the applicable
securities laws. The submission of a stockholder proposal does not guarantee
that it will be included in our proxy statement. For additional discussion,
refer to the section entitled &#147;Stockholder Nominations and Proposals for 2017
Annual Meeting&#148;.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>7</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>

<P align=justify><B><FONT face="Times New Roman" size=2>What is householding and
how does it affect me?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Some brokers and other
nominee record holders may be participating in the practice of &#147;householding&#148;
proxy statements. This means that only one copy of this Proxy Statement and 2015
Annual Report on Form 10-K or the Notice may have been sent to multiple
stockholders in a stockholder&#146;s household. Once you have received notice from
your broker that they will be &#147;householding&#148; communications to your address,
&#147;householding&#148; will continue until you are notified otherwise or until you
revoke your consent. If, at any time, you no longer wish to participate in
&#147;householding&#148; and would prefer to receive separate copies of the proxy
statement, annual report or the notice of internet availability of proxy
materials, please notify your broker or our Investor Relations department. We
will promptly deliver copies of the Proxy Statement and our 2015 Annual Report
on Form 10-K or the Notice to any stockholder who contacts our Investor
Relations department at (650) 473-7765 or by mail addressed to Investor
Relations, Geron Corporation, 149 Commonwealth Drive, Suite 2070, Menlo Park,
California 94025, requesting such copies. If a stockholder is receiving multiple
copies of the proxy statement and annual report at the stockholder&#146;s household
and would like to receive a single copy of the proxy statement and annual report
for a stockholder&#146;s household in the future, stockholders should contact their
broker, other nominee record holder, or our Investor Relations department to
request mailing of a single copy of the proxy statement and annual
report.</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>MATTERS TO BE CONSIDERED
AT THE 2016 ANNUAL MEETING</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="proposal1"></A>PROPOSAL 1
</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>ELECTION OF DIRECTORS
</FONT></B></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Board Structure
</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our Board currently
consists of seven members, six of whom are &#147;independent,&#148; as that term is
defined by NASDAQ Rule 5605(a)(2). Our Bylaws provide for the classification of
the Board into three classes, as nearly equal in number as possible, with
staggered terms of office. Our Bylaws also provide that upon expiration of the
term of office for a class of directors, nominees for such class will be elected
for a term of three years or until their successors are duly elected and
qualified.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The term of office of the
Class II directors, Hoyoung Huh, M.D., Ph.D., and Daniel M. Bradbury, will
expire at the Annual Meeting in May 2016. Proxies may only be voted for the two
Class II directors nominated for election at the Annual Meeting. The Class III
directors, Karin Eastham, V. Bryan Lawlis, Ph.D., and Susan M. Molineaux, Ph.D.,
have one year remaining on their terms of office. The Class I directors, John A.
Scarlett, M.D., and Robert J. Spiegel, M.D., FACP, have two years remaining on
their terms of office.</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>NOMINEES FOR ELECTION TO
THE BOARD OF DIRECTORS<BR>For a Three Year Term Expiring at the<BR>2019 Annual
Meeting </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board has selected two
nominees for Class II directors, both of whom are currently directors of Geron
and were previously elected by the stockholders. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Set forth below is a brief
biography of each nominee for Class II director, including their ages, the
periods during which they have served as a director of Geron, and information
furnished by them as to principal occupations and public company directorships
held by them. The biographies below also include a discussion of the specific
experience, qualifications, attributes or skills of each nominee that led the
Nominating and Corporate Governance Committee</FONT><B><FONT face="Times New Roman" size=2> </FONT></B><FONT face="Times New Roman" size=2>and the Board to conclude, as of the date of this Proxy Statement, that
each nominee for Class II director should continue to serve as a director. Each
person nominated for election has consented to being named as a nominee in this
proxy statement and has agreed to serve if elected, and the Board has no reason
to believe that any nominee will be unable to serve.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>8</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><B><FONT face="Times New Roman" size=2>Class II Director
Nominees (Term Expiring at the 2019 Annual Meeting) </FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Name</FONT></B></TD>
    <TD noWrap align=left width="39%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%"><B><FONT face="Times New Roman" size=1>Age</FONT></B></TD>
    <TD noWrap align=left width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Principal Occupation</FONT></B></TD>
    <TD noWrap align=left width="54%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="40%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Hoyoung Huh, M.D., Ph.D.</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>46</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="55%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Independent Director</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="40%" colSpan=2><FONT face="Times New Roman" size=2>Daniel M. Bradbury</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"><FONT face="Times New Roman" size=2>54</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="55%" colSpan=2><FONT face="Times New Roman" size=2>Independent
Director</FONT></TD></TR></TABLE><BR>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Hoyoung Huh, M.D.,
Ph.D.</FONT></I><FONT face="Times New Roman" size=2>, has been the Chairman of
the Board since September 2011, served as our interim Executive Chairman from
February 2011 to September 2011, and has served as a director of Geron since May
2010. He is also Chairman of the board of directors of CytomX Therapeutics,
Inc., an emerging medical technology company and a director of AntriaBio, Inc.,
a biopharmaceutical company focused on developing therapies for diabetes.
Additionally, Dr. Huh serves on the boards of directors of several
privately-held companies. Dr. Huh served as a director of ADDEX Pharmaceuticals,
a pharmaceutical discovery and development company, from May 2011 to May 2014;
as Chairman of the board of directors and Chief Executive Officer of BiPar
Sciences, Inc., a wholly-owned subsidiary of Sanofi-Aventis, a global
pharmaceutical company, from February 2008 to December 2011; as a director of
Facet Biotech, a wholly-owned subsidiary of Abbott, a global, broad-based health
care company, from September 2009 to April 2010; and as a director of Nektar
Therapeutics, a clinical-stage biopharmaceutical company, from February 2008 to
May 2009. Dr. Huh has held several senior management positions in the
biopharmaceutical industry, including President and Chief Executive Officer at
BiPar and Chief Operating Officer and Senior Vice President of Business
Development and Marketing at Nektar. Prior to Nektar, Dr. Huh was a partner at
McKinsey &amp; Company, a global management consulting firm, where he was in the
biotechnology and biopharmaceutical sectors. Prior to McKinsey, he held
positions as a physician and researcher at Cornell University Medical College
and Sloan-Kettering Cancer Center. Dr. Huh holds an A.B. in biochemistry from
Dartmouth College and an M.D. and Ph.D. in genetics and cell biology from
Cornell University Medical College and Sloan-Kettering Institute.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board believes Dr.
Huh&#146;s management and operational experience as President and Chief Executive
Officer of BiPar Sciences and Chief Operating Officer of Nektar Therapeutics,
his significant expertise with implementing strategic and line management
initiatives from McKinsey and his knowledge of biotechnology and pharmaceutical
collaborations, qualifies Dr. Huh to be nominated as a director and serve as
Chairman of the Board.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Daniel M.
Bradbury</FONT></I><B><I><FONT face="Times New Roman" size=2>
</FONT></I></B><FONT face="Times New Roman" size=2>has served as a director of
Geron since September 2012. He also serves as a member of the boards of
directors of Illumina, Inc., a manufacturer of life science tools and reagents;
Corcept Therapeutics, a company focused on the discovery and development of
drugs that regulate the effects of cortisol; Biocon Ltd., a company focused on
reducing therapy costs of chronic diseases like diabetes, cancer and autoimmune
diseases; and Syngene International Ltd., a contract research and manufacturing
organization focused on providing multidisciplinary skills in chemistry and
biology services, as well as being a member of the board of trustees of the Keck
Graduate Institute. Mr. Bradbury also served on the board of directors of BioMed
Realty Trust, Inc., a real estate investment trust focused on providing real
estate to the life science industry, from January 2013 to January 2016. He also
serves on the University of California San Diego, Rady School of Management&#146;s
Advisory Council, Investor Growth Capital Advisory Board and the BioMed Ventures
Advisory Committee. Mr. Bradbury held several senior positions at Amylin
Pharmaceuticals, Inc., a biopharmaceutical company focused on diabetes and
metabolic disorders, including Chief Executive Officer from March 2007 until its
acquisition by Bristol-Myers Squibb Company in August 2012. In addition, Mr.
Bradbury served as a member of the board of directors of Amylin from June 2006
until August 2012. Prior to joining Amylin, he spent ten years at SmithKline
Beecham Pharmaceuticals, a pharmaceutical company, holding a number of sales and
marketing positions. He received a Bachelor of Pharmacy from Nottingham
University and a Diploma in Management Studies from Harrow and Ealing Colleges
of Higher Education in the United Kingdom.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board believes that Mr.
Bradbury&#146;s extensive experience in the biopharmaceutical industry, together with
his experience in the research, development and commercialization of
pharmaceutical drug products, qualifies Mr. Bradbury to be nominated as a
director.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>9</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><B><FONT face="Times New Roman" size=2>Vote Required and Board
Recommendation</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Directors are elected by a
plurality of the votes of the holders of shares present in person or represented
by proxy at the meeting. The two nominees receiving the highest number of &#147;FOR&#148;
votes properly cast in person or by proxy at the meeting will be elected as a
Class II director of Geron. The election of directors is a non-routine matter on
which a broker or other nominee is not empowered to vote. Accordingly, if the
beneficial owner does not give a broker specific instructions, the beneficially
owned shares may not be voted on this proposal and will not be counted in
determining the number of shares necessary for election. Broker non-votes will
not have any effect on the outcome of this proposal. In tabulating the voting
results for the election of directors, only &#147;FOR&#148; and &#147;WITHHOLD&#148; votes are
counted. In the event that any nominee should be unavailable for election as a
result of an unexpected occurrence, such shares will be voted for the election
of such substitute nominee as our Nominating and Corporate Governance Committee
and Board may propose. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Although the election of
directors at the Annual Meeting is uncontested and directors are elected by a
plurality of votes cast, and we therefore expect that each of the named nominees
for director will be elected at the Annual Meeting, under our Corporate
Governance Guidelines, any nominee for director is required to submit an offer
of resignation for consideration by the Nominating and Corporate Governance
Committee if such nominee for director (in an uncontested election) receives a
greater number of &#147;WITHHOLD&#148; votes from his or her election than votes &#147;FOR&#148;
such election. In such case, the Nominating and Corporate Governance Committee
will then consider all of the relevant facts and circumstances and recommend to
the Board the action to be taken with respect to such offer of resignation. For
more information on this policy see the section entitled &#147;Corporate Governance
Matters &#150; Corporate Governance Guidelines&#148;. </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>The Board of Directors
Unanimously Recommends That Stockholders<BR></FONT></B><B><FONT face="Times New Roman" size=2>Vote <U>FOR</U> the Election of Each Nominee to
the Board of Directors</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>MEMBERS OF THE BOARD OF
DIRECTORS CONTINUING IN OFFICE</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Set forth below is a brief
biography of each continuing director composing the remainder of the Board with
terms expiring as shown, including their ages, the periods during which they
have served as a director of Geron, and information furnished by them as to
principal occupations and public company directorships held by them. The
biographies below also include a discussion of the specific experience,
qualifications, attributes or skills of each continuing director that led the
Nominating and Corporate Governance Committee and the Board to conclude, as of
the date of this Proxy Statement, that the applicable director should continue
to serve as a director.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Class III Directors
(Term Expiring at the 2017 Annual Meeting)</FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Name</FONT></B></TD>
    <TD noWrap align=left width="39%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%"><B><FONT face="Times New Roman" size=1>Age</FONT></B></TD>
    <TD noWrap align=left width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Principal Occupation</FONT></B></TD>
    <TD noWrap align=left width="55%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="40%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Karin Eastham</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>66</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="56%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Independent Director</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="40%" colSpan=2><FONT face="Times New Roman" size=2>V.
      Bryan Lawlis, Ph.D.</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"><FONT face="Times New Roman" size=2>64</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="56%" colSpan=2><FONT face="Times New Roman" size=2>President and Chief Executive Officer, Itero
      Biopharmaceuticals LLC</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="40%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Susan M. Molineaux, Ph.D.</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>62</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="56%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>President and Chief Executive Officer,
      Calithera Biosciences, Inc.</FONT></TD></TR></TABLE><BR>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Karin
Eastham</FONT></I><B><I><FONT face="Times New Roman" size=2>
</FONT></I></B><FONT face="Times New Roman" size=2>has served as a director of
Geron since March 2009. Ms. Eastham also serves as a director for MorphoSys AG,
a Frankfurt Stock Exchange-listed biotechnology company; Illumina, Inc., a
manufacturer of life science tools and reagents; and Veracyte, Inc., a molecular
diagnostics company. Ms. Eastham also served as a director of Trius
Therapeutics, Inc., a biopharmaceutical company, from 2009 until its sale in
2013; Amylin Pharmaceuticals, Inc., a biopharmaceutical company focused on
diabetes and metabolic disorders, from 2005 until its sale in 2012; and
Genoptix, Inc., a provider of specialized laboratory services, from 2008 until
its sale in 2011. Ms. Eastham has held several senior management positions in
finance in the biopharmaceutical industry, including with the Burnham Institute
for Medical Research, a non-profit corporation engaged in basic biomedical
research; Diversa Corporation, a biotechnology company; CombiChem, Inc., a
computational chemistry company; Cytel Corporation, a biopharmaceutical company;
and Boehringer Mannheim Corporation, a biopharmaceutical company. Ms. Eastham
holds a B.S. and an M.B.A. from Indiana University and is a Certified Public
Accountant.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>10</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board believes Ms.
Eastham&#146;s understanding of biotechnology companies combined with her business
leadership and financial experience, her contributions to the Board&#146;s
understanding of corporate governance and strategy for life science companies
through her experience as a director in the biopharmaceutical industry and her
extensive senior management experience in the biopharmaceutical industry,
particularly in key corporate finance and accounting positions, qualifies Ms.
Eastham to serve as a director.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>V. Bryan Lawlis,
Ph.D.</FONT></I><FONT face="Times New Roman" size=2>, has served as a director
of Geron since March 2012. He currently serves as a director for BioMarin
Pharmaceuticals, Inc., a biopharmaceutical company specializing in rare genetic
diseases; Coherus Biosciences, Inc., a biologics platform company specializing
in biosimilars; and at several privately-held biotechnology companies. From
August 2013 to September 2014, Dr. Lawlis served as a director for KaloBios
Pharmaceuticals, Inc., a biopharmaceutical company specializing in customized
antibodies for the treatment of human disease. Dr. Lawlis is also the President
and Chief Executive Officer of Itero Biopharmaceuticals LLC, a privately-held,
early stage biopharmaceutical company that he co-founded in 2006, and serves as
an advisor to Phoenix Venture Partners, a venture capital firm specializing in
manufacturing technologies. Dr. Lawlis has held several senior management
positions in the biopharmaceutical industry, including President and Chief
Executive Officer of Aradigm Corporation, a specialty drug company focused on
drug delivery technologies, and President and Chief Executive Officer of Covance
Biotechnology Services, a contract biopharmaceutical manufacturing operation,
which he co-founded. Dr. Lawlis holds a B.A. in microbiology from the University
of Texas at Austin and a Ph.D. in biochemistry from Washington State
University</FONT><I><FONT face="Times New Roman" size=2>.</FONT></I></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board believes Dr.
Lawlis&#146; extensive experience in manufacturing biotechnology and other
pharmaceutical products, research and development of drug products and managing
and conducting clinical trials and drug regulatory processes, qualifies Dr.
Lawlis to serve as a director.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Susan M. Molineaux,
Ph.D.</FONT></I><FONT face="Times New Roman" size=2>, has served as a director
of Geron since September 2012. She has been Chief Executive Officer and
President of Calithera Biosciences, Inc., a biotechnology company developing
oncology therapeutics, since co-founding the company in June 2010. She also
serves as a member of the board of directors of Theravance Biopharma, Inc., a
biopharmaceutical company, since April 2015. Prior to Calithera, Dr. Molineaux
co-founded Proteolix, Inc., a privately-held oncology-oriented biopharmaceutical
company, where she served as Chief Scientific Officer from December 2003 until
December 2005 and from February 2009 until November 2009, and as President and
Chief Executive Officer from January 2006 until February 2009, until the
company&#146;s acquisition by Onyx Pharmaceuticals, Inc., a global oncology-oriented
biopharmaceutical company, in November 2009. Previously, Dr. Molineaux held
several senior management positions in the biopharmaceutical industry, including
Vice President of Biology at Rigel Pharmaceuticals, Inc., a biopharmaceutical
company focused on inflammatory and autoimmune diseases; Vice President of
Biology at Praelux, Inc.; and Vice President of Drug Development at Praecis
Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company. Dr.
Molineaux holds a B.S. in biology from Smith College, a Ph.D. in molecular
biology from Johns Hopkins University, and completed a postdoctoral fellowship
at Columbia University. She currently is a member of the board of directors of
We Teach Science, a San Francisco Bay Area mentoring program for students in
math and science. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board believes Dr.
Molineaux&#146;s extensive experience in pharmaceutical and oncology drug
development, and her expertise in managing and conducting clinical trials,
qualifies Dr. Molineaux to serve as a director.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Class I Directors (Term
Expiring at the 2018 Annual Meeting)</FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Name</FONT></B></TD>
    <TD noWrap align=left width="39%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%"><B><FONT face="Times New Roman" size=1>Age</FONT></B></TD>
    <TD noWrap align=left width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Principal
      Occupation/Position with the Company</FONT></B></TD>
    <TD noWrap align=left width="55%">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD noWrap align=left width="40%" colSpan=2><FONT face="Times New Roman" size=2>John
      A. Scarlett, M.D.</FONT></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="2%"><FONT face="Times New Roman" size=2>65</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="56%" colSpan=2><FONT face="Times New Roman" size=2>President and Chief Executive Officer</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="40%" colSpan=2><FONT face="Times New Roman" size=2>Robert J. Spiegel, M.D., FACP</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"><FONT face="Times New Roman" size=2>66</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="56%" colSpan=2><FONT face="Times New Roman" size=2>Chief Medical Officer, PTC Therapeutics,
  Inc.</FONT></TD></TR></TABLE><BR>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.,
</FONT></I><FONT face="Times New Roman" size=2>has served as our Chief Executive
Officer and a director since joining Geron in September 2011 and President since
January 2012. Dr. Scarlett also serves as a director for Chiasma, Inc., a
biopharmaceutical company focused on transforming injectable drugs into oral
medications, since February 2015. Prior to joining Geron, Dr. Scarlett served as
President, Chief Executive Officer and a member of the board of directors of
Proteolix, Inc., a privately-held, oncology-oriented biopharmaceutical company,
from February </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>11</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><FONT face="Times New Roman" size=2>2009 until its acquisition
by Onyx Pharmaceuticals, Inc., an oncology-oriented biopharmaceutical company,
in November 2009. From February 2002 until its acquisition by Ipsen, S.A. in
October 2008, Dr. Scarlett served as the Chief Executive Officer and a member of
the board of directors of Tercica, Inc., an endocrinology-oriented
biopharmaceutical company, and also as its President from February 2002 through
February 2007. From March 1993 to May 2001, Dr. Scarlett served as President and
Chief Executive Officer of Sensus Drug Development Corporation. In 1995, he
co-founded Covance Biotechnology Services, Inc., a contract biopharmaceutical
manufacturing operation, and served as a member of its board of directors from
inception to 2000. From 1991 to 1993, Dr. Scarlett headed the North American
Clinical Development Center and served as Senior Vice President of Medical and
Scientific Affairs at Novo Nordisk Pharmaceuticals, Inc., a wholly-owned
subsidiary of Novo Nordisk A/S. Dr. Scarlett received his B.A. degree in
chemistry from Earlham College and his M.D. from the University of Chicago,
Pritzker School of Medicine.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>As the only management
representative on the Board, Dr. Scarlett brings management&#146;s perspective to
board discussions about Geron&#146;s business and strategic direction. In addition,
the Board believes Dr. Scarlett&#146;s medical background and extensive drug
development experience, which provides substantial understanding of potential
clinical product opportunities, qualifies Dr. Scarlett to serve as a director.
</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Robert J. Spiegel,
M.D.</FONT></I><FONT face="Times New Roman" size=2>, </FONT><I><FONT face="Times New Roman" size=2>FACP</FONT></I><FONT face="Times New Roman" size=2>, has served as a director of Geron since May 2010. Dr. Spiegel currently
serves as Chief Medical Officer of PTC Therapeutics, Inc., a biopharmaceutical
company focused on discovering and developing treatments for rare and neglected
disorders; as an Associate Fellow at the University of Pennsylvania Center for
Bioethics; and as an Associate Professor at the Weill Cornell Medical School. He
is also a director of Edge Therapeutics, Inc., a biopharmaceutical company;
Sucampo Pharmaceuticals, Inc., a biopharmaceutical company; and Avior Computing
Corporation, a governance risk and compliance process technology company. He
served as a director for the Cancer Institute of New Jersey from 1999 to 2009
and as a director of Cancer Care New Jersey from 1995 to 2011. After 26 years
with the Schering-Plough Corporation (now Merck &amp; Co.), a global healthcare
company, Dr. Spiegel retired in 2009 as Chief Medical Officer and Senior Vice
President of the Schering-Plough Research Institute, the pharmaceutical research
arm of the Schering-Plough Corporation. His career at Schering-Plough involved
various positions, including Director of clinical research for oncology, Vice
President of clinical research, and Senior Vice President of worldwide clinical
research. Following a residency in internal medicine, Dr. Spiegel completed a
fellowship in medical oncology at the National Cancer Institute, and from 1981
to 1999 he held academic positions at the National Cancer Institute and New York
University Cancer Center. Dr. Spiegel holds a B.A. from Yale University and an
M.D. from the University of Pennsylvania.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board believes Dr.
Spiegel&#146;s extensive medical experience developing oncology products, his deep
understanding of pharmaceutical research and development and broad expertise in
gaining regulatory approval for drug candidates, enhances the Board&#146;s ability to
critically assess the progress and potential of imetelstat, and qualifies Dr.
Spiegel to serve as a director.</FONT></P>
<P align=center><A NAME="CorporateGovernanceMatters"></A><B><FONT face="Times New Roman" size=2>CORPORATE GOVERNANCE
MATTERS</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We have an ongoing
commitment to excellence in corporate governance and business practices. In
furtherance of this commitment, we regularly monitor developments in the area of
corporate governance and review our processes, policies and procedures in light
of such developments. We comply with the rules and regulations promulgated by
the SEC and NASDAQ, and implement additional corporate governance practices that
we believe are in the best interest of Geron and our stockholders.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Corporate Governance
Guidelines</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our Board has adopted
Corporate Governance Guidelines that set forth key principles to guide the Board
in their exercise of responsibilities and serve the interests of Geron and our
stockholders. Our Corporate Governance Guidelines include provisions whereby any
nominee for director shall submit an offer of resignation for consideration by
the Nominating and Corporate Governance Committee of the Board, if such nominee
for director in an uncontested election receives a greater number of &#147;WITHHOLD&#148;
votes from his or her election than votes &#147;FOR&#148; such election. The Nominating
and Corporate Governance Committee would then consider all </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>12</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><FONT face="Times New Roman" size=2>of the relevant facts and
circumstances and recommend to the Board the action to be taken with respect to
such offer of resignation. Promptly following the Board&#146;s decision, we would
disclose that decision and an explanation of such decision in a filing with the
SEC or a press release. The current form of the Corporate Governance Guidelines
can be found on the Corporate Governance page under the Investor Relations
section of our website at www.geron.com. In addition, these guidelines are
available in print to any stockholder who requests a copy. Please direct all
requests to our Corporate Secretary, Geron Corporation, 149 Commonwealth Drive,
Suite 2070, Menlo Park, California 94025. In accordance with these guidelines, a
member of our Board may serve as a director of another company only to the
extent such position does not conflict or interfere with such person&#146;s service
as a director of Geron.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Board
Independence</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In accordance with NASDAQ
listing standards and Geron&#146;s Corporate Governance Guidelines, our Board has
affirmatively determined that all nominees for election at the Annual Meeting
and all current and continuing directors, other than Dr. Scarlett, are
independent under NASDAQ listing standards. The Board consults with our counsel
to ensure that the Board&#146;s determinations are consistent with relevant
securities and other laws and regulations regarding the definition of
&#147;independent,&#148; including those set forth in pertinent listing standards of
NASDAQ, as in effect from time-to-time.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>One class of the Board is
elected annually, and each class of directors stands for election every three
years. Our Board is comprised of seven directors, one of whom is an executive
officer and six of whom were affirmatively determined by the Board to be
independent, meeting the objective requirements set forth by the SEC and NASDAQ,
and having no relationship, direct or indirect, to Geron other than as
stockholders or through their service on the Board.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Board Leadership
Structure</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board has an
independent Chair, Dr. Huh, who has authority, among other things, to call and
preside over Board meetings, including meetings of the independent directors, to
set meeting agendas and to determine materials to be distributed to the Board.
Accordingly, the Board Chair has substantial ability to shape the work of the
Board. We believe that separation of the positions of Board Chair and Chief
Executive Officer reinforces the independence of the Board in its oversight of
the business and affairs of Geron. As a result, we believe that having an
independent Board Chair enhances the effectiveness of the Board as a whole. In
addition, we believe that having an independent Board Chair creates an
environment that is more conducive to objective evaluation and oversight of
management&#146;s performance, increasing management accountability and improving the
ability of the Board to monitor whether management&#146;s actions are in the best
interests of Geron and our stockholders.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board regularly meets
in executive sessions without the presence of the non-independent director or
management.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Board&#146;s Role in Risk
Oversight</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Geron is subject to a
variety of risks, which generally include any undesired event, circumstance or
outcome that could affect Geron&#146;s ability to achieve its objectives or adversely
impact Geron&#146;s business, operations or financial condition. Some risks may be
readily perceived and even quantified, while others are unexpected or
unforeseeable. Risks can be external, such as those arising from the
macroeconomic or industry environment, government policies or regulations,
competitors&#146; activities or natural disasters. Alternatively, risks can arise as
a result of our business or financial activities.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board and Geron&#146;s
management team work together to manage Geron&#146;s risks. It is management&#146;s
responsibility to manage risk and bring to the Board&#146;s attention the material
risks to the Company. The Board has an active role in overseeing management of
the Company&#146;s risks. The Board regularly reviews information regarding our
credit, liquidity and operations, as well as the risks associated with each. In
addition, our Corporate Governance Guidelines specify that each of our Board
committees oversees the risks within its areas of responsibilities. While each
committee is responsible for evaluating certain risks and overseeing the
management of such risks within its respective oversight area, the entire Board
is regularly informed through committee reports about such risks.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>13</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
of the Board is responsible for overseeing the management of risks relating to
Geron&#146;s employment policies and executive compensation plans and arrangements.
In connection with the structuring of the compensation elements for executive
officers, the Compensation Committee, together with the Board, considers whether
such programs, individually or in the aggregate, encourage executive officers to
take unnecessary risks.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Audit Committee of the
Board oversees management of financial risks. In addition to fulfilling its
responsibilities for the oversight of our financial reporting processes and
annual audit of Geron&#146;s financial statements, the Audit Committee also reviews
with the independent auditors and the Company&#146;s management the adequacy and
effectiveness of our policies and procedures to assess, monitor and manage fraud
risk and Geron&#146;s ethical compliance program. The Audit Committee takes the
appropriate actions to set the best practices and highest standards for quality
financial reporting, sound business risk practices and ethical
behavior.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Nominating and
Corporate Governance Committee of the Board manages Geron&#146;s corporate governance
practices, including certain risks that those practices are intended to address.
In addition, the Nominating and Corporate Governance Committee reviews risks
associated with the independence of the Board, potential conflicts of interest
and risks relating to management and Board succession planning.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Board Committees and
Meetings</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>It is Geron&#146;s policy to
encourage directors to attend annual meetings of stockholders. All of our
current directors attended our 2015 Annual Meeting. During the fiscal year ended
December 31, 2015, the Board held seven meetings. The Board has an Audit
Committee, a Compensation Committee, and a Nominating and Corporate Governance
Committee. During the fiscal year ended December 31, 2015, each of the directors
attended at least 86% of the aggregate number of meetings of the Board and the
committees on which the director served during the portion of the last fiscal
year for which he or she was a director or committee member.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Audit
Committee</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Audit Committee, which
is comprised of Ms. Eastham, Mr. Bradbury and Dr. Lawlis, met nine times in
2015. All of the members of the Audit Committee are, &#147;independent&#148; as required
by NASDAQ Rule 5605(c)(2)(A). The Board has determined that all of the members
of the Audit Committee are financially literate and that two members of the
Audit Committee, Ms. Eastham and Mr. Bradbury, have accounting and financial
management expertise that qualifies each as an &#147;Audit Committee Financial
Expert,&#148; as such term is defined in Item 407(d)(5) of Regulation S-K promulgated
by the SEC. The Audit Committee&#146;s responsibilities include: (i) sole authority
to select, oversee and replace Geron&#146;s independent registered public accounting
firm and pre-approve any fees paid to such firm, (ii) consulting with the
independent auditors with regard to the plan and scope of the annual audit of
financial statements, (iii) reviewing, in consultation with the independent
auditors, their report of the audit or proposed report of the audit, and the
accompanying management letter, if any, and (iv) consulting with the independent
auditors and management with regard to the adequacy of Geron&#146;s internal
controls. The Audit Committee operates under a written charter that satisfies
the applicable standards of the SEC and NASDAQ. A copy of the Audit Committee
charter is available on our website at www.geron.com. See more information about
the Audit Committee in the section entitled &#147;Audit Committee Report&#148;.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Compensation
Committee</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee,
which met eight times in 2015, was comprised of Drs. Hofstaetter, Lawlis and
Spiegel, until Dr. Hofstaetter&#146;s retirement from the Board and the Compensation
Committee on the date of our Annual Meeting in May 2015. The Board appointed Ms.
Eastham to the Compensation Committee as of the date of our Annual Meeting in
May 2015, thereafter our Compensation Committee has been comprised of Drs.
Lawlis and Spiegel and Ms. Eastham. All of the current members of the
Compensation Committee are, and Dr. Hofstaetter was, &#147;independent&#148; as required
by NASDAQ Rules 5605(a)(2) and 5605(d)(2). In determining whether Drs. Lawlis
and Spiegel and Ms. Eastham are, and Dr. Hofstaetter was, independent within the
meaning of NASDAQ Rules pertaining to membership of the Compensation Committee,
our Board determined, based on its consideration </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>14</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><FONT face="Times New Roman" size=2>of factors specifically
relevant to determining whether any such director has a relationship to us that
is material to that director&#146;s ability to be independent from management in
connection with the duties of a compensation committee member, that no member of
the Compensation Committee has a relationship that would impair that member&#146;s
ability to make independent judgments about our executive
compensation.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation
Committee&#146;s responsibilities include making recommendations concerning
compensation of executive officers, administering Geron&#146;s incentive compensation
and benefit plans, and performing such other functions regarding compensation as
the Board may delegate. In addition, the Compensation Committee has authority to
administer the 2011 Incentive Award Plan (the &#147;2011 Plan&#148;) and the 2014 Employee
Stock Purchase Plan. The Compensation Committee operates under a written charter
that satisfies the applicable standards of NASDAQ. A copy of the Compensation
Committee charter is available on our website at www.geron.com.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Under its charter, the
Compensation Committee has the sole authority, as it deems appropriate, to
retain and/or replace, at Geron&#146;s expense, as needed, any independent counsel,
compensation and benefits consultants and other outside experts or advisors as
the Compensation Committee believes to be necessary or appropriate. In this
regard, the Compensation Committee has engaged Radford, an Aon Hewitt Company
(&#147;Radford&#148;), since December 2011 as a compensation consultant to evaluate
non-employee director and executive compensation in comparison to industry
peers. For information regarding the Compensation Committee&#146;s processes and
procedures for the consideration and determination of executive compensation,
including the role of Radford and our Chief Executive Officer in the
determination of executive compensation, see the section entitled &#147;Compensation
Discussion and Analysis &#150; Role of the Compensation Committee&#148;. With respect to
director compensation matters, our Board determines and sets non-employee
director compensation. Our compensation arrangements for our non-employee
directors, including Radford&#146;s role with respect to such arrangements for 2015,
are described under the section entitled &#147;Compensation of Directors.&#148; The
charter of the Compensation Committee allows it to delegate responsibilities to
a subcommittee of the Compensation Committee, but only to the extent consistent
with our certificate of incorporation, Bylaws, NASDAQ rules and Section 162(m)
of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;).</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><U>Compensation Committee
Interlocks and Insider Participation</U></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Drs. Lawlis and Spiegel
served on the Compensation Committee for the entire fiscal year ended December
31, 2015, and Dr. Hofstaetter served on the Compensation Committee until his
retirement from the Board and the Compensation Committee on the date of our
Annual Meeting in May 2015. Since the date of our Annual Meeting in May 2015,
Ms. Eastham has served on our Compensation Committee with Drs. Lawlis and
Spiegel. Not one of Drs. Hofstaetter, Lawlis or Spiegel, nor Ms. Eastham, is a
former or current officer or employee of Geron. None of our executive officers
serves as a member of a compensation committee of any entity that has one or
more executive officers serving as a member of our Board or Compensation
Committee.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Nominating and
Corporate Governance Committee</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Nominating and
Corporate Governance Committee&#146;s responsibilities include developing, reviewing
and recommending to the Board corporate governance guidelines and principles
applicable to Geron, making recommendations to the Board for candidates to be
nominated for election or re-election as a director by the stockholders or by
the Board and the corporate governance functions described in the Nominating and
Corporate Governance Committee&#146;s charter. Until the date of our annual meeting
in May 2015, the members of the Nominating and Corporate Governance Committee
were Ms. Eastham and Drs. Molineaux and Huh. On the date of our annual meeting
in 2015, the Board appointed Ms. Eastham to our Compensation Committee, and Mr.
Bradbury was appointed by the Board to replace Ms. Eastham on our Nominating and
Corporate Governance Committee. The current members of the Nominating and
Corporate Governance Committee are, and during her tenure on the Nominating and
Corporate Governance Committee Ms. Eastham was, &#147;independent&#148; as defined in
NASDAQ Rule 5605(a)(2). The Nominating and Corporate Governance Committee met on
four occasions during 2015. The Nominating and Corporate Governance Committee
will consider nominees for director nominated by stockholders upon submission in
writing to our Corporate Secretary of the names of such nominees in accordance
with our Bylaws. Members of the Nominating and Corporate Governance Committee
also obtain recommendations for potential directors from their and other Board
members&#146; contacts in our industry, and may from time to time engage a search
firm to assist in identifying potential directors. Specific qualifications and
the </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>15</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><FONT face="Times New Roman" size=2>process for recommending
director candidates are provided in more detail under the section entitled
&#147;Director Nominees Recommended by Stockholders&#148; and &#147;Director Qualifications&#148;
below. The Nominating and Corporate Governance Committee will investigate,
evaluate and interview, as appropriate, a director candidate with regard to his
or her individual characteristics as well as how those characteristics fit with
the needs of the Board as a whole. The Nominating and Corporate Governance
Committee operates under a written charter that satisfies the applicable
standards of NASDAQ. A copy of the Nominating and Corporate Governance Committee
charter is available on our website at www.geron.com. </FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Code of
Conduct</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In 2003, we adopted a Code
of Conduct, which is available in its entirety on the Corporate Governance page
in the Investor Relations section of our website at www.geron.com and to any
stockholder otherwise requesting a copy. All our employees, officers, and
directors, including the Chief Executive Officer and Chief Financial Officer,
are required to adhere to the Code of Conduct in discharging their work-related
responsibilities. Employees are required to report any conduct that they believe
in good faith to be an actual or apparent violation of the Code of Conduct.
Amendments to the Code of Conduct, and any waivers from the Code of Conduct
granted to directors or executive officers, will be made available through our
website as they are adopted. Accordingly, we intend to satisfy the disclosure
requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver
from, a provision of the Code of Conduct by posting such information on our
website at the website address and location specified above.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In keeping with the
Sarbanes-Oxley Act of 2002, the Audit Committee has established procedures for
the receipt and handling of complaints received by us regarding accounting,
internal accounting controls or auditing matters. Contact information for the
Chairperson of the Audit Committee has been distributed to all employees to
allow for the confidential, anonymous submission by our employees of concerns
regarding accounting or auditing matters.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Communications with the
Board</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Stockholders wishing to
communicate with the Board, or with a specific Board member, may do so by
writing to the Board, or to the particular Board member, and delivering the
communication in person or mailing it to: Board of Directors, c/o Stephen N.
Rosenfield, Corporate Secretary, Geron Corporation, 149 Commonwealth Drive,
Suite 2070, Menlo Park, CA 94025. All mail addressed in this manner will be
delivered to the Chair or Chairs of the Committees with responsibilities
touching most closely on the matters addressed in the communication. From
time-to-time, the Board may change the process by which stockholders may
communicate with the Board or its members. Please refer to our website for any
changes to this process.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>16</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="CompensationofDirectors"></A>COMPENSATION OF
DIRECTORS</FONT></B></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Cash
Compensation</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Since March 2014, our
compensation arrangements for our non-employee directors have been set forth in
our Non-Employee Director Compensation Policy (the &#147;Director Compensation
Policy&#148;). The Director Compensation Policy outlines cash and equity compensation
automatically payable to non-employee members of the Board, unless such
non-employee director declines receipt of such cash or equity compensation by
written notice to us. The following table describes the 2015 annual cash
compensation applicable to each role performed by non-employee directors in
2015:</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>Base</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="text-align: center" width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Additional</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Role</FONT></B></TD>
    <TD noWrap align=left width="94%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=1>Retainer</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Retainer</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Board member</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$42,500</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>N/A</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" colSpan=2><FONT face="Times New Roman" size=2>Chairman of the Board</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>30,000</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Audit Committee
      Chair<SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>25,000</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" colSpan=2><FONT face="Times New Roman" size=2>Compensation Committee Chair<SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>15,000</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Nominating and Corporate
      Governance Committee Chair<SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>10,000</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" colSpan=2><FONT face="Times New Roman" size=2>Audit Committee member</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>12,500</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Compensation Committee
      member</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>7,500</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" colSpan=2><FONT face="Times New Roman" size=2>Nominating and Corporate Governance Committee
member</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>5,000</FONT></TD></TR></TABLE>
<div>____________________</div><BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Committee Chair does
      not also receive additional Committee member
  compensation.</FONT></TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In 2015, the annual
non-employee director cash compensation was paid quarterly in arrears in cash,
or, at each director&#146;s election, in fully vested shares of our Common Stock
issued under the 2011 Plan based on the closing price of our Common Stock as
reported by the NASDAQ Global Select Market on the date retainers would have
otherwise been paid.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Additionally, under the
Director Compensation Policy, non-employee directors are eligible to receive
equity grants, as more fully described below under the sub-section entitled
&#147;Equity Compensation.&#148; Non-employee directors also receive reimbursement for
out-of-pocket expenses incurred in connection with attendance at meetings of the
Board.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Director Compensation
Table</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following table
provides compensation information for the fiscal year ended December 31, 2015
(&#147;fiscal 2015&#148;), for each non-employee member of the Board who served in such
capacity during fiscal 2015. Dr. Scarlett does not receive any compensation for
his Board service.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="97%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Fees</FONT></B></TD>
    <TD noWrap style="text-align: center"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="97%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Earned</FONT></B></TD>
    <TD noWrap style="text-align: center"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="97%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>or Paid</FONT></B></TD>
    <TD noWrap style="text-align: center"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%" colSpan=2><B><FONT face="Times New Roman" size=1>Option</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="97%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>in Cash</FONT></B></TD>
    <TD noWrap style="text-align: center"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%" colSpan=2><B><FONT face="Times New Roman" size=1>Awards</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%" colSpan=2><B><FONT face="Times New Roman" size=1>Total</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Director</FONT></B></TD>
    <TD noWrap align=left width="96%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>($)</FONT></B></TD>
    <TD noWrap style="text-align: center"></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%" colSpan=2><B><FONT face="Times New Roman" size=1>($)<SUP>(1)</SUP></FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%" colSpan=2><B><FONT face="Times New Roman" size=1>($)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="97%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Bradbury, Daniel</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>58,091</FONT></TD>
    <TD noWrap align=right bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>96,229</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>154,320</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="97%" colSpan=2><FONT face="Times New Roman" size=2>Eastham, Karin</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>74,045</FONT></TD>
    <TD noWrap align=right></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>96,229</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>170,274</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="97%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Hofstaetter,
      Thomas<SUP>(2)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>19,093</FONT></TD>
    <TD noWrap align=right bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>19,093</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="97%" colSpan=2><FONT face="Times New Roman" size=2>Huh,
      Hoyoung</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>77,500</FONT></TD>
    <TD noWrap align=right></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>96,229</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>173,729</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="97%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Lawlis, V. Bryan</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>62,500</FONT></TD>
    <TD noWrap align=right bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>96,229</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>158,729</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="97%" colSpan=2><FONT face="Times New Roman" size=2>Molineaux, Susan</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>52,500</FONT></TD>
    <TD noWrap align=right><FONT size=2 face="Times New Roman"><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2><SUP></SUP></FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>96,229</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>148,729</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="97%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Spiegel, Robert</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>57,500</FONT></TD>
    <TD noWrap align=right bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>96,229</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>153,729</FONT></TD></TR></TABLE>
<div>____________________</div><BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Amounts represent the
      aggregate grant date fair value of stock option awards granted during the
      fiscal year ended December 31, 2015 as calculated in accordance with
      Financial Accounting Standards Board Accounting Standards Codification
      Topic 718, or FASB ASC Topic 718. For additional information, refer
      to</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>17</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Note 8 of the
      financial statements in our Annual Report on Form 10-K for the year ended
      December 31, 2015 regarding assumptions underlying the valuation of stock
      option awards and the calculation method. Please see the section entitled
      &#147;Outstanding Equity Awards at Fiscal Year-End for Non-Employee Directors&#148;
      for information regarding the aggregate number of stock option awards held
      by the non-employee members of the Board at December 31,
2015.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Dr. Hofstaetter
      retired from the Board in May 2015.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Represents fees paid
      in stock in lieu of cash through the issuance of an aggregate 14,015
      shares of Geron Common Stock under the 2011
Plan.</FONT></TD></TR></TABLE>
<P align=justify><B><FONT face="Times New Roman" size=2>Equity
Compensation</FONT></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Terms of
Awards</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Pursuant to the Director
Compensation Policy, each of our non-employee directors is eligible for stock
option grants on an annual basis and, for each person who first becomes a
non-employee director, an initial stock option grant. Non-employee director
stock options under the Director Compensation Policy are granted pursuant to the
2011 Plan.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Initial
Grants</FONT></I><FONT face="Times New Roman" size=2>. Each person who becomes a
non-employee director, whether by election by Geron&#146;s stockholders or by
appointment by the Board to fill a vacancy, will automatically be granted an
option to purchase 100,000 shares of Common Stock on the date such person first
becomes a non-employee director (the &#147;Initial Grant&#148;). The Initial Grant will
vest annually over three years upon each anniversary of the date of appointment
to the Board.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Annual
Grants</FONT></I><FONT face="Times New Roman" size=2>. On the date of each
annual meeting of our stockholders, each non-employee director (other than any
director receiving an Initial Grant on the date of such annual meeting) who is
then serving as a non-employee director and who will continue as a non-employee
director following the date of such annual meeting will automatically be granted
an option to purchase 50,000 shares of Common Stock (the &#147;Annual Grant&#148;). The
Annual Grant will vest in full on the earlier of: (i) the date of the next
annual meeting of our stockholders or (ii) the first anniversary of the date of
grant, subject to the non-employee director&#146;s continuous service. During 2015,
the number of shares of Common Stock subject to annual option grants was 35,000;
accordingly, each non-employee director, other than Dr. Hofstaetter, received an
annual option grant to purchase 35,000 shares of Common Stock on the date of our
2015 Annual Meeting of Stockholders. In February 2016, the Director Compensation
Policy was amended to increase the size of the Initial and Annual Grants, as
explained below. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Exercise Price and Term
of Options</FONT></I><FONT face="Times New Roman" size=2>. The exercise price of
all options granted under the 2011 Plan is equal to the fair market value of a
share of our Common Stock as reported by the NASDAQ Global Select Market on the
date of grant of the option. Options granted under the 2011 Plan have a term of
ten years from the date of grant, unless terminated earlier.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Exercise Period
Post-Termination</FONT></I><FONT face="Times New Roman" size=2>. The options
issued pursuant to the 2011 Plan remain exercisable until the earlier of the
original expiration date of the option or 36 months following the optionee&#146;s
termination of service as our director, unless such termination is a result of
death or permanent and total disability, in which case the options (both those
already exercisable and those that would have become exercisable had the
director remained on the Board for up to an additional 36 months) remain
exercisable until the earlier of the original expiration date of the option or
for up to a 36 month period following the optionee&#146;s termination of
service.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The 2011 Plan allows for
grants of discretionary restricted stock awards. In prior years, directors have
also received grants of performance-based restricted stock awards under our 2006
Directors&#146; Stock Option Plan (the &#147;2006 Directors&#146; Plan&#148;), which plan terminated
in March 2014. No restricted stock awards were granted under the 2011 Plan in
2015.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>18</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In February 2016, Radford
conducted a review of non-employee director compensation in comparison to an
industry peer group for 2016 that was selected based upon Geron&#146;s current market
capitalization, revenue, stage of development and size of company. Based on this
review, and Radford&#146;s recommendation, the Board approved an amendment to the
Director Compensation Policy to increase the size of the Initial Grant described
above from 70,000 to 100,000 shares of Common Stock and the size of the Annual
Grant from 35,000 to 50,000 shares of Common Stock, effective February 11,
2016.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Effect of Certain
Corporate Events</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>2011
Plan</FONT></I><FONT face="Times New Roman" size=2>. As set forth in each option
agreement under the 2011 Plan, the vesting for each Initial Grant and Annual
Grant will accelerate in full in the event of a Change in Control of Geron (as
defined in the 2011 Plan and described below under the section entitled
&#147;Compensation Discussion and Analysis &#150; Severance and Change in Control Benefits
&#150; Equity Plans&#148;).</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>2006 Directors&#146;
Plan</FONT></I><FONT face="Times New Roman" size=2>. Prior to March 2014, equity
awards were granted under the 2006 Directors&#146; Plan. Under the 2006 Directors&#146;
Plan, in the event of the dissolution or liquidation of the Company, a sale of
all or substantially all of the assets of the Company, the merger or
consolidation of the Company with or into another corporation in which the
Company is not the surviving corporation or any other capital reorganization in
which more than 50% of the shares of the Company entitled to vote are exchanged,
each non-employee director shall have a reasonable time within which to exercise
the option, including any part of the option that would not otherwise be
exercisable, prior to the effectiveness of such dissolution, liquidation, sale,
merger or reorganization, at the end of which time the option shall terminate.
In addition, except as otherwise provided in an award agreement, unvested shares
subject to awards of restricted stock and restricted stock units will become
fully vested immediately prior to the date of such dissolution, liquidation,
sale, merger, consolidation or reorganization.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Option Grants to
Non-Employee Directors in 2015</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following table sets
forth the following information with respect to non-employee directors (seven
persons) for the fiscal year ended December 31, 2015: (i) stock options granted
under the 2011 Plan; and (ii) the grant date fair value of stock options
granted. </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Option Awards</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Granted</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=4><B><FONT face="Times New Roman" size=1>Grant Date Fair Value
    of</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Grant</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>During 2015</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=4><B><FONT face="Times New Roman" size=1>Option Awards
  Granted</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Director</FONT></B></TD>
    <TD noWrap align=left width="87%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Date</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>(#)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=4><B><FONT face="Times New Roman" size=1>During 2015
      ($)</FONT></B><B><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Bradbury, Daniel</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>5/18/15</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><SUP>(2)</SUP></FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>96,229</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" colSpan=2><FONT face="Times New Roman" size=2>Eastham, Karin</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>5/18/15</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2><SUP>(2)</SUP></FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>96,229</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Hofstaetter, Thomas<SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" colSpan=2><FONT face="Times New Roman" size=2>Huh,
      Hoyoung</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>5/18/15</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2><SUP>(2)</SUP></FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>96,229</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Lawlis, V. Bryan</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>5/18/15</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><SUP>(2)</SUP></FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>96,229</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" colSpan=2><FONT face="Times New Roman" size=2>Molineaux, Susan</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>5/18/15</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2><SUP>(2)</SUP></FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>96,229</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Spiegel, Robert</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>5/18/15</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><SUP>(2)</SUP></FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>96,229</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR></TABLE>
<DIV>____________________</DIV><BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Amounts represent the
      grant date fair value of each stock option granted in 2015 calculated in
      accordance with FASB ASC Topic 718. For additional information, refer to
      Note 8 of the financial statements in our Annual Report on Form 10-K for
      the year ended December 31, 2015 regarding assumptions underlying the
      valuation of stock option awards and the calculation method.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Stock option vests on
      the earlier of: (i) the date of the next Annual Meeting or (ii) the first
      anniversary of the date of grant of such option, subject to the
      non-employee director&#146;s continuous service to the Company.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Dr. Hofstaetter
      retired from the Board in May 2015.</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>19</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Outstanding Equity
Awards at Fiscal Year-End for Non-Employee Directors</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following table sets
forth stock options outstanding for each non-employee director as of December
31, 2015. </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="98%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap style="text-align: center" width="7%" colSpan=7><B><FONT face="Times New Roman" size=1>Option Awards
      Outstanding</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="98%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=7><B><FONT face="Times New Roman" size=1>as of December
      31, 2015</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Director</FONT></B></TD>
    <TD noWrap align=left width="97%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Exercisable
      (#)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Unexercisable
      (#)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="98%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Bradbury, Daniel</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>140,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="98%" colSpan=2><FONT face="Times New Roman" size=2>Eastham, Karin</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>215,500</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="98%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Hofstaetter,
      Thomas<SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>76,375</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="98%" colSpan=2><FONT face="Times New Roman" size=2>Huh,
      Hoyoung</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>297,500</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="98%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Lawlis, V. Bryan</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>175,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="98%" colSpan=2><FONT face="Times New Roman" size=2>Molineaux, Susan</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>140,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="98%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Spiegel, Robert</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>175,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR></TABLE>

<div>____________________</div><BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Dr. Hofstaetter
      retired from the Board in May 2015.</FONT></TD></TR></TABLE>
<P align=center><A NAME="proposal2"></A><B><FONT face="Times New Roman" size=2>PROPOSAL 2</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>ADVISORY VOTE TO APPROVE
NAMED EXECUTIVE OFFICER COMPENSATION</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>As required by Section 951
of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Section 14A
of the Exchange Act, the Board is requesting stockholders to vote, on a
non-binding advisory basis, to approve the compensation paid to Geron&#146;s Named
Executive Officers as disclosed in this Proxy Statement in the sections
entitled, &#147;Compensation Discussion and Analysis&#148; and &#147;Executive Compensation
Tables.&#148; This proposal, commonly known as a &#147;say-on-pay&#148; proposal, gives
stockholders the opportunity to express their views on the compensation of
Geron&#146;s Named Executive Officers. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
continually reviews the compensation program for our executive officers,
including the Named Executive Officers, to determine whether the compensation
program achieves our desired goals of aligning our executive compensation
structure with the Company&#146;s stockholders&#146; interests and current market
practices. As part of its ongoing review, the Compensation Committee considered
the &#147;say-on-pay&#148; advisory vote from our 2015 Annual Meeting of Stockholders
(where approximately 91.3% of the stockholders voting on the advisory proposal
supported the proposal). We believe the outcome of the 2015 &#147;say-on-pay&#148;
advisory vote reflects our stockholders&#146; support of our executive compensation
approach, specifically the changes we implemented in the past, as discussed
below. Accordingly, no design changes were made to the executive compensation
program due to the 2015 &#147;say-on-pay&#148; advisory vote. The Compensation Committee
values the opinions of our stockholders and will continue to monitor the outcome
of future &#147;say-on-pay&#148; proposals, as well as feedback received throughout the
year from our stockholders, when making compensation decisions for our executive
officers.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In 2013, the Compensation
Committee conducted a comprehensive stockholder outreach program, and in
response, made several changes to the Company&#146;s executive compensation program.
Some of the key changes made to the executive compensation program included: i)
implementing a &#147;double-trigger&#148; requirement in order for cash severance to be
paid under our Amended Severance Plan; ii) implementing anti-hedging and
anti-pledging clauses in our Insider Trading Policy; and iii) amending all
executive officer employment agreements to include clawback provisions requiring
relinquishment of bonuses in the event an executive officer has engaged in any
misconduct or in any act or omission that would constitute cause for termination
of employment. In addition, the Compensation Committee continues to ensure that
its compensation disclosures describe the relationship between pay and
performance by providing strategic context for the corporate goal achievements.
</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>As discussed in detail in
the section entitled &#147;Compensation Discussion and Analysis&#148; of this Proxy
Statement, Geron&#146;s executive compensation strategy and structure is designed to:
i) reward successful execution of business strategy; ii) attract and retain
qualified management; and iii) align management and stockholder interests. The
Compensation Committee strives to act in the long-term best interests of Geron
and our stockholders. As described in the section entitled &#147;Compensation
Discussion and Analysis&#148;, the Compensation Committee </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>20</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><FONT face="Times New Roman" size=2>structured our 2015
executive compensation program to emphasize pay for performance and to be
competitive with the companies with whom we compete for executive talent. The
Compensation Committee believes that Geron&#146;s executive compensation program is
strongly aligned with the long-term interests of our stockholders. Please read
the &#147;Compensation Discussion and Analysis&#148; section of the Proxy Statement for
additional details about our executive compensation program, including
information about the 2015 compensation of our Named Executive
Officers.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Advisory Vote and Board
Recommendation</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We request stockholder
approval of the 2015 compensation of our Named Executive Officers as disclosed
in this Proxy Statement pursuant to the SEC&#146;s compensation disclosure rules
which disclosure includes the section entitled &#147;Compensation Discussion and
Analysis,&#148; and the compensation tables and accompanying narrative disclosures
within the section entitled &#147;Executive Compensation Tables&#148; of this Proxy
Statement. This vote is not intended to address any specific element of
compensation, but rather the overall compensation of our Named Executive
Officers and the compensation philosophy, policies and practices described in
this Proxy Statement. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Accordingly, the Board
recommends that stockholders vote in favor of the following
resolution:</FONT></P>
<P style="padding-left: 15pt" align=justify><B><FONT face="Times New Roman" size=2>&#147;RESOLVED, that the
stockholders approve, on a non-binding advisory basis, the compensation paid to
Geron&#146;s Named Executive Officers, as disclosed in the Compensation Discussion
and Analysis section, the tabular disclosure regarding such compensation and the
accompanying narrative disclosure set forth in the Proxy Statement relating to
the Company&#146;s 2016 Annual Meeting of Stockholders.&#148;</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Approval of the above
resolution requires the affirmative vote of the shares present in person or
represented by proxy at this meeting. Abstentions will have the same effect as a
vote against this proposal, and broker non-votes will have no effect on the
outcome of this proposal. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Stockholders are not being
asked to approve or disapprove the Board&#146;s recommendation. As this is an
advisory vote, the outcome of the vote is non-binding on us with respect to
future executive officer compensation decisions, including those related to our
Named Executive Officers, or otherwise. However, the Board and the Compensation
Committee will review the results of the vote and take them into account when
considering future executive officer compensation policies and decisions.
</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board has approved
holding a &#147;say-on-pay&#148; advisory vote every year. Unless the Board modifies its
policy on the frequency of future &#147;say-on-pay&#148; advisory votes, the next
&#147;say-on-pay&#148; advisory vote will be held at the 2017 Annual Meeting of
Stockholders. In addition, our stockholders will be able to indicate by advisory
vote at the 2017 Annual Meeting of Stockholders their preference as to the
frequency of future advisory votes.</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>The Board of Directors
Unanimously Recommends That<BR></FONT></B><B><FONT face="Times New Roman" size=2>Stockholders Vote <U>FOR</U> Proposal 2</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="CompensationDiscussionandAnalysis"></A>COMPENSATION DISCUSSION
AND ANALYSIS</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>This Compensation
Discussion and Analysis section presents and discusses executive compensation
policies and practices and the compensation decisions relating to the &#147;Named
Executive Officers&#148; (as defined below) for the 2015 fiscal year, and includes
the following:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><FONT face="Times New Roman" size=2>an
      executive summary of the compensation program for the Named Executive
      Officers;<BR>&nbsp; </FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">an overview of the executive compensation
      program;<BR>&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">the role of the Compensation
      Committee;<BR>&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">a detailed discussion and analysis of the
      Compensation Committee&#146;s specific decisions about the 2015 compensation
      for the Named Executive Officers;<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><FONT face="Times New Roman" size=2>a
      description of the employment agreements for the Named Executive Officers;
      and <BR>&nbsp;</FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><FONT face="Times New Roman" size=2>a summary
      of the potential severance benefits for the Named Executive Officers in
      the event of a change in control. </FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>21</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In addition to the
historical information contained herein, this Compensation Discussion and
Analysis also contains forward-looking statements based on current plans,
considerations, expectations and determinations regarding future compensation
decisions. The actual compensation program that we adopt in the future may
differ materially from the current program summarized in this discussion.
</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following executive
officers are collectively referred to herein as the Named Executive
Officers:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>Dr. John A. Scarlett,
      President and Chief Executive Officer; <BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">Ms. Olivia K. Bloom, Executive Vice President,
      Finance, Chief Financial Officer and Treasurer;<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">Ms. Melissa A. Kelly Behrs, Executive Vice
      President, Business Development and Portfolio &amp; Alliance Management;
      <BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><FONT face="Times New Roman" size=2>Dr. Andrew
      J. Grethlein, Executive Vice President, Development and Technical
      Operations; and <BR>&nbsp;</FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><FONT face="Times New Roman" size=2>Mr. Stephen
      N. Rosenfield, Executive Vice President, General Counsel and Corporate
      Secretary. </FONT></TD></TR></TABLE>
<P align=justify><B><FONT face="Times New Roman" size=2>Executive
Summary</FONT></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Effect of Prior Year Stockholder
Advisory Vote on Executive Compensation</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>At our 2015 Annual Meeting
of Stockholders held in May 2015, we sought an advisory vote from our
stockholders regarding the compensation of our named executive officers
(commonly referred to as a &#147;say-on-pay&#148; proposal). The 2015 &#147;say-on-pay&#148;
proposal was approved, with approximately 91.3% of votes cast supporting the
proposal. The Compensation Committee considers the results of the advisory vote
as it completes its annual review of each pay element and the compensation
packages provided to our Named Executive Officers and other executive officers.
The Compensation Committee considered the outcome of the 2015 &#147;say-on&#150;pay&#148; vote
and did not make any changes to Geron&#146;s executive compensation program for 2015
as a result of the vote.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Business Highlights that Impacted
2015 Compensation Decisions</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In 2015, executive
compensation decisions were influenced highly by retention challenges stemming
from the significant uncertainty relating to our future, given that we are
wholly dependent on the collaboration with Janssen Biotech, Inc. (&#147;Janssen&#148;) to
further develop, manufacture and commercialize imetelstat, which was our sole
product candidate, and the unknown outcome of our efforts to identify and
acquire and/or in-license other oncology products, product candidates, programs
or companies to grow and diversify our business. In addition, the previous
restructurings we implemented, including an organizational resizing in March
2015, have significantly reduced our personnel resources, which requires that
most of the remaining employees, including executive officers, must perform
additional and a broader range of responsibilities to ensure achievement of our
corporate objectives. Lastly, our compensation program has been designed to
effectively compete for qualified biotechnology employees, including executive
officers, in local market environment where numerous opportunities are
available. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our corporate goals for
2015 primarily focused on supporting our collaboration with Janssen to
facilitate initiation of two imetelstat clinical trials in two hematologic
malignancies by Janssen, the search and evaluation process regarding potential
assets or companies for us to acquire and/or in-license and maintaining fiscal
responsibility. The Compensation Committee and the Board evaluated our key
achievements in 2015 and determined that we fully achieved our 2015 corporate
goals. The Compensation Committee and the Board also determined that our Named
Executive Officers, including our Chief Executive Officer, made crucial
contributions towards accomplishment of these corporate goals, as well as
successfully leading individual, team, departmental and functional performance
and achievements. For details regarding our achievement of corporate goals in
2015, see the section entitled &#147;Compensation Discussion and Analysis &#150; 2015
Corporate Goal Achievement Factor&#148;. </FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Emphasis on Pay for
Performance</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We structure a significant
portion of our executive officers&#146; total compensation to be variable, at risk
and tied directly to our measurable performance. For 2015, 76.9% of our Chief
Executive Officer&#146;s total compensation was linked to performance. &#147;Total
compensation&#148; referred to in this Compensation Discussion and Analysis consists
of annual base salary, annual incentive bonus and the grant date value of equity
awards as reported in the &#147;Summary Compensation Table&#148;.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>22</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The annual incentive bonus
for our Chief Executive Officer is entirely dependent upon the achievement of
our annual corporate goals, which are approved at the beginning of the year by
our Board. The annual incentive bonus for our other Named Executive Officers is
dependent upon achievement of our annual corporate goals, as well as each
executive officer&#146;s achievement of their respective individual goals and
demonstration of our corporate values. None of our Named Executive Officers,
including our Chief Executive Officer, are entitled to guaranteed or minimum
bonuses under our annual incentive bonus plan.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Long-term incentive awards
for 2015 consisted solely of stock options, which provide value only if the
market price of our Common Stock increases, and then only if the executive
officer continues in our employment. Therefore, these equity awards strongly
align our executive officers&#146; interests with those of our stockholders by
providing a continuing financial incentive to maximize long-term value, keeping
the executive officers&#146; total compensation opportunity competitive and
encouraging our executive officers to remain in the long-term employ of our
Company. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
believes that this structure: (i) strongly aligns the interests of our executive
officers with those of our stockholders by placing a considerable proportion of
our executive officers&#146; total compensation &#147;at risk&#148; because it is contingent on
the appreciation in value of our Common Stock; (ii) ties their compensation to
the achievement of specific and objective corporate goals; and (iii) promotes
retention.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Market
Positioning</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
actively reviews and assesses our executive compensation program in light of the
highly competitive employment environment in the San Francisco Bay Area, the
challenge of recruiting, motivating and retaining executive officers in an
industry with much longer business cycles than other commercial industries, and
evolving compensation governance and best practices. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
uses Radford, an independent compensation consultant, to assess our executive
compensation program against market data. The Radford market data provides
information on the total compensation paid to executive officers in comparable
positions and responsibilities. The Compensation Committee referenced this
market data, along with other factors, when setting our Named Executive
Officers&#146; 2015 total compensation (base salary, annual incentive bonus and
equity awards value). The Compensation Committee believes referencing Radford&#146;s
market data is appropriate because competition for executive management is
intense in our industry and in our geographic area, and continued leadership
from our executive officers is deemed critical to our success. For more
information on our use of market data, see &#147;Use of Market Data&#148;
below.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Commitment to Compensation
Governance</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We are committed to having
strong governance standards with respect to our compensation program, procedures
and practices, which include:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><I><FONT face="Times New Roman" size=2>Independent
      Compensation Consultant Advice.</FONT></I><FONT face="Times New Roman" size=2> The Compensation Committee engages, on an annual basis, an
      experienced, independent compensation consultant who reports directly to
      the Compensation Committee to advise on executive cash and equity
      compensation matters. <BR>&nbsp;</FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><I><FONT face="Times New Roman" size=2>Responsible Internal
      Pay Equity.</FONT></I><FONT face="Times New Roman" size=2> For 2015, our
      Chief Executive Officer&#146;s total cash compensation was less than two and
      one-half times the average total cash compensation of our other Named
      Executive Officers, which reflects internal fairness and an important
      element designed to avoid excessive compensation of the Chief Executive
      Officer. <BR>&nbsp;</FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><I><FONT face="Times New Roman" size=2>Limited Personal
      Benefits.</FONT></I><FONT face="Times New Roman" size=2> Our executive
      officers are eligible for the same benefits as non-executive, salaried
      employees, and do not receive any personal benefits other than
      reimbursements for housing costs and travel expenses for Dr. Scarlett, our
      President and Chief Executive Officer, for the commute from his principal
      residence in Texas to our headquarters in Menlo Park, California.
      <BR>&nbsp;</FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><I><FONT face="Times New Roman" size=2>No Tax Gross-Ups on
      Compensation.</FONT></I><FONT face="Times New Roman" size=2> None of our
      executive officers receive tax related gross-ups on any element of
      compensation. </FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>23</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><I><FONT face="Times New Roman" size=2>No Single-Trigger
      Change in Control Cash Benefits.</FONT></I><FONT face="Times New Roman" size=2> Executive officer employment agreements and our Amended Severance
      Plan (as defined under the sub-section entitled &#147;Severance and Change in
      Control Benefits&#148;) permit payment of cash benefits in connection with a
      Change in Control (as defined under the sub-section entitled &#147;Severance
      and Change in Control Benefits&#148;) only if an executive officer&#146;s position
      is terminated or the executive officer resigns due to a material adverse
      change in his or her employment terms. <BR>&nbsp;</FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><EM><FONT face="Times New Roman">Clawback
      Terms.</FONT></EM><FONT face="Times New Roman" size=2> Executive officer
      employment agreements require that an executive officer forfeit his/her
      entire annual incentive bonus if we determine that such executive officer
      has engaged in any misconduct intended to affect the payment of his or her
      annual incentive bonus, or has otherwise engaged in any act or omission
      that would constitute cause for termination of his/her employment, as
      defined by his or her employment agreement. <BR>&nbsp;</FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><I><FONT face="Times New Roman" size=2>No Retirement
      Benefits.</FONT></I><FONT face="Times New Roman" size=2> We do not offer
      any defined benefit pension plans or health benefits during
      retirement.<BR>&nbsp; </FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><I><FONT face="Times New Roman" size=2>No Hedging or
      Pledging.</FONT></I><FONT face="Times New Roman" size=2> Our Insider
      Trading Policy prohibits employees from engaging in speculative trading
      activities, including hedging or pledging company securities as
      collateral. Accordingly, our employees, including our executive officers,
      may not hedge the economic risk of, or pledge ownership of, our Common
      Stock. </FONT></TD></TR></TABLE>
<P align=justify><B><FONT face="Times New Roman" size=2>Overview of the
Executive Compensation Program </FONT></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Philosophy and Objectives
</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The overall objective of
our compensation program is to support business objectives by attracting,
retaining and engaging the highest caliber of employees, including executive
officers, while maintaining a fiscally responsible position in a highly
competitive employment environment. Consistent with this overall objective, the
goals of the executive compensation program are to:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><FONT face="Times New Roman" size=2>pay
      appropriate cash and equity compensation to executive officers for
      retention purposes during periods of significant uncertainty;
      <BR>&nbsp;</FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">attract and retain executive officers that can
      lead capably by incentivizing them with competitive cash and non-cash
      compensation opportunities;<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><FONT face="Times New Roman" size=2>enable a
      high performing culture by employing and retaining successful and
      experienced executive officers; <BR>&nbsp;</FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><FONT face="Times New Roman" size=2>encourage
      and inspire executive officers to achieve key corporate strategic and
      financial objectives by linking incentive award opportunities to the
      achievement of individual and corporate goals; and <BR>&nbsp;</FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><FONT face="Times New Roman" size=2>align the
      interests of executive officers with stockholders by motivating executive
      officers to focus on achievements that will result in an increase in value
      for our stockholders and reward executive officers for excellence in
      performance. </FONT></TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
reviews and approves the compensation of our executive officers (except for the
Chief Executive Officer, whose compensation is approved by the Board upon
recommendation from the Compensation Committee), including salaries, annual
incentive bonuses, equity awards and any other benefits. As discussed in further
detail below, the 2015 compensation program for the Named Executive Officers was
intended to strike an appropriate balance among base salary, annual incentive
bonuses and equity awards. The Compensation Committee strives to act in the best
interests of Geron and our stockholders, as well as to ensure that the elements
of compensation do not, individually or in the aggregate, encourage excessive
risk taking.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>24</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Components </FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The components of the
executive compensation program consist primarily of base salary, annual
incentive bonuses, equity awards and broad-based benefits that we offer to all
employees. To provide competitive total compensation to executive officers, we
utilize a mix of cash (base salaries and annual incentive bonuses) and long-term
incentives (equity awards) that are competitive with the San Francisco Bay Area
employment market. The Compensation Committee has structured our executive
compensation program to ensure that executive officers are compensated in a
manner consistent with stockholder interests, competitive pay practices and
applicable requirements of regulatory bodies. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
does not have any formal policies for allocating compensation among the various
components of compensation. Instead, the Compensation Committee uses its
judgment to establish for each Named Executive Officer a mix of current,
short-term and long-term incentive compensation, and cash and equity
compensation that it believes appropriate to achieve the compensation and
corporate objectives described above. However, because we believe it is
important to our success to aggressively pursue long-term goals, to avoid
excessive risk taking, to preserve our cash resources, and to further our
pay-for-performance philosophy, a significant portion of our Named Executive
Officers&#146; total compensation is comprised of performance-based bonus
opportunities and long-term equity awards, which align the Named Executive
Officers&#146; incentives with the interests of our stockholders.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><U>Base
Salary</U></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Base salaries serve to
provide fixed cash compensation to our executive officers for performing daily
responsibilities, and also provide stability and security. We establish base
salaries for our executive officers when they join our Company or upon
promotion. In addition, base salaries for executive officers are reviewed and
determined by the Compensation Committee (or the Board with respect to our Chief
Executive Officer, upon recommendation from the Compensation Committee) on an
annual basis, in consultation with our independent compensation consultant,
Radford. Such annual adjustments are based on factors which may include each
executive officer&#146;s position and specific responsibilities, individual
performance, level of experience, achievement of corporate and strategic goals,
and a review of competitive salary, total compensation market data, and cost of
living increases in the San Francisco Bay Area. The Compensation Committee does
not apply any specific formulas to determine increases in base salaries for our
executive officers, but instead makes an evaluation of each executive officer&#146;s
contributions to Geron&#146;s long-term success. Generally, any increase in base
salary beyond a cost of living increase is based on an evaluation of the
individual&#146;s performance, changes in responsibilities or position and the
individual&#146;s criticality to our future plans. Increases in base salary,
including cost of living increases, typically take effect on January
1<SUP>st</SUP> of each calendar year.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><U>Annual Incentive
Bonuses</U></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Under our annual incentive
bonus plan, every employee, including executive officers, has an established
annual incentive bonus target, which is equal to a percentage of the employee&#146;s
base salary. This percentage increases as levels of responsibility and title
increase. Each employee&#146;s actual earned annual incentive bonus, if any, is
calculated based on: (1) corporate goal achievement (the &#147;corporate goal
achievement factor&#148;), (2) individual performance achievements (the &#147;individual
performance factor&#148;) and (3) support of corporate values (the &#147;corporate values
performance factor&#148;). </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>For more senior employees
and executive officers, the corporate goal achievement factor is weighted more
heavily and thus has greater influence on the annual incentive bonus, as
performance from these individuals has a larger impact on corporate goal
achievement. This practice is designed to create a direct link between executive
compensation and achievement of operational and financial objectives to provide
motivation for executive officers to implement strategic initiatives intended to
meet or exceed pre-established corporate goals.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>At the beginning of each
year, the Chief Executive Officer develops, with input from our executive
management, the annual corporate goals, which generally relate to our
operational and financial objectives, together with recommended weightings for
each goal, and presents the annual corporate goals and recommended weightings to
the Compensation Committee and the Board. The weighting for each corporate goal
depends on its importance and business value for Geron and our stockholders. The
Board reviews the corporate goals and weightings and adjusts them as necessary
prior to approval. </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>25</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>As part of the annual
year-end performance review process, the Compensation Committee, taking into
consideration recommendations from the Chief Executive Officer, evaluates the
overall achievement of our corporate goals during the preceding year and other
significant company accomplishments, while taking into consideration the degree
of difficulty in achieving the corporate goals and any particular events or
circumstances that impacted performance. The corporate goal achievement factor
generally ranges from 0 to 1.0 and is approved by the Board upon recommendation
from the Compensation Committee based upon the Board&#146;s assessment of the
Company&#146;s achievement of that year&#146;s annual corporate goals. The Board has the
discretion to approve a corporate goal achievement factor above 1.0 in
extraordinary circumstances where it determines such an increase is
warranted.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Chief Executive
Officer&#146;s annual incentive bonus is based entirely on the corporate goal
achievement factor. The annual incentive bonus for each of our Named Executive
Officers, other than the Chief Executive Officer, is based on the corporate goal
achievement factor, the individual performance factor and the corporate values
performance factor. The Chief Executive Officer presents to the Compensation
Committee written assessments of the performance and achievements, including
support of our corporate values, for each of the executive officers (other than
himself) for the prior year and recommends the individual performance factor and
the corporate values performance factor for each executive officer (other than
himself). The Compensation Committee reviews the individual performance factor
and the corporate values performance factor for each of the executive officers
(other than the Chief Executive Officer) and adjusts the factors as necessary
prior to approval. The corporate values performance factor ranges from 0 to 1.0,
based on the extent to which an executive officer, including the Named Executive
Officers, other than the Chief Executive Officer, supported corporate value
adherence. The individual performance factor may range from 0 to 1.3, and this
is the primary factor that increases an annual incentive bonus above the annual
target incentive bonus percentage for any executive officer, including the Named
Executive Officers, other than the Chief Executive Officer. The Compensation
Committee has the discretion to approve an individual performance factor above
1.3 upon evaluation of appropriate criteria. There are no minimum or guaranteed
bonus payments for employees, including the Named Executive Officers.
</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><U>Equity Awards</U>
</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Equity awards are designed
to encourage high performance by and long-term tenure for executive officers,
thereby strongly aligning executive officers&#146; interests with the interests of
our stockholders. Equity awards in 2015 were comprised solely of stock option
grants under our 2011 Plan. Such grants encourage employee ownership in Geron,
link pay with performance and align the interests of stockholders and employees.
Only through sustained, increasing price per share performance in our Common
Stock, can our employees, including the Named Executive Officers, have an
opportunity to realize any value from equity-based awards. The Compensation
Committee (and the Board, with respect to our Chief Executive Officer)
determines the size of any stock option grant according to each executive
officer&#146;s position. To do so, the Compensation Committee generally references
the market data provided by Radford. The Compensation Committee also takes into
consideration each Named Executive Officer&#146;s recent performance history, his or
her potential for future responsibility, and criticality of his or her work to
the long-term success of the Company. Other factors may include equity awards
previously granted, the amount of actual versus theoretical equity value per
year that has been derived to date by the individual, the current actual value
of unvested equity grants for each individual, the percentage of stock option
grants with exercise prices greater than Geron&#146;s current stock price and the
number of stock option grants that have expired unexercised as a result of
market conditions. The Compensation Committee has the discretion to give
relative weight to each of these factors as it sets the size of the stock option
grant to appropriately create an opportunity for reward based on increasing
stockholder value. There is no set formula for the granting of stock options or
other equity awards to employees, including the Named Executive Officers.
</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
grants equity awards to newly hired and existing executive officers, except the
Chief Executive Officer, with respect to whom the Board determines equity awards
based on the recommendation of the Compensation Committee. Our general policy is
to grant stock options and other equity awards on fixed dates determined in
advance, although there are occasions when grants are made on other dates. All
required approvals are obtained in advance of or on the actual grant date. Other
than stock option grants to new hires, stock option grants to executive officers
are generally approved once a year (typically near the beginning of the year)
unless an executive officer is promoted, in which case a grant will normally be
made at the time of such promotion, </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>26</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><FONT face="Times New Roman" size=2>or, in rare circumstances,
for recognition of outstanding performance. With respect to annual stock option
grants to our continuing executive officers, these grants are typically approved
early in each fiscal year and prior to the full release of our annual financial
and operating results for that year. Since our full annual financial and
operating results are typically not disclosed prior to approval of annual stock
option grants for our executive officers, in 2015, we adopted an equity
incentive grant policy that provides that if at the time the Compensation
Committee (or the Board, in the case of the Chief Executive Officer) approves
annual equity awards to our executive officers (and other employees) when our
trading window is closed, then the annual equity awards that are approved for
executive officers (and other employees) will be granted on the second trading
day following the filing date with SEC of our next quarterly or annual report
that occurs after the date on which such grants are approved by the Board or the
Compensation Committee, as applicable. Accordingly, our equity incentive grant
policy provides the market with an opportunity to absorb the financial and other
information included in our annual and periodic reports before annual equity
awards are effective. As a result, the timing of annual equity awards to our
continuing executive officers is not coordinated in a manner that intentionally
benefits our executive officers; rather, the policy is designed with the
objective to generally allow the market price of our common stock to reflect our
then-current results and prospects at the time the annual equity grant becomes
effective and the exercise price is set.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The exercise price of all
stock option grants is equal to the closing price of Geron Common Stock as
reported by the NASDAQ Global Select Market on the date of grant, so executive
officers who receive stock option grants do not realize any compensation from
such stock option grants unless the stock price increases above the exercise
price. In this manner, the interests of our stockholders, and executive officers
during their employment, are aligned for the long-term success of
Geron.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Geron&#146;s standard vesting
schedule for the first stock option grant awarded to newly hired employees,
including executive officers, provides that 12.5% of the shares granted will
vest six months after the date of the grant, and the remaining shares will vest
in equal monthly installments over the following 42 months so that vesting is
complete four years from the date of grant, provided the employee continues to
provide services to the Company during that time. Additional option grants made
after an employee, including an executive officer, has provided services to the
Company for more than six months generally vest monthly from the date of grant
over four years.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><U>Broad-Based Benefits and
Other Compensation</U></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Benefit programs include a variety of health
insurance plans,401(k) plan with Company matching contributions  at Board-approved levels, employee stock purchase plan and
flexible spending 125  cafeteria plan covering health and dependent care services. These benefits are  offered to all
employees, including executive officers. We do not offer defined  benefit pension or other supplementary retirement benefits
to employees.  Currently, Dr. Scarlett also receives housing and travel expense reimbursements  for the commute from his
principal residence in Texas to our headquarters in  Menlo Park, California.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Role of the Compensation
Committee</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
acts on behalf of the Board with respect to overseeing our compensation program
and policies and in determining total compensation for executive officers,
including the Named Executive Officers, other than our Chief Executive Officer.
Compensation Committee members are independent of management and meet the NASDAQ
listing standards for independence. Typically, the Compensation Committee meets
at least once quarterly and with greater frequency if necessary. The agenda for
each meeting is usually developed by the Chair of the Compensation Committee, in
consultation with the Chief Executive Officer, Executive Director of Human
Resources, General Counsel and Radford. The Compensation Committee also meets in
executive session without the presence of any employees. The Compensation
Committee exercises independent judgment in allocating between cash and equity
compensation. In setting the annual level of cash and equity compensation for
executive officers, the Compensation Committee typically considers various
factors, which include: corporate performance, our achievement toward meeting
annual corporate goals, each executive officer&#146;s individual performance, the
criticality of each executive officer&#146;s skill set, and market data for our
industry. Each of these factors is balanced against Geron&#146;s ability to award
cash and equity incentives. The Compensation Committee has the authority to
retain special counsel and other experts, including compensation consultants, to
support their responsibilities in determining executive officer compensation and
related benefits. Since December 2011, the </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>27</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><FONT face="Times New Roman" size=2>Compensation Committee has
retained Radford as its independent compensation consultant due to its extensive
analytical and consulting work in the biotech/pharmaceutical industry. In this
capacity, Radford has provided documentary support, including industry data from
third-party salary survey sources, and recommendations related to cash and
equity compensation for executive officers and members of the Board.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In February 2015, the  Compensation
Committee reviewed information from Radford about potential  conflicts of interest and analyzed whether the work of Radford
as a compensation  consultant has raised any conflict of interest, taking into consideration the  following factors: i) the
provision of other services to Geron by Radford or any  other Aon Hewitt Company; ii) the amount of fees Geron paid to
Radford or any  other Aon Hewitt Company as a percentage of the firm&#146;s total revenue; iii)  Radford&#146;s policies and
procedures that are designed to prevent conflicts of  interest; iv) any business or personal relationship of Radford, any
other Aon  Hewitt Company or the individual compensation advisors employed by Radford with  an executive officer of the
Company; v) any business or personal relationship of  the individual compensation advisors with any member of the
Compensation  Committee; and vi) any Geron Common Stock owned by the individual compensation  advisors employed by Radford.
Based on these factors, the Compensation Committee  determined that there were no conflicts of interest with respect to
Radford  providing services to the Compensation Committee. In 2015, fees paid to Radford for their services as a compensation
consultant to the  Compensation Committee regarding executive and Board compensation amounted to less than 1% of Radford's
total revenue for the same period. In February 2016, the Compensation Committee performed a similar analysis of Radford&#146;s
independence, and noted no conflicts of interest.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
reviews, and thereafter recommends to the Board, both the establishment and
assessment of achievement of annual corporate goals for the annual incentive
bonus plan. With respect to the assessment of achievement of annual corporate
goals, the Board considers the recommendations of the Compensation Committee and
may accept or modify such recommendations before approval. To aid the
Compensation Committee in its responsibilities, the Chief Executive Officer,
with assistance from the General Counsel and Executive Director of Human
Resources, provides the Compensation Committee with recommendations relating to
the achievement of our annual corporate goals, individual performance of
executive officers and cash and equity compensation recommendations for each
executive officer. In making decisions concerning compensation for executive
officers, the Compensation Committee gives considerable weight to the Chief
Executive Officer&#146;s performance evaluations of the executive officers, since he
has direct knowledge of the criticality of their work, performance and
contributions. The Compensation Committee does not consult with any other
executive officer with regard to its decisions. The Chief Executive Officer does
not participate in the Compensation Committee&#146;s or Board&#146;s deliberations or
decisions with regard to his own compensation, which must be approved by the
Board.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Use of Market
Data</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In January 2015, based on
the recommendation of Radford, the Compensation Committee determined that
Radford&#146;s 2015 Global Life Sciences Survey data, rather than a defined peer
group, was appropriate for determining competitive benchmarks in connection with
2015 executive officer compensation decisions. Radford recommended that the
Compensation Committee not define a peer group for 2015 due to the significant
changes in our business at the end of 2014, including our substantial dependence
on our collaboration with Janssen to further develop, manufacture and
commercialize imetelstat, our volatile market capitalization, reduced headcount,
declining research and development expenses and necessity to retain key
executive officers. Accordingly, in evaluating 2015 executive compensation, the
Compensation Committee referenced the Radford Global Life Sciences Survey, which
consisted of market data from 73 biopharmaceutical companies that were public,
pre-commercial and had headcounts of fewer than 100 employees, in order to
reference market data more closely aligned with Geron&#146;s competitive position in
2015. We refer to the data from Radford that the Compensation Committee reviewed
as the &#147;market data&#148;.
</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation
Committee&#146;s compensation decision-making strategy for 2015, in consultation with
Radford, was to reference the market data provided by Radford in combination
with multiple other factors, such as the executive officers&#146; respective levels
of experience and responsibility, prior performance, specific skills or
competencies, criticality for retention, internal pay equity, the desired pay
mix (including the other compensation elements provided to the executive officers), and our budget,
in assessing the appropriate total compensation</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>28</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><FONT face="Times New Roman" size=2>(consisting of base salary, annual incentive bonus and value of equity
awards) for all Named Executive Officers for 2015. Due to the characteristics of the companies referenced in the 2015 market
data provided by Radford, the compensation values for executive officers at such companies were generally lower than compensation
values for executive officers in the 2014 peer group utilized by the Compensation Committee in 2014. Consequently, total
compensation for all Named Executive Officers resulted in being at or above the 75<SUP>th</SUP> percentile of the 2015 market
data. The Compensation Committee deemed this level to be appropriate due to the significant business changes at the Company
in 2015, including our corporate restructuring in 2015, and in recognition of the additional and broader range of
responsibilities required of our executive officers to achieve our corporate objectives. The Compensation Committee also
believes this strategy was necessary and appropriate in 2015 in order to retain top executive talent in the competitive
environment in which we operate.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Compensation Risk
Assessment</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
annually evaluates Geron&#146;s compensation elements of base salary, annual
incentive bonuses, equity awards, severance and change in control benefits,
other benefits and Geron&#146;s compensation philosophy generally as it relates to
all employees. The Compensation Committee believes the following elements of
Geron&#146;s compensation practices that comprise our compensation program mitigate
the risks associated with our compensation practices:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">performance assessment based upon a mix of
      individual and corporate performance and achievement;<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><FONT face="Times New Roman" size=2>annual
      incentive bonuses determined by performance with no minimum payments;
      <BR>&nbsp;</FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><FONT face="Times New Roman" size=2>utilization
      of a combination of cash and equity awards to encourage short-term and
      long-term incentives; <BR>&nbsp;</FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><FONT face="Times New Roman" size=2>absence of
      employment agreements or contracts that contain multi-year guarantees of
      salary increases, non-performance-based bonuses or equity compensation;
      and <BR>&nbsp;</FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><FONT face="Times New Roman" size=2>emphasis on
      equity amongst our employees and in comparison with external benchmarks.
      </FONT></TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
has reviewed our compensation policies and practices as they relate to all
employees and has determined that such policies and practices do not present any
risks that are reasonably likely to have a material adverse effect on
Geron.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Compensation Decisions
in 2015</FONT></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>2015 Base
Salaries</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2>In the first quarter of
2015, the Compensation Committee performed its annual analysis of base salaries
for all of our executive officers using market data provided by Radford. The
market data analysis showed that each of our Named Executive Officers&#146; base
salaries at the end of 2014 was at or around the 75<SUP>th</SUP> percentile of
the market data provided by Radford. In setting salaries for 2015, the
Compensation Committee considered the results of the market data analysis, the
recent individual performance of each Named Executive Officer in 2014, breadth
and length of service, the anticipated level of difficulty in replacing an
executive officer with someone of comparable experience and skill, especially
given significant uncertainty relating to our future, since we are wholly
dependent on the collaboration with Janssen to further develop, manufacture and
commercialize imetelstat, which was our sole product candidate, and the unknown
outcome of our efforts to identify and acquire and/or in-license other oncology
products, product candidates, programs or companies to grow and diversify our
business. Based on the foregoing considerations, including the need for
retention of the Named Executive Officers, and based on the recommendation of
Radford, the Compensation Committee and, with respect to Dr. Scarlett, the
Board, approved a cost of living adjustment of 3.0% for each of the Named
Executive Officers. </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>29</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><FONT face="Times New Roman" size=2>The following 2015 base
salaries for the Named Executive Officers were effective as of January 1,
2015.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>2014</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=4><B><FONT face="Times New Roman" size=1>Salary</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>2015</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"><B><FONT face="Times New Roman" size=1>Named Executive
    Officer</FONT></B></TD>
    <TD noWrap align=left width="82%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Base
    Salary</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=4><B><FONT face="Times New Roman" size=1>Increase
      (%)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Base
    Salary</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>586,500</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>604,095</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2><FONT face="Times New Roman" size=2>Olivia K. Bloom</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>365,000</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>3.0</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>375,950</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Melissa A. Kelly Behrs</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>352,000</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>362,560</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2><FONT face="Times New Roman" size=2>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>379,000</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>3.0</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>390,370</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Stephen N. Rosenfield, J.D.</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>390,000</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>401,700</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><SUP>(1)</SUP></FONT></TD></TR></TABLE><DIV>____________________</DIV><BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)</FONT></TD>
    <TD vAlign=top noWrap>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top width="100%"><FONT face="Times New Roman" size=2>We employ
      Mr. Rosenfield at 80% full-time equivalent. Thus, the actual base salary
      paid to Mr. Rosenfield is 80% of the amounts presented in the
    table.</FONT></TD></TR></TABLE>
<P align=justify><B><I><FONT face="Times New Roman" size=2>2015 Annual Incentive
Bonuses</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Named Executive
Officers&#146; 2015 annual incentive bonus targets, as a percentage of base salary,
which were 45% for the executive vice president position, and 60% for the Chief
Executive Officer position, remained at the same historical levels that we have
applied since 2010. The market data provided by Radford showed the annual
incentive bonus targets for each of our Named Executive Officers in 2015 were
above the 75<SUP>th</SUP> percentile of the market data provided by Radford. The
Compensation Committee determined that these 2015 targets were appropriate in
light of the broad range of functions for which our Named Executive Officers
were accountable to ensure achievement of our 2015 corporate objectives, and
strengthened our ability to retain our Named Executive Officers in a competitive
job market. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>For 2015, Dr. Scarlett&#146;s
annual incentive bonus was 100% contingent upon achievement of our corporate
goals. For 2015, other than Dr. Scarlett, each Named Executive Officer&#146;s annual
incentive bonus was contingent on the following: 50% upon achievement of our
corporate goals, 30% upon achievement of individual goals, and 20% upon
individual support and manifestation of our corporate values. The table below
summarizes the annual incentive bonus targets as a percentage of annual salary
for each of our Named Executive Officers for 2015. </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Annual Incentive
    Bonus</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="5%"><B><FONT face="Times New Roman" size=1>Named Executive
    Officer</FONT></B></TD>
    <TD noWrap align=left width="88%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Target as a %
      of Salary</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>60</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" colSpan=2><FONT face="Times New Roman" size=2>Olivia K. Bloom</FONT></TD>
    <TD noWrap align=right width="2%">&nbsp;</TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>45</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="2%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Melissa A. Kelly Behrs</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>45</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" colSpan=2><FONT face="Times New Roman" size=2>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD noWrap align=right width="2%">&nbsp;</TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>45</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Stephen N. Rosenfield, J.D.</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>45</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>30</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><FONT face="Times New Roman" size=2><U>2015 Corporate Goal
Achievement Factor</U></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The table below summarizes
the corporate goals approved by the Board for 2015, including assigned
weightings, and the Compensation Committee&#146;s and Board&#146;s assessment of the level
of achievement of those goals in 2015. The corporate goals for 2015 primarily
focused on supporting our collaboration with Janssen to facilitate initiation of
two imetelstat clinical trials in two hematologic malignancies by Janssen, the
search and evaluation process of potential assets or companies for us to acquire
and/or in-license and maintaining fiscal responsibility. Based on the
achievements noted below, the Board deemed these corporate goals to be fully
achieved for 2015.</FONT></P>
<TABLE style="LINE-HEIGHT: normal; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; BORDER-LEFT: #000000 1pt solid; WIDTH: 34%; PADDING-TOP: 2pt; TEXT-ALIGN: left" noWrap></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; TEXT-ALIGN: left" noWrap></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 35%; PADDING-TOP: 2pt; TEXT-ALIGN: left" noWrap></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Percentage</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; TEXT-ALIGN: left" noWrap></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; BORDER-LEFT: #000000 1pt solid; WIDTH: 34%; PADDING-TOP: 2pt; TEXT-ALIGN: left" noWrap></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Weighting</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 35%; PADDING-TOP: 2pt; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Highlights of</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Achievement</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Total</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; BORDER-LEFT: #000000 1pt solid; WIDTH: 34%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left" noWrap><B><FONT face="Times New Roman" size=1>2015 Corporate
      Goals</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>(A)</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 35%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Company
      Performance</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>(B)</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>(A x B)</FONT></B></TD></TR>
  <TR>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; BORDER-LEFT: #000000 1pt solid; WIDTH: 34%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left" bgColor=#cceeff>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -15.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">1)</FONT><FONT face="Times New Roman" size=2>Complete Geron&#146;s transition of imetelstat
      development related activities to Janssen by end of Q3
    2015.</FONT></DIV></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 10%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap bgColor=#cceeff>
      <P align=center><FONT face="Times New Roman" size=2>25%</FONT></P></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 35%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left" bgColor=#cceeff>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Transmitted Investigational New Drug
      applications (INDs), protocols, data, and files, including transfer of
      regulatory and pharmacovigilance responsibilities.</FONT></DIV>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Transferred clinical and regulatory
      oversight for clinical study being conducted at Mayo Clinic to
      Janssen.</FONT></DIV>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Established connections and relationships
      between our scientific advisory board members, preclinical researchers,
      clinical investigators, patient advocacy groups and liver safety experts
      and Janssen.</FONT></DIV>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Created central repository for all files to
      support potential future regulatory filings for imetelstat.</FONT></DIV>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>All activities completed by May 2015 to
      enable Janssen to commence a global Clinical Development Plan for
      imetelstat by mid-year.</FONT></DIV></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 10%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap bgColor=#cceeff>
      <P align=center><FONT face="Times New Roman" size=2>100%</FONT></P></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 10%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap bgColor=#cceeff>
      <P align=center><FONT face="Times New Roman" size=2>25%</FONT></P></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>31</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<TABLE style="LINE-HEIGHT: normal; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; BORDER-LEFT: #000000 1pt solid; WIDTH: 34%; PADDING-TOP: 2pt; TEXT-ALIGN: left" noWrap></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; TEXT-ALIGN: left" noWrap></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 35%; PADDING-TOP: 2pt; TEXT-ALIGN: left" noWrap></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Percentage</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; TEXT-ALIGN: left" noWrap></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; BORDER-LEFT: #000000 1pt solid; WIDTH: 34%; PADDING-TOP: 2pt; TEXT-ALIGN: left" noWrap></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Weighting</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 35%; PADDING-TOP: 2pt; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Highlights of</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Achievement</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Total</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; BORDER-LEFT: #000000 1pt solid; WIDTH: 34%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left" noWrap><B><FONT face="Times New Roman" size=1>2015 Corporate
      Goals</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>(A)</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 35%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Company
      Performance</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>(B)</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>(A x B)</FONT></B></TD></TR>
  <TR>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; BORDER-LEFT: #000000 1pt solid; WIDTH: 34%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left" bgColor=#cceeff>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -15.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">2)</FONT><FONT face="Times New Roman" size=2>Complete Geron&#146;s transition of imetelstat
      manufacturing related activities to Janssen by end of Q4
    2015.</FONT></DIV></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 10%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap bgColor=#cceeff>
      <P align=center><FONT face="Times New Roman" size=2>25%</FONT></P></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 35%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left" bgColor=#cceeff>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Provided procurement services for
      manufacturing imetelstat.</FONT></DIV>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Trained global Janssen manufacturing and
      quality personnel on imetelstat supply chain and
      manufacturing.</FONT></DIV>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Transferred manufacturing and quality files
      to create master repository for potential future regulatory
      filings.</FONT></DIV>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Assigned manufacturing contracts and
      established new vendor relationships.</FONT></DIV>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>All activities completed by September 2015
      to enable Janssen to assume full responsibility for imetelstat
      manufacturing.</FONT></DIV></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 10%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap bgColor=#cceeff>
      <P align=center><FONT face="Times New Roman" size=2>100%</FONT></P></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 10%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap bgColor=#cceeff>
      <P align=center><FONT face="Times New Roman" size=2>25%</FONT></P></TD></TR>
  <TR>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; BORDER-LEFT: #000000 1pt solid; WIDTH: 34%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left">
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -15.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">3)</FONT><FONT face="Times New Roman" size=2>Actively engage Janssen in program oversight
      and joint decision making.</FONT></DIV></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 10%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap>
      <P align=center><FONT face="Times New Roman" size=2>15%</FONT></P></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 35%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left">
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Established and participated on Joint
      Steering Committee and Joint Development Committee to ensure clinical
      activities performed by Janssen were consistent with the executed
      agreement.</FONT></DIV>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Actively contributed to the designs of Phase
      2 clinical trial of imetelstat in myelofibrosis (IMbark<SUP>TM</SUP>) that
      opened to patient enrollment in July 2015 and the Phase 2/3 clinical trial
      of imetelstat in myelodysplastic syndromes (IMerge<SUP>TM</SUP>) that
      opened to patient enrollment in December 2015.</FONT></DIV>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Initiated various working groups to oversee
      imetelstat program operations, including finance, intellectual property,
      manufacturing, and publications.</FONT></DIV></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 10%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap>
      <P align=center><FONT face="Times New Roman" size=2>100%</FONT></P></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 10%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap>
      <P align=center><FONT face="Times New Roman" size=2>15%</FONT></P></TD></TR>
  <TR>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; BORDER-LEFT: #000000 1pt solid; WIDTH: 34%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left" bgColor=#cceeff>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -15.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">4)</FONT><FONT face="Times New Roman" size=2>Formulate asset criteria for potential
      in-licenses or acquisition candidates.</FONT></DIV></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 10%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap bgColor=#cceeff>
      <P align=center><FONT face="Times New Roman" size=2>5%</FONT></P></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 35%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left" bgColor=#cceeff>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Developed criteria to search and identify
      potential products, product candidates, programs or companies to acquire
      and/or in license.</FONT></DIV>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Presented criteria to the Board and approved
      in May 2015.</FONT></DIV></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 10%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap bgColor=#cceeff>
      <P align=center><FONT face="Times New Roman" size=2>100%</FONT></P></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 10%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap bgColor=#cceeff>
      <P align=center><FONT face="Times New Roman" size=2>5%</FONT></P></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>32</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<TABLE style="LINE-HEIGHT: normal; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 4pt; BORDER-LEFT: #000000 1pt solid; WIDTH: 34%; TEXT-ALIGN: left" noWrap></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 4pt; WIDTH: 10%; TEXT-ALIGN: left" noWrap></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 4pt; WIDTH: 35%; TEXT-ALIGN: left" noWrap></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 4pt; WIDTH: 10%; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Percentage</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 4pt; WIDTH: 10%; TEXT-ALIGN: left" noWrap></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; BORDER-LEFT: #000000 1pt solid; WIDTH: 34%; TEXT-ALIGN: left" noWrap></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; WIDTH: 10%; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Weighting</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; WIDTH: 35%; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Highlights of</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; WIDTH: 10%; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Achievement</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; WIDTH: 10%; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Total</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; BORDER-LEFT: #000000 1pt solid; WIDTH: 34%; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left" noWrap><B><FONT face="Times New Roman" size=1>2015 Corporate
      Goals</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>(A)</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 35%; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>Company
      Performance</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>(B)</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=1>(A x B)</FONT></B></TD></TR>
  <TR>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; BORDER-LEFT: #000000 1pt solid; WIDTH: 34%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left" bgColor=#cceeff>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -15.5pt"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">5)</FONT><FONT face="Times New Roman" size=2>Conduct due diligence review of appropriate
      asset candidates.</FONT></DIV></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 10%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap bgColor=#cceeff>
      <P><FONT face="Times New Roman" size=2>20%</FONT></P></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; WIDTH: 35%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left" bgColor=#cceeff>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Conducted scientific, clinical and financial
      diligence on potential opportunities.</FONT></DIV>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Presented findings and conclusions to the
      Board.</FONT></DIV></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 10%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap bgColor=#cceeff>
      <P><FONT face="Times New Roman" size=2>100%</FONT></P></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 10%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap bgColor=#cceeff>
      <P><FONT face="Times New Roman" size=2>20%</FONT></P></TD></TR>
  <TR>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; BORDER-LEFT: #000000 1pt solid; WIDTH: 34%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left">
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -15.5pt"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">6)</FONT><FONT face="Times New Roman" size=2>Manage expenditures to Board- approved
      budget.</FONT></DIV></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 10%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap>
      <P><FONT face="Times New Roman" size=2>10%</FONT></P></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; WIDTH: 35%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left">
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Controlled expenses to be in line with
      established budget to maintain sufficient cash resources to support
      collaborative development of imetelstat.</FONT></DIV></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 10%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap>
      <P><FONT face="Times New Roman" size=2>100%</FONT></P></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; VERTICAL-ALIGN: top; WIDTH: 10%; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap>
      <P><FONT face="Times New Roman" size=2>10%</FONT></P></TD></TR>
  <TR>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; BORDER-LEFT: #000000 1pt solid; WIDTH: 34%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: left" noWrap bgColor=#cceeff>
      <P align=justify><B><FONT face="Times New Roman" size=2>Total</FONT></B></P></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap bgColor=#cceeff>
      <P align=center><FONT face="Times New Roman" size=2>100%</FONT></P></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 35%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap bgColor=#cceeff></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap bgColor=#cceeff></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; WIDTH: 10%; PADDING-TOP: 2pt; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap bgColor=#cceeff>
      <P align=center><FONT face="Times New Roman" size=2>100%</FONT></P></TD></TR></TABLE>
<P align=justify><FONT face="Times New Roman" size=2><U>Individual Performance
and Corporate Values Performance Factors</U></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>For all employees in 2015,
including the Named Executive Officers other than the Chief Executive Officer,
actual individual performance factors awarded ranged from 1.0 to 1.2. Each Named
Executive Officer&#146;s 2015 individual performance factor was based on personal
performance in accomplishing individual, team, departmental and functional goals
and objectives and his or her support of achieving 2015 corporate goals,
including performance and achievements beyond the original pre-established
corporate, individual, team, departmental and functional goals.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our corporate values are
authenticity, accountability, excellence, integrity and respect. The
Compensation Committee determined that the actual individual corporate values
performance factor was 1.0 for each of the Named Executive Officers, whose
actions during 2015 demonstrated their full support and manifestation of our
corporate values.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following are the
annual incentive bonus targets and weighting percentages used to calculate the
2015 annual incentive bonus for each of the Named Executive Officers as well as
the 2015 actual bonus percentage awarded.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>(A)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>(B)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">
      <P>&nbsp;</P></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>(C)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>(D)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>(E)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>(F)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>(G)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>= (A*B*C)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>+ (A*D*E)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>+ (A*F*G)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>Annual</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>Annual</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>Incentive</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>2015</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>2015</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>Incentive</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>Bonus</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Corporate</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>Corporate</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>2015</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>Corporate</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>Bonus</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>Target</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Goal</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>Goal</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>Individual</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>Individual</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>Corporate</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>Values</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>Awarded</FONT></B></TD></TR>
  <TR>
    <TD noWrap align=left width="82%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">as a</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="3%" colSpan=3><STRONG><FONT size=1 face="Times New Roman">Achievement</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">Achievement </FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">Performance </FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">Performance</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">Values</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">Performance </FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">as a % of</FONT></STRONG></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Named Executive
    Officer</FONT></B></TD>
    <TD noWrap align=left width="81%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=1>% of Salary</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Weighting</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=1>Factor</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=1>Weighting</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=1>Factor</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=1>Weighting</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=1>Factor</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=1>Salary</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>60%</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>100%</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1.0</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>60.0%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><FONT face="Times New Roman" size=2>Olivia K. Bloom</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>45%</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>50%</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>1.0</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>30%</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>1.1</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>20%</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>1.0</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>46.4%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Melissa A. Kelly Behrs</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>45%</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>50%</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1.0</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>30%</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1.2</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>20%</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1.0</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>47.7%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><FONT face="Times New Roman" size=2>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>45%</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>50%</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>1.0</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>30%</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>1.1</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>20%</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>1.0</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>46.4%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Stephen N. Rosenfield, J.D.</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>45%</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>50%</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1.0</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>30%</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1.1</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>20%</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1.0</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>46.4%</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>33</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>For 2015, the Compensation
Committee considered Dr. Scarlett&#146;s recommendations for each Named Executive
Officer&#146;s individual performance and corporate values performance factors, and
approved the individual and corporate values performance factors for each Named
Executive Officer, as discussed in detail below.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Ms. Bloom was awarded an
individual performance factor of 1.1 and a corporate values performance factor
of 1.0 based primarily on the following achievements and contributions she made
during 2015:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>established a Finance
      Working Group with Janssen to ensure collaboration expenses aligned with
      budgets, program activities and allowed spending
      categories;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>provided financial
      expertise in conducting diligence of potential business development
      opportunities as well as preserving financial options to support any
      potential transactions;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>monitored and
      controlled operating expenses to stay within budgeted spending levels,
      including analysis of budget changes during corporate restructuring and
      transition of clinical development activities to
      Janssen;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>developed and
      directed a successful investor relations plan to create and maintain
      investor interest; and<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>instituted a
      Communications Working Group with Janssen to ensure timely and appropriate
      disclosures about the imetelstat program
  activities.</FONT></P></TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Ms. Behrs was awarded an
individual performance factor of 1.2 and a corporate values performance factor
of 1.0 based primarily on the following achievements and contributions she made
during 2015:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>performed key role in
      ensuring timely and successful technical transition of the imetelstat
      program to Janssen, enabling Janssen to execute the global Clinical
      Development Plan anticipated under the licensing agreement and to assume
      full responsibility for product manufacturing;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>performed key role as
      member of Joint Steering Committee, to ensure active monitoring of
      progress versus key program goals and to ensure active and impactful
      participation by Geron in all key alliance decision
      making;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>led a
      multi-disciplinary technical team including consultants and in-house
      personnel to conduct a comprehensive screening, profiling, and
      prioritization process to evaluate priority business development
      opportunities identified; and<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>conducted diligence
      of potential business development opportunities, including corporate
      structure and personnel, clinical development plans, regulatory strategy,
      commercialization potential and transaction
  feasibility.</FONT></P></TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Dr. Grethlein was awarded
an individual performance factor of 1.1 and a corporate values performance
factor of 1.0 based primarily on the following achievements and contributions he
made during 2015:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>led the transition of
      imetelstat development related activities to Janssen to enable initiation
      of clinical trials by Janssen in accordance with the licensing
      agreement;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>led the transition of
      imetelstat manufacturing related activities to Janssen to enable initiation of
      clinical trials by Janssen in accordance with the licensing
      agreement;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>provided timely and
      perceptive input as a member of the Joint Development Committee with
      Janssen to ensure appropriate program decision making;
      and<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>provided technical
      development and operational expertise in conducting diligence of business
      development opportunities.</FONT></P></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>34</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Mr. Rosenfield was awarded
an individual performance factor of 1.1 and a corporate values performance
factor of 1.0 based primarily on the following achievements and contributions he
made during 2015:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>rendered expert legal
      advice and guidance to management, the Board and Board committees
      throughout the year, regarding the ongoing purported class action
      securities lawsuits and related derivative lawsuits and the potential
      implications of business development activities, particularly in the areas
      of corporate law, securities law, contracts, employment matters and
      intellectual property matters;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>provided risk
      management and detailed strategic and tactical legal and business counsel,
      as particularly evidenced by careful and timely review of key SEC
      documents, including preparation and review of all risk factors called out
      in such documents, and other documents, including press releases, Form
      8-Ks and analyst, business development and investor
      presentations;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>supervised the Human
      Resources function and oversaw structuring of compensation elements that
      provided motivation for employees during a corporate restructuring,
      including fostering various initiatives to encourage positive employee
      morale and retention; and<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>supervised the Legal
      function and ensured continuation of all key activities within the
      department at a high level, including providing legal support for
      diligence of business development opportunities and maintaining imetelstat
      intellectual property under the Janssen
  collaboration.</FONT></P></TD></TR></TABLE>
<P align=justify><FONT face="Times New Roman" size=2><U>2015 Annual Incentive
Bonus for Chief Executive Officer</U></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Dr. Scarlett&#146;s 2015 annual
incentive bonus was structured to be 100% dependent on corporate goal
achievement. Accordingly, with the Board approved corporate goal achievement
factor of 100%, the Compensation Committee recommended, and the Board approved
that Dr. Scarlett should receive 100% of his 2015 target annual incentive
bonus.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>2015 Equity
Awards</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In order to link pay with
performance, align the interests of stockholders and employees, and encourage
employee ownership in Geron, in March 2015, the Compensation Committee approved
stock option grants to the Named Executive Officers, and the Board approved a
stock option grant to the Chief Executive Officer. In determining the
appropriate size and value of stock option grants in 2015 for our Named
Executive Officers, the Compensation Committee considered the market data from
Radford and the status of stock option grants held by the Named Executive
Officers, to assess the number of equity awards that would provide an
appropriate incentive for retention of our Named Executive Officers. In light of
the objective to retain existing executive officers, and in recognition of the
additional and a broader range of responsibilities required of our executive
officers to ensure achievement of our corporate objectives, the Compensation
Committee determined that in 2015 utilizing the 60<SUP>th</SUP> to
75<SUP>th</SUP> percentile of the market data provided by Radford was
appropriate in setting the stock option grants to the Named Executive Officers.
The Compensation Committee also determined that the equity awards granted to the
Named Executive Officers in 2015 should continue to consist only of stock
options rather than restricted stock awards that vest over time because stock
options deliver future value only if the price per share of our Common Stock
increases above the exercise price, thus aligning the interests of our executive
officers and stockholders for the long-term success of Geron.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our Named Executive
Officers received the following stock option grants in March 2015:</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="98%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>2015 Stock</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="98%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>Option Grant</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Named Executive
    Officer</FONT></B></TD>
    <TD noWrap align=left width="97%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=1>(# of shares)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="98%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>600,000</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="98%" colSpan=2><FONT face="Times New Roman" size=2>Olivia K. Bloom</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>210,000</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="98%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Melissa A. Kelly Behrs</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>210,000</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="98%" colSpan=2><FONT face="Times New Roman" size=2>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>210,000</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="98%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Stephen N. Rosenfield, J.D.</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>210,000</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>35</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The exercise price for the
March 2015 stock option grants was equal to the closing price of Geron Common
Stock as reported by the NASDAQ Global Select Market on the date of grant and
the vesting schedule is monthly over four years from the date of grant, provided
the employee continues to provide services to Geron. See the section entitled
&#147;Grants of Plan-Based Awards for 2015&#148; for additional information regarding
stock option grants to Named Executive Officers in 2015.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Other
Compensation</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Geron offers a
comprehensive array of benefit programs to its employees, including Named
Executive Officers. These include:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>comprehensive
      medical, dental, vision coverage and life
    insurance;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>a &#147;cafeteria&#148; plan
      administered pursuant to Section 125 of the Code. The cafeteria plan
      includes Geron&#146;s medical and dental insurance, medical reimbursement, and
      dependent care reimbursement plans;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>a 401(k) plan, which
      is a retirement savings defined contribution plan established in
      accordance with Section 401(a) of the Code. For 2015, we provided a fully
      vested employer matching contribution in cash equal to 50% of each
      employee&#146;s annual contributions; and<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>an Employee Stock
      Purchase Plan, which is implemented and administered pursuant to Section
      423 of the Code.</FONT></P></TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Executive officers pay for
30% of their health premium cost, which is deducted from their gross salary.
Other employees pay either 16% or 25% of their health premium cost.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We do not offer any pension
plans or health benefits during retirement.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Perquisites</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In accordance with the
terms of his employment agreement, Dr. Scarlett receives reimbursement for
housing expenses (not to exceed $2,000 per month) and travel costs (not to
exceed $20,000 per year) in connection with the commute from his personal
residence in Texas to our headquarters in Menlo Park, California. These
commuting expense benefits were negotiated with Dr. Scarlett at the time of his
initial employment and were deemed a reasonable expense and necessary inducement
to his commencement of employment with us. Dr. Scarlett does not receive
separate compensation for serving as a member of our Board.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Employment
Agreements</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We have entered into a
written employment agreement with each of the Named Executive Officers setting
forth the terms of their employment. The agreements also provide for certain
severance benefits upon a covered termination of the Named Executive Officer&#146;s
employment, and for accelerated vesting of options in connection with a change
in control transaction, which terms are further described below under the
section entitled &#147;Severance and Change in Control Benefits.&#148; Each of our Named
Executive Officers is employed &#147;at will.&#148;</FONT></P>

<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We entered into an employment
agreement with Dr. Scarlett dated September 29, 2011, in connection with
commencement of his employment with us. Dr. Scarlett&#146;s employment agreement
originally provided him with an annual base salary of $550,000, subject to
increase, and an annual incentive bonus targeted at 60% of his annual base
salary. On February 11, 2014, we amended Dr. Scarlett&#146;s employment agreement to
provide for an annual base salary of $586,500, subject to increase, and to
include a clawback provision that provides that Dr. Scarlett&#146;s annual incentive
bonus is subject to forfeiture or repayment to the Company should the Company
determine, in its reasonable discretion, that Dr. Scarlett has engaged in any
misconduct intended to affect the payment of his annual discretionary bonus, or
has otherwise engaged in any act or omission that would constitute cause for
termination of employment (the &#147;clawback provision&#148;).</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We entered into an
employment agreement with Ms. Bloom dated December 7, 2012, in connection with
her appointment as our Senior Vice President, Finance, Chief Financial Officer
and Treasurer, to provide an annual base salary of $330,000 and an annual
incentive bonus targeted at 40% of her annual base salary. On September 24,
2013, we amended Ms. Bloom&#146;s employment agreement to provide that Ms. Bloom&#146;s
annual incentive </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>36</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><FONT face="Times New Roman" size=2>bonus is subject to
forfeiture or repayment to the Company pursuant to the same clawback provision
described above for Dr. Scarlett, but with respect to Ms. Bloom. On February 11,
2014, in connection with her promotion to Executive Vice President, we amended
Ms. Bloom&#146;s employment agreement to provide for an annual base salary of
$365,000, subject to increase, and an annual incentive bonus targeted at 45% of
her annual base salary.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We entered into an
employment agreement with Ms. Behrs effective January 31, 2013, to provide an
annual base salary of $341,550, subject to increase, and an annual incentive
bonus targeted at 40% of her annual base salary. On September 24, 2013, we
amended Ms. Behrs&#146; employment agreement to provide that Ms. Behrs&#146; annual
incentive bonus is subject to forfeiture or repayment to the Company pursuant to
the same clawback provision described above for Dr. Scarlett, but with respect
to Ms. Behrs. On February 11, 2014, in connection with her promotion to
Executive Vice President, we amended Ms. Behrs&#146; employment agreement to provide
for an annual base salary of $352,000, subject to increase, and an annual
incentive bonus targeted at 45% of her annual base salary.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We entered into an
employment agreement with Dr. Grethlein effective September 17, 2012, in
connection with commencement of his employment with us, to provide an annual
base salary of $355,000 and an annual incentive bonus targeted at 45% of his
annual base salary. On February 11, 2014, we amended Dr. Grethlein&#146;s employment
agreement to provide for an annual base salary of $379,000, subject to increase,
and to provide that Dr. Grethlein&#146;s annual incentive bonus is subject to
forfeiture or repayment to the Company pursuant to the same clawback provision
described above for Dr. Scarlett, but with respect to Dr. Grethlein.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We entered into an
employment agreement with Mr. Rosenfield effective February 16, 2012, in
connection with commencement of his employment with us, to provide an annual
base salary of $292,000, pro-rated to reflect Mr. Rosenfield&#146;s 80% of a
full-time work schedule, and an annual incentive bonus targeted at 45% of his
annual base salary. On September 24, 2013, we amended Mr. Rosenfield&#146;s
employment agreement to provide that Mr. Rosenfield&#146;s annual incentive bonus is
subject to forfeiture or repayment to the Company pursuant to the same clawback
provision described above for Dr. Scarlett, but with respect to Mr.
Rosenfield.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Severance and Change in
Control Benefits</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our Named Executive
Officers are entitled to certain severance and change in control benefits under
the terms of our Amended Severance Plan, their employment agreements and our
equity plans. These severance and change in control provisions are intended to
allow employees, including Named Executive Officers, to focus their attention on
the business operations of Geron in the face of the potentially disruptive
impact of a proposed change in control transaction, to assess takeover bids
objectively without regard to the potential impact on their own job security and
to allow for a smooth transition in the event of a change in control of
Geron.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
believes that the severance benefits we offer remain essential to fulfill the
objectives to recruit, retain and develop key management talent in the
competitive San Francisco Bay Area employment market. These arrangements enable
us to recruit and retain high-quality management talent because they provide
reasonable protection to the executive officer in the event that he or she is
not retained under limited circumstances. We do not provide for any excise tax
gross-ups in the Amended Severance Plan or in any individual employment
agreement with a Named Executive Officer.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Amended Severance
Plan</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In September 2002, the
Board approved a Severance Plan that originally became effective on January 21,
2003 and was subsequently amended and restated, most recently in May 2013
(collectively referred to herein as the &#147;Amended Severance Plan&#148;). The May 2013
amendment included modifications that require a &#147;double trigger&#148; for cash
severance benefits to be paid to employees, including Named Executive Officers,
in the event of a Change in Control, as defined below. Under this &#147;double
trigger&#148; requirement, severance benefits are paid only upon the occurrence of a
Change in Control and a termination of employment, with such termination being
either by the Company or because the employee resigns due to a material change
in their employment terms. Prior to the May 2013 amendment, the Amended
Severance Plan had provided a &#147;single trigger&#148; for payment of cash severance
benefits upon a Change in Control. The &#147;single trigger&#148; was removed from the
Amended Severance Plan in response to stockholders feedback and because the
Board believes that a &#147;double trigger&#148; is considered industry standard and
provides appropriate protection for our employees, including our Named Executive
Officers, in the </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>37</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><FONT face="Times New Roman" size=2>event of a termination of
employment due to a change in control if such termination is by the Company or
because the employee resigns due to a material change in their employment terms,
but not solely as a result of a change in control.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Amended Severance Plan
applies to all employees, including the Named Executive Officers, who are not
subject to a performance improvement plan. Severance benefits provided under the
employment agreements with the Named Executive Officers are generally reduced by
the same type of severance payments the Named Executive Officer is entitled to
receive under the Amended Severance Plan in order to prevent duplication of
benefits.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>As noted above, the Amended
Severance Plan provides for severance benefits to the Named Executive Officers
under a &#147;double trigger&#148; situation. In the Amended Severance Plan, this
situation is defined as a Change in Control Triggering Event. If such an event
were to occur, each of our Named Executive Officers is entitled to a payment
equal to 15 months (18 months, with respect to Dr. Scarlett) of his or her base
salary then in effect as of such Change in Control triggering event and payment
of COBRA premiums for up to 15 months (18 months, with respect to Dr. Scarlett),
which is consistent with severance plans offered at companies similar in size in
our industry and competitive market environment.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Under the Amended Severance
Plan, a Change in Control Triggering Event is a termination without Cause in
connection with a Change in Control (which has the same definition as under the
2011 Plan described below) or within 12 months following a Change in Control.
Additionally, if an individual is terminated by the Company in connection with a
Change in Control but immediately accepts employment with the Company&#146;s
successor or acquirer, they will not be deemed to have had a Change in Control
Triggering Event unless: i) such individual is subsequently terminated without
Cause by the successor or acquirer within the 12 months following the Change in
Control; ii) such individual resigns employment with the Company because in
connection with a Change in Control he or she is offered terms of employment
(new or continuing) by the Company or the Company&#146;s successor or acquirer within
30 days after the Change in Control that results in a material change in the
terms of employment; or iii) after accepting (or continuing) employment with the
Company or the Company&#146;s successor or acquirer after a Change in Control, such
individual resigns employment within 12 months following the Change in Control
due to a material change in terms of employment as defined below.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>For purposes of the Amended
Severance Plan a &#147;material change in terms of employment&#148; shall occur if one of
the following events occurs without the employee&#146;s consent: i) base salary is
materially reduced from that in effect immediately prior to the Change in
Control; ii) if as of the Change in Control they are employed at the director
level or above, they are subject to a material reduction in their duties
(including responsibilities and/or authority); iii) their principal work
location is to be moved to a location that is either more than 45 miles from
their principal work location immediately prior to the Change in Control or more
than 30 miles farther from their principal weekday residence than was their
principal work location immediately prior to the Change in Control; or iv) the
Company or the Company&#146;s successor or acquirer materially breaches the terms of
any employment or similar service agreement with the employee. Additionally, in
order for the resignation to be deemed due to a material change in terms of
their employment, the employee must provide written notice to the Company&#146;s
General Counsel within 30 days after the first occurrence of the event giving
rise to a material change in their terms of employment setting forth the basis
for their resignation, allow the Company at least 30 days from receipt of such
written notice to cure such event, and if such event is not reasonably cured
within such period, the employee resignation from all positions they then hold
with the Company is effective not later than 90 days after the expiration of the
cure period.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>For purposes of the Amended
Severance Plan, &#147;Cause&#148; generally means an employee&#146;s continued failure to
satisfactorily perform duties, willful act or omission constituting dishonesty,
fraud or other malfeasance against the Company, conviction of a felony,
debarment by the FDA from working in or providing services to any pharmaceutical
or biotechnology company or other ineligibility under any law or regulation to
perform the employee&#146;s duties to the Company, or breach of any material Company
policies.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Payment of any benefits
under the Amended Severance Plan is conditioned on the timely provision of an
effective release of claims against Geron.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>38</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Employment
Agreements</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Under Dr. Scarlett&#146;s
employment agreement, in the event of a Covered Termination (as defined below)
and subject to his provision of a release of claims against Geron, Dr. Scarlett
will be entitled to: i) any unpaid target annual incentive bonus to which he
would have become entitled for any fiscal year that ends on or before the
termination date had he remained employed through the payment date, payable in a
single lump-sum payment; ii) a lump-sum severance payment equal to 24 months of
his base salary then in effect as of such termination; iii) continued healthcare
coverage as permitted under COBRA for a period of one year following a Covered
Termination at the same cost as in effect immediately prior to such termination;
and iv) the vested portion of any stock options or other exercisable equity
interest in Geron will remain outstanding until the earlier of the second
anniversary of the date of termination and the original expiration date of such
award. In addition, Dr. Scarlett&#146;s employment agreement provides that the
initial option granted to him will vest in full upon a change in control if he
is providing services through the date of such change in control. In addition,
other stock options granted to Dr. Scarlett will vest in full upon a Change in
Control (as defined in the relevant equity plan under which the options were
granted) if Dr. Scarlett is providing services through the date of such Change
in Control. As described above, Dr. Scarlett is also eligible to participate in
Geron&#146;s Amended Severance Plan, provided that any severance benefits payable
under Dr. Scarlett&#146;s employment agreement, other than annual incentive bonuses
and extended exercisability of any stock options or equity awards, shall be
reduced by the amount of severance or other cash payable to Dr. Scarlett under
the Amended Severance Plan.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Under the employment
agreements for each of the other Named Executive Officers, in the event of a
Covered Termination and subject to a release of claims against Geron, each Named
Executive Officer will be entitled to a lump-sum severance payment equal to 12
months of base salary then in effect as of such termination, a pro-rated portion
of any target annual incentive bonus, continued COBRA coverage for a period of
one year following a Covered Termination, and the vested portion of any stock
options or other exercisable equity interest in Geron in either case shall
remain exercisable until the earlier of the second anniversary of the date of
termination and the original expiration date of such award. In addition, stock
options granted to each of the Named Executive Officers will vest in full upon a
Change in Control (as defined in the relevant equity plan under which the
options were granted) if the Named Executive Officer is providing services
through the date of such Change in Control. As described above, each of the
Named Executive Officers is also eligible to participate in Geron&#146;s Amended
Severance Plan, provided that any severance benefits payable under the Named
Executive Officer&#146;s employment agreements, other than annual incentive bonuses
and extended exercisability of any stock options or equity awards, shall be
reduced by the amount of severance or other cash payable to the Named Executive
Officers under the Amended Severance Plan.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>For the purposes of the
Named Executive Officers&#146; employment agreements, a &#147;Covered Termination&#148;
generally means an Involuntary Termination Without Cause that occurs at any
time, provided that such termination constitutes a &#147;separation from service&#148;
within the meaning of Section 409A of the Code, and &#147;Involuntary Termination
Without Cause&#148; generally means an executive officer&#146;s dismissal or discharge
other than: i) for cause or ii) following an involuntary or voluntary filing of
bankruptcy, an assignment for the benefit of creditors, a liquidation of our
assets in a formal proceeding or otherwise or any other event of insolvency by
Geron, in any case, without an offer of comparable employment by Geron or a
successor, acquirer, or affiliate of Geron.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>For purposes of the Named
Executive Officers&#146; employment agreements, &#147;Cause&#148; generally means the executive
officer&#146;s: i) willful act or omission constituting dishonesty, fraud or other
malfeasance against the Company; ii) conviction of a felony; iii) debarment by
the FDA from working in or providing services to any pharmaceutical or
biotechnology company or other ineligibility under any law or regulation to
perform the employee&#146;s duties to the Company; or iv) breach of any material
Company policies.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The potential severance
payments under each of the employment agreements for the Named Executive
Officers were designed to compensate them for the loss of their income following
a Covered Termination. The Compensation Committee believes such benefits are
reasonable and appropriate in light of the lengthy time period it generally
takes high-level executive officers to secure new positions with
responsibilities and compensation that are commensurate with their expertise and
experience. Also, the Compensation Committee believes that such severance
benefits are in the best interests of Geron and its stockholders insofar as
Geron competes for executive talent in a highly competitive market in which
companies customarily offer similar benefits to senior executives.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>39</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Equity
Plans</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>As set forth in each
individual stock option or restricted stock award agreement under the 2011 Plan,
in the event of a Change in Control of Geron (defined below), the vesting of
each outstanding option and award held by all employees and outside directors
will accelerate so that each option shall become fully exercisable for all of
the outstanding shares subject to such option immediately prior to the
consummation of such transaction and each other type of award shall be fully
vested with all forfeiture restrictions on any or all of such awards to lapse.
For purposes of the 2011 Plan, a &#147;Change in Control&#148; generally means and
includes each of the following: a) as a result of any merger or consolidation,
the voting securities of Geron outstanding immediately prior thereto represent
(either by remaining outstanding or by being converted into voting securities of
the surviving or acquiring entity) less than 49% of the combined voting power of
the voting securities of Geron or such surviving or acquiring entity outstanding
immediately after such merger or consolidation; b) during any period of 24
consecutive calendar months, the individuals who at the beginning of such period
constitute the board of directors, and any new directors whose election by such
board of directors or nomination for election by stockholders was approved by a
vote of at least two-thirds of the members of such board of directors who were
either directors on such board of directors at the beginning of the period or
whose election or nomination for election as directors was previously so
approved, for any reason cease to constitute at least a majority of the members
thereof; c) any individual, entity or group becomes the beneficial owner of more
than 20% of the then outstanding shares of Geron Common Stock; d) any sale of
all or substantially all of the assets of Geron; or e) the complete liquidation
or dissolution of Geron.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In the event of a merger,
acquisition or similar change in control, the 1996 Directors&#146; Stock Option Plan,
the 2002 Equity Incentive Plan and the 2006 Directors&#146; Plan provide through each
respective plan or the individual stock option or restricted stock award
agreements or both, that each outstanding option and award held by all employees
or outside directors will accelerate so that each option will be fully
exercisable for all of the shares subject to such option immediately prior to
the effective date of the transaction and each other type of award shall be
fully vested. In addition, upon the occurrence of such transaction, the 2002
Equity Incentive Plan and the 2006 Directors&#146; Plan provide that all of the
outstanding repurchase rights of Geron with respect to shares of Common Stock
acquired upon exercise of options granted, as well as shares of restricted stock
under the 2002 Equity Incentive Plan and the 2006 Directors&#146; Plan, will
terminate.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Tax and Accounting
Implications for Executive Compensation</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
is responsible for addressing the issues raised by Section 162(m) of the Code,
which makes certain &#147;non-performance-based&#148; compensation to certain executive
officers of Geron in excess of $1,000,000 non-deductible to us. To qualify as
&#147;performance-based&#148; under Section 162(m), compensation payments must be
determined pursuant to a plan, by a committee of at least two &#147;outside&#148;
directors (as defined in the regulations promulgated under the Code) and must be
based on achieving objective performance goals. In addition, the material terms
of the plan must be disclosed to and approved by stockholders and the outside
directors or the Compensation Committee, as applicable, must certify that the
performance goals were achieved before payments can be awarded.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
will continue to examine the effects of Section 162(m), to monitor the level of
compensation paid to executive officers and take appropriate action in response
to the provisions of Section 162(m), to the extent practicable while maintaining
competitive compensation practices. To maintain flexibility in compensating
executive officers in a manner designed to promote varying corporate goals, the
Compensation Committee reserves the right to recommend and award compensation
that is not deductible under Section 162(m).</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In addition to considering
the tax consequences, the Compensation Committee considers the accounting
consequences of its decisions, including the impact of expenses being recognized
in connection with equity-based awards, in determining the size and form of
different equity-based awards.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>40</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="CompensationCommitteeReport"></A>COMPENSATION COMMITTEE
REPORT</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our Compensation Committee
has reviewed and discussed the Compensation Discussion and Analysis required by
Item 402(b) of Regulation S-K and contained within this Proxy Statement with
management and, based on such review and discussions, our Compensation Committee
recommended to our Board that the Compensation Discussion and Analysis be
included in this Proxy Statement and incorporated into our Annual Report on Form
10-K for the year ended December 31, 2015.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Submitted on March 21, 2016
by the members of the Compensation Committee of the Board of
Directors:</FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: normal; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="70%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"><FONT face="Times New Roman" size=2>Robert J. Spiegel, M.D., FACP</FONT></TD>
    <TD noWrap align=left width="49%"><FONT face="Times New Roman" size=2>Compensation Committee Chair</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"><FONT face="Times New Roman" size=2>Karin Eastham</FONT></TD>
    <TD noWrap align=left width="49%"><FONT face="Times New Roman" size=2>Compensation Committee Member</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"><FONT face="Times New Roman" size=2>V.
      Bryan Lawlis, Ph.D.</FONT></TD>
    <TD noWrap align=left width="49%"><FONT face="Times New Roman" size=2>Compensation Committee
Member</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify><I><FONT face="Times New Roman" size=2>This Section is not
&#147;soliciting material,&#148; is not deemed &#147; filed&#148; with the SEC and is not to be
incorporated by reference in any filing of the Company under the Securities
Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended,
other than in Geron&#146;s Annual Report on Form 10-K where it shall be deemed to be
furnished, whether made before or after the date hereof and irrespective of any
general incorporation language in any such filing.</FONT></I></P>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="ExecutiveCompensationTables"></A>EXECUTIVE COMPENSATION
TABLES</FONT></B></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Summary Compensation
Table</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following table
includes information concerning compensation for the years ended December 31,
2015, 2014 and 2013 to our Principal Executive Officer, Principal Financial
Officer and our three other most highly compensated executive officers of the
Company as of December 31, 2015 (our &#147;Named Executive Officers&#148;).</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="71%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=1>Non-Equity</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=1>All</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="71%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Option</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=1>Incentive Plan</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=1>Other</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR>
    <TD noWrap align=left width="71%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" colSpan=2><STRONG><FONT face="Times New Roman" size=1>Salary</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><STRONG><FONT face="Times New Roman" size=1>Bonus</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" colSpan=2><STRONG><FONT face="Times New Roman" size=1>Awards</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=3><STRONG><FONT face="Times New Roman" size=1>Compensation </FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=3><STRONG><FONT face="Times New Roman" size=1>Compensation</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" colSpan=2><STRONG><FONT face="Times New Roman" size=1>Total</FONT></STRONG></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Name and Principal
      Position</FONT></B></TD>
    <TD noWrap align=left width="70%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=1>Year</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>($)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>($)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>($)<SUP>(1)</SUP></FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face="Times New Roman" size=1>($)<SUP>(2)</SUP></FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face="Times New Roman" size=1>($)<SUP>(3)</SUP></FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>($)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="71%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=1>John A. Scarlett, M.D.</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2015</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>604,095</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>&nbsp;&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>1,859,340</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$362,457</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$61,793</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2,887,685</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="71%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;President and Chief
      Executive Officer</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2014</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>586,500</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>70,380</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5,001,416</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=1>351,900</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=1>60,807</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>6,071,003</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="71%" bgColor=#cceeff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2013</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>569,250</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>1,308,242</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=1>341,550</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=1>59,299</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2,278,341</FONT></TD></TR>
  <TR>
    <TD width="99%" bgColor=#cceeff colSpan=26>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="71%" colSpan=2><FONT face="Times New Roman" size=1>Olivia K. Bloom</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>2015</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>375,950</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>650,769</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>$174,253</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>$12,468</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>1,213,440</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="71%" colSpan=2><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive Vice President,
      Finance,</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>2014</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>365,000</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>16,425</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1><SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>1,468,600</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>174,105</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>12,126</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>2,036,256</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="71%" colSpan=2><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer
      and Treasurer</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>2013</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>330,000</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>462,899</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>135,960</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>28,297</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>957,156</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=26>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="71%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=1>Melissa A. Kelly Behrs</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2015</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>362,560</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>650,769</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$172,941</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$35,257</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>1,221,527</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="71%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive Vice President,
      Bus. Dev.</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2014</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>352,000</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>15,840</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>1,468,600</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=1>172,656</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=1>33,467</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2,042,563</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="71%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and Portfolio &amp;
      Alliance Management</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2013</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>341,550</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>417,480</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=1>148,916</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=1>38,310</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>946,256</FONT></TD></TR>
  <TR>
    <TD width="99%" bgColor=#cceeff colSpan=26>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="71%" colSpan=2><FONT face="Times New Roman" size=1>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>2015</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>390,370</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>&nbsp;&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>650,769</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>$180,937</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>$36,308</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>1,258,384</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="71%" colSpan=2><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive Vice
      President,</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>2014</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>379,000</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>17,055</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1><SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>1,468,600</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>180,783</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>34,379</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>2,079,817</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="71%" colSpan=2><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development and
      Technical</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>2013</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>367,425</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>294,630</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>170,301</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>34,219</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>866,575</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="71%" colSpan=2><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operations</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD width="99%" colSpan=26>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="71%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=1>Stephen N. Rosenfield, J.D.</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2015</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>321,360</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(5)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>650,769</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$148,950</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$13,872</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>1,134,951</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="71%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive Vice President,
      General</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2014</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>312,000</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(5)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>14,040</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>1,468,600</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=1>148,824</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=1>13,347</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>1,956,811</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="71%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counsel and Corporate
      Secretary</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2013</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>302,220</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(5)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>415,916</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=1>146,199</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=1>19,039</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>883,374</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>41</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<div>____________________</div><BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Amounts represent the
      aggregate grant date fair value of stock option awards granted during the
      applicable fiscal year as calculated in accordance with FASB ASC Topic
      718. For additional information, refer to Note 8 of the financial
      statements in our Annual Report on Form 10-K for the year ended December
      31, 2015 regarding assumptions underlying the valuation of stock option
      awards and the calculation method. For 2013, amounts shown under the
      &#147;Option Awards&#148; column for Ms. Bloom, Mr. Rosenfield and Ms. Behrs also
      include the aggregate incremental fair value associated with the
      modification of stock options modified in 2013. Refer to the supplemental
      table of the section entitled &#147;Outstanding Equity Awards at Fiscal
      Year-End&#148; for information as to each Named Executive Officers&#146; vested and
      unvested stock option holdings, and under the section entitled &#147;Grants of
      Plan-Based Awards for 2015&#148; for the number of stock options granted during
      2015.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Amounts disclosed
      under the &#147;Non-Equity Incentive Plan Compensation&#148; column represent the
      annual incentive bonuses earned pursuant to our annual incentive bonus
      plan. For further discussion see the section entitled &#147;Compensation
      Discussion and Analysis &#150; 2015 Annual Incentive Bonuses&#148;.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Amounts shown
      include, as applicable: (i) reimbursements for housing and travel
      expenses; (ii) the portion of life and health insurance premiums paid by
      the Company; and (iii) the matching contributions made to the Geron 401(k)
      Plan on behalf of the Named Executive Officers. Amounts for the year ended
      December 31, 2015 were as follows:</FONT></TD></TR></TABLE><Br>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="83%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Housing and Travel</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Insurance</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>401(k)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="83%" colSpan=2></TD>
    <TD align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Reimbursements</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Premiums</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Match</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Total</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Named Executive
      Officer</FONT></B></TD>
    <TD noWrap align=left width="82%"></TD>
    <TD noWrap align=left width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>($)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>($)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>($)<SUP>(a)</SUP></FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>($)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="83%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><STRONG><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT></STRONG></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>44,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><STRONG><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT></STRONG></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>17,793</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>61,793</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="83%" colSpan=2><FONT face="Times New Roman" size=2>Olivia K. Bloom</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>3,468</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>9,000</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>12,468</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="83%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Melissa A. Kelly Behrs</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>24,236</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>11,021</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>35,257</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="83%" colSpan=2><FONT face="Times New Roman" size=2>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>24,308</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>12,000</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>36,308</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="83%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Stephen N. Rosenfield, J.D.</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1,872</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>12,000</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>13,872</FONT></TD></TR></TABLE>
<div style="padding-left:20pt ">____________________</div><BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Under Geron&#146;s 401(k)
      Plan, all participating employees may contribute up to the annual Internal
      Revenue Service contribution limit. In December 2014, the Board approved a
      matching contribution equal to 50% of each employee&#146;s annual contributions
      during 2015. The matching contribution was made in cash on January 15,
      2016.</FONT></TD></TR></TABLE><BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Amounts represent the
      discretionary portion of the annual incentive bonus awarded to each Named
      Executive Officer in 2014.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(5)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>The actual base
      salary amounts reflect Mr. Rosenfield&#146;s employment at 80% full-time
      equivalent.</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>42</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><B><FONT face="Times New Roman" size=2>Grants of Plan-Based
Awards for 2015</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following table sets
forth information regarding grants of plan-based awards with respect to each of
the Named Executive Officers for the fiscal year ended December 31,
2015:</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=1>All</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Estimated</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=1>Other</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Possible</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=1>Option</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Payouts Under</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=1>Awards:</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Grant Date</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Non-Equity</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=1>Number of</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Exercise</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Fair Value of</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Incentive Plan </FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=2><STRONG><FONT face="Times New Roman" size=1>Securities</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Price</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Stock</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Awards</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=1>Underlying </FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3>&nbsp;
      <STRONG><FONT face="Times New Roman" size=1>of Stock</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Option</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><B><FONT face="Times New Roman" size=1>Approval</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Grant</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Target</FONT></B><B><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=1>Options</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Options</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Awards</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Named Executive
      Officer</FONT></B></TD>
    <TD noWrap align=left width="78%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=1>Date</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Date</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>($)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face="Times New Roman" size=1>(#)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>($/Sh)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>($)<SUP>(2)</SUP></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3/11/15</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3/13/15</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp; 600,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT size=2>&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp; $</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>4.34</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT size=2>&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1,859,340</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" bgColor=#cceeff colSpan=2>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>362,457</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD></TR>
  <TR>
    <TD width="100%" bgColor=#cceeff colSpan=21>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" colSpan=2><FONT face="Times New Roman" size=2>Olivia K. Bloom</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>3/6/15</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>3/13/15</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>210,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>4.34</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>650,769</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>169,178</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=21>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Melissa A. Kelly Behrs</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3/6/15</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3/13/15</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>210,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>4.34</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>650,769</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>163,152</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD></TR>
  <TR>
    <TD width="100%" bgColor=#cceeff colSpan=21>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" colSpan=2><FONT face="Times New Roman" size=2>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>3/6/15</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>3/13/15</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>210,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>4.34</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>650,769</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>175,667</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=21>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Stephen N. Rosenfield, J.D.</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3/6/15</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3/13/15</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>210,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>4.34</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>650,769</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>144,612</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD></TR></TABLE>

<div>____________________</div><BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>This column sets
      forth the target amount of each Named Executive Officer&#146;s annual incentive
      bonus award for the fiscal year ended December 31, 2015 under our annual
      incentive bonus plan. Accordingly, the amounts set forth in this column do
      not represent actual compensation earned by the Named Executive Officers
      for the fiscal year ended December 31, 2015. For the actual compensation
      paid to our Named Executive Officers for the fiscal year ended December
      31, 2015, see the section entitled &#147;Summary Compensation Table&#148;. For
      further discussion see the section entitled &#147;Compensation Discussion and
      Analysis &#150; 2015 Annual Incentive Bonuses&#148;.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Amounts represent the
      grant date fair value of each stock option granted in 2015 calculated in
      accordance with FASB ASC Topic 718. For additional information, refer to
      Note 8 of the financial statements in our Annual Report on Form 10-K for
      the year ended December 31, 2015 regarding assumptions underlying the
      valuation of stock option awards and the calculation method.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Stock option vests in
      a series of 48 equal consecutive monthly installments commencing March 13,
      2015, provided the executive officer continues to provide services to the
      Company.</FONT></TD></TR></TABLE>
<P align=justify><B><FONT face="Times New Roman" size=2>Narrative Disclosure to
Summary Compensation Table and Grants of Plan-Based Awards Table</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Employment
Agreements</FONT></I><FONT face="Times New Roman" size=2>. Each of our Named
Executive Officers has entered into a written employment agreement with Geron.
Descriptions of our employment agreements with our Named Executive Officers are
included under the section entitled &#147;Compensation Discussion and Analysis &#150;
Employment Agreements&#148;. Our Named Executive Officers are entitled to certain
severance benefits payable in connection with a Covered Termination and upon a
change in control of Geron under their employment agreements as described under
the section entitled &#147;Compensation Discussion and Analysis &#150; Severance and
Change in Control Benefits&#148;.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>43</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Severance
Plan</FONT></I><FONT face="Times New Roman" size=2>. Our Amended Severance Plan
provides for all of our employees, including each of our Named Executive
Officers, to receive a cash severance payment and other benefits on a
&#147;double-trigger&#148; basis. Description of our Amended Severance Plan is included
under the section entitled &#147;Compensation Discussion and Analysis &#150; Severance and
Change in Control Benefits&#148;. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Annual Incentive
Bonuses</FONT></I><FONT face="Times New Roman" size=2>. We provide for annual
incentive bonuses to reward executive officers for performance in the prior
fiscal year. For more information regarding our annual incentive bonus plan, see
the section entitled &#147;Compensation Discussion and Analysis &#150; 2015 Annual
Incentive Bonuses&#148;. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Equity
Awards</FONT></I><FONT face="Times New Roman" size=2>. All stock options awarded
to our Named Executive Officers during 2015 were granted under our 2011 Plan.
Descriptions of the terms of the stock options granted to our Named Executive
Officers are included under the section entitled &#147;Compensation Discussion and
Analysis &#150; Components &#150; 2015 Equity Awards&#148;. Events that can accelerate the
vesting of our stock options are described under the section entitled
&#147;Compensation Discussion and Analysis &#150; Severance and Change in Control
Benefits&#148;.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our 2011 Plan was approved
by our Board and our stockholders in 2011 and replaced our Amended and Restated
2002 Equity Incentive Plan. The 2011 Plan provides for the grant of stock
options, restricted stock, restricted stock units, performance awards and other
stock and cash awards. The exercise price of a stock option may not be less than
100% of the closing price of Geron Common Stock as reported by the NASDAQ Global
Select Market on the date of grant. Stock options generally have a term of ten
years, but may terminate sooner in connection with the holder&#146;s termination of
service with us. Stock options vest based on conditions determined by the
Compensation Committee or the Board, which typically include continued service,
but may also include performance goals and/or other conditions. All equity
awards granted under the 2011 Plan are subject to acceleration under certain
change in control circumstances described under the section entitled
&#147;Compensation Discussion and Analysis &#150; Severance and Change in Control
Benefits&#148;.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Outstanding Equity
Awards at Fiscal Year-End </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following table
includes information with respect to all outstanding equity awards held by our
Named Executive Officers as of December 31, 2015.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="14%" colSpan=14><B><FONT face="Times New Roman" size=1>Option
      Awards</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Number</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Number</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>of</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>of</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Securities</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Securities</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Underlying</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Underlying</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Unexercised </FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3>&nbsp;
      <STRONG><FONT face="Times New Roman" size=1>Unexercised</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><B><FONT face="Times New Roman" size=1>Option</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Options</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Options</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><B><FONT face="Times New Roman" size=1>Exercise</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><B><FONT face="Times New Roman" size=1>Option</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Grant</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Exercisable </FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" colSpan=3>&nbsp;
      <STRONG><FONT face="Times New Roman" size=1>Unexercisable</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><B><FONT face="Times New Roman" size=1>Price</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><B><FONT face="Times New Roman" size=1>Expiration</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Named Executive
      Officer</FONT></B></TD>
    <TD noWrap align=left width="84%"></TD>
    <TD noWrap align=right width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Date</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>(#)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>(#)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=1>($/Sh)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=1>Date</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=1>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>9/29/11</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>1,000,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$2.16</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>9/29/21</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/17/12</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>452,396</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>52,604</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$1.41</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/17/22</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2/13/13</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>949,167</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>390,833</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$1.50</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2/13/23</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2/11/14</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>614,167</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>725,833</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$5.09</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2/11/24</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>3/13/15</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>112,500</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>487,500</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$4.34</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>3/13/25</FONT></TD></TR>
  <TR>
    <TD width="100%" bgColor=#cceeff colSpan=17>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2><FONT face="Times New Roman" size=1>Olivia K. Bloom</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>5/24/06</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>33,750</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>$6.63</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>5/24/16</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>5/23/07</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>20,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>$9.32</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>5/23/17</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>5/28/08</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>20,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>$3.97</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>5/28/18</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>5/28/08</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>10,829</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>$3.97</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>5/28/18</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>5/29/09</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>20,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>$6.52</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>5/29/19</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>5/29/09</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>7,500</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>$6.52</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>5/29/19</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>5/29/09</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>20,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>$6.52</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>5/29/19</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>5/19/10</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>20,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>$5.29</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>5/19/20</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>5/20/11</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>50,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>$4.65</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>5/20/21</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>5/17/12</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>192,604</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>22,396</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>$1.41</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>5/17/22</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>2/12/13</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>283,333</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>116,667</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>$1.51</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>2/12/23</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>2/10/14</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>183,333</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>216,667</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>$5.01</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>2/10/24</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>3/13/15</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>39,375</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>170,625</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>$4.34</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=1>3/13/25</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>44</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>

<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD NOWRAP COLSPAN="20" STYLE="text-align: center; width: 24%; border-bottom: Black 1pt solid"><B><FONT face="Times New Roman" size=1>Option Awards</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Number</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Number</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>of</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>of</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Securities</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Securities</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Underlying</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Underlying</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Unexercised</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><STRONG><FONT size=1 face="Times New Roman">Unexercised</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=4><B><FONT face="Times New Roman" size=1>Option</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Options</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Options</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=4><B><FONT face="Times New Roman" size=1>Exercise</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Option</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Grant</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Exercisable</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><STRONG><FONT size=1 face="Times New Roman">Unexercisable</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=4><B><FONT face="Times New Roman" size=1>Price</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Expiration</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"><B><FONT face="Times New Roman" size=1>Named Executive
    Officer</FONT></B></TD>
    <TD noWrap align=left width="72%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Date</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>(#)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>(#)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=4><B><FONT face="Times New Roman" size=1>($/Sh)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Date</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=1>Melissa A. Kelly Behrs</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT size=1 face="Times New Roman">&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/24/06</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT size=1 face="Times New Roman">&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>60,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT size=1 face="Times New Roman">&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>6.63</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/24/16</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp; </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/23/07</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>50,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>9.32</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/23/17</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/28/08</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>50,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>3.97</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/28/18</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/28/08</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>14,167</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>3.97</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/28/18</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/29/09</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>50,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>6.52</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/29/19</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/29/09</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>20,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>6.52</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/29/19</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/19/10</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>50,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5.29</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/19/20</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/19/10</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>10,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5.29</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/19/20</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/20/11</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>50,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>4.65</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/20/21</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/17/12</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>268,750</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>31,250</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>1.41</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/17/22</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2/12/13</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>212,500</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>87,500</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>1.51</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2/12/23</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2/10/14</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>183,333</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>216,667</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5.01</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2/10/24</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>3/13/15</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>39,375</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>170,625</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>4.34</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>3/13/25</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD width="99%" bgColor=#cceeff colSpan=22>&nbsp;&nbsp; </TD>
    <TD width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" colSpan=2><FONT face="Times New Roman" size=1>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>9/19/12</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1><SUP>(2)</SUP></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>487,500</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>112,500</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>1.70</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>9/19/22</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>2/12/13</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>212,500</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>87,500</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>1.51</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>2/12/23</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>2/10/14</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>183,333</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>216,667</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>5.01</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>2/10/24</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>3/13/15</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>39,375</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>170,625</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>4.34</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>3/13/25</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR>
    <TD width="99%" colSpan=22>&nbsp;&nbsp; </TD>
    <TD width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=1>Stephen N. Rosenfield, J.D.</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>11/1/11</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>36,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2.22</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>11/1/21</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2/16/12</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(5)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>407,292</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>17,708</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2.14</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2/16/22</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/17/12</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(6)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>179,167</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>20,833</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>1.41</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5/17/22</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2/12/13</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>297,500</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>122,500</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>1.51</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2/12/23</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2/10/14</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>183,333</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>216,667</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>5.01</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>2/10/24</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>3/13/15</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>39,375</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>170,625</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=1>4.34</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=1>3/13/25</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD></TR></TABLE><DIV>____________________</DIV>&nbsp;&nbsp;

<TABLE cellSpacing=0 cellPadding=0 border=0 style="text-align: justify">

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD vAlign=top width="100%"><FONT face="Times New Roman" size=2>Stock
      option vests in a series of 48 equal consecutive monthly installments
      commencing from the date of grant, provided the executive officer
      continues to provide services to the Company.</FONT></TD></TR>
  <TR>
    <TD vAlign=top colSpan=2>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD vAlign=top width="100%"><FONT face="Times New Roman" size=2>Stock
      option vests as follows: 75,000 shares on March 17, 2013 and the remaining
      525,000 shares in a series of 42 equal consecutive monthly installments
      commencing from March 17, 2013, provided the executive officer continues
      to provide services to the Company.</FONT></TD></TR>
  <TR>
    <TD vAlign=top colSpan=2>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD vAlign=top width="100%"><FONT face="Times New Roman" size=2>Stock
      option vests as follows: 12,500 shares on April 12, 2013 and the remaining
      287,500 shares in a series of 46 equal consecutive monthly installments
      commencing from April 12, 2013, provided the executive officer continues
      to provide services to the Company.</FONT></TD></TR>
  <TR>
    <TD vAlign=top colSpan=2>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(4)</FONT></TD>
    <TD vAlign=top width="100%"><FONT face="Times New Roman" size=2>Stock
      option was granted in connection with Mr. Rosenfield&#146;s consulting
      agreement prior to his employment with the Company.</FONT></TD></TR>
  <TR>
    <TD vAlign=top colSpan=2>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(5)</FONT></TD>
    <TD vAlign=top width="100%"><FONT face="Times New Roman" size=2>Stock
      option vests as follows: 53,125 shares on August 16, 2012 and the
      remaining 371,875 shares in a series of 42 equal consecutive monthly
      installments commencing from August 16, 2012, provided the executive
      officer continues to provide services to the Company.</FONT></TD></TR>
  <TR>
    <TD vAlign=top colSpan=2>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(6)</FONT></TD>
    <TD vAlign=top width="100%"><FONT face="Times New Roman" size=2>Stock
      option vests as follows: 12,500 shares on August 17, 2012 and the
      remaining 187,500 shares in a series of 45 equal consecutive monthly
      installments commencing from August 17, 2012, provided the executive
      officer continues to provide services to the
Company.</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>45</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><B><FONT face="Times New Roman" size=2>Option Exercises and
Restricted Stock Awards Vested in 2015</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following table
includes certain information with respect to the vesting of restricted stock
awards held by the Named Executive Officers during the fiscal year ended
December 31, 2015. No options were exercised by the Named Executive Officers
during the fiscal year ended December 31, 2015. </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Number of</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=4><B><FONT face="Times New Roman" size=1>Value</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Shares Acquired</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=4><B><FONT face="Times New Roman" size=1>Realized
    on</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>On Vesting</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=4><B><FONT face="Times New Roman" size=1>Vesting</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"><B><FONT face="Times New Roman" size=1>Named Executive
      Officer</FONT></B></TD>
    <TD noWrap align=left width="88%">&nbsp;</TD>
    <TD noWrap align=right width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face="Times New Roman" size=1></FONT></B><B><FONT face="Times New Roman" size=1>(#)<SUP>(1)</SUP></FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=4><B><FONT face="Times New Roman" size=1>($)<SUP>(2)</SUP></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" colSpan=2><FONT face="Times New Roman" size=2>Olivia K. Bloom</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>6,250</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>23,969</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Melissa A. Kelly Behrs</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>6,250</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>23,969</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" colSpan=2><FONT face="Times New Roman" size=2>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Stephen N. Rosenfield,
    J.D.</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR></TABLE><DIV>____________________</DIV><BR>

<TABLE cellSpacing=0 cellPadding=0 border=0 style="text-align: justify">

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Represents the
      vesting of previously granted restricted stock awards.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>The value realized is
      based upon the closing price of our Common Stock as reported by the NASDAQ
      Global Select Market on the vesting date multiplied by the number of
      shares of restricted stock vested.</FONT></TD></TR></TABLE>
<P align=justify><B><FONT face="Times New Roman" size=2>Pension
Benefits</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>None of the Named Executive
Officers participates in or has an account balance under any defined benefit
pension or retirement plans sponsored by the Company.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Non-Qualified Deferred
Compensation</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>None of the Named Executive
Officers participates in or has an account balance under non-qualified defined
contribution plans or other non-qualified deferred compensation plans maintained
by the Company.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Additional
Benefits</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Named Executive
Officers are eligible to participate in our benefit plans generally available to
all employees, as described in the section entitled &#147;Compensation Discussion and
Analysis &#150; Other Compensation.&#148;</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Potential Payments Upon
Termination or Change in Control</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>See discussion of potential
payments upon termination or change in control in the section entitled,
&#147;Compensation Discussion and Analysis &#150; Severance and Change in Control
Benefits.&#148;</FONT></P>

 <P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The table below summarizes potential maximum payments under the
Amended Severance Plan, or individual employment agreements, as applicable, for
the Named Executive Officers and our equity plans if a qualifying termination
and/or change in control event occurred on December 31, 2015.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"><B><FONT face="Times New Roman" size=1>Named Executive
      Officer</FONT></B></TD>
    <TD noWrap align=left width="78%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=1>Benefit</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=4><B><FONT face="Times New Roman" size=1>Covered<BR><B><FONT face="Times New Roman" size=1>Termination</FONT></B><BR><B><FONT face="Times New Roman" size=1>(No Change
      in<BR></FONT></B>Control)<SUP>(1)</SUP></FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><B><FONT face="Times New Roman" size=1>Termination<BR><B><FONT face="Times New Roman" size=1>Without Cause or</FONT></B><BR><B><FONT face="Times New Roman" size=1>for Good Reason<BR></FONT></B>(Change in
      Control)<SUP>(2)(3)</SUP></FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><FONT face="Times New Roman" size=1><STRONG>Change in<BR><FONT face="Times New Roman" size=1>Control</FONT><BR></STRONG><FONT face="Times New Roman" size=1><STRONG>Without<BR></STRONG></FONT><STRONG>Termination<SUP>(3)</SUP></STRONG></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Severance</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff>&nbsp;&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1,570,647</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1,570,647</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#cceeff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Continued</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#cceeff colSpan=2>&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Healthcare</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#cceeff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Benefits</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>23,877</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>35,816</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#cceeff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Option</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="81%" bgColor=#cceeff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Vesting</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1,729,564</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1,729,564</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD style="WIDTH: 81%; TEXT-ALIGN: left" noWrap width="81%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Total</FONT></TD>
    <TD style="WIDTH: 1%; TEXT-ALIGN: left" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="WIDTH: 1%; TEXT-ALIGN: left" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="WIDTH: 1%; TEXT-ALIGN: right" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="WIDTH: 1%; TEXT-ALIGN: right" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="WIDTH: 1%; BORDER-BOTTOM: #000000 2pt double; TEXT-ALIGN: right" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="WIDTH: 1%; BORDER-BOTTOM: #000000 2pt double; TEXT-ALIGN: right" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1,594,524</FONT></TD>
    <TD style="WIDTH: 1%; TEXT-ALIGN: left" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="WIDTH: 1%; TEXT-ALIGN: left" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="WIDTH: 1%; TEXT-ALIGN: left" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="WIDTH: 1%; BORDER-BOTTOM: #000000 2pt double; TEXT-ALIGN: left" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="WIDTH: 2%; BORDER-BOTTOM: #000000 2pt double; TEXT-ALIGN: right" noWrap width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3,336,027</FONT></TD>
    <TD style="WIDTH: 1%; TEXT-ALIGN: right" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="WIDTH: 1%; TEXT-ALIGN: right" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="WIDTH: 1%; TEXT-ALIGN: right" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="WIDTH: 1%; BORDER-BOTTOM: #000000 2pt double; TEXT-ALIGN: right" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="WIDTH: 2%; BORDER-BOTTOM: #000000 2pt double; TEXT-ALIGN: right" noWrap width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1,729,564</FONT></TD>
    <TD style="WIDTH: 1%; TEXT-ALIGN: right" noWrap width="1%" bgColor=#cceeff></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>46</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%"><B><FONT face="Times New Roman" size=1>Named Executive
      Officer</FONT></B></TD>
    <TD noWrap align=left width="78%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%"><B><FONT face="Times New Roman" size=1>Benefit</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=4><B><FONT face="Times New Roman" size=1>Covered<BR><B><FONT face="Times New Roman" size=1>Termination</FONT></B><BR><B><FONT face="Times New Roman" size=1>(No Change
      in<BR></FONT></B>Control)<SUP>(1)</SUP></FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><B><FONT face="Times New Roman" size=1>Termination<BR><B><FONT face="Times New Roman" size=1>Without Cause or</FONT></B><BR><B><FONT face="Times New Roman" size=1>for Good Reason<BR></FONT></B>(Change in
      Control)<SUP>(2)(3)</SUP></FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><B><FONT face="Times New Roman" size=1>Change in<BR><B><FONT face="Times New Roman" size=1>Control</FONT></B><BR><B><FONT face="Times New Roman" size=1>Without<BR></FONT></B>Termination<SUP>(3)</SUP></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Olivia K. Bloom</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Severance</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>545,128</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>639,115</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Continued</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Healthcare</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Benefits</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3,468</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>4,335</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff colSpan=2>&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Option</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Vesting</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>550,632</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>550,632</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Total</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>548,596</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1,194,082</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>550,632</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD width="99%" bgColor=#cceeff colSpan=18>&nbsp;&nbsp; </TD>
    <TD width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#ffffff colSpan=2><FONT face="Times New Roman" size=2>Melissa A. Kelly Behrs</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Severance</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>525,712</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>616,352</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="2%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#ffffff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Continued</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="2%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="2%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#ffffff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Healthcare</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="2%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="2%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#ffffff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Benefits</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>32,807</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>41,009</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="2%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#ffffff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Option</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="2%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="2%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#ffffff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Vesting</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>483,875</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>483,875</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#ffffff colSpan=2><FONT face="Times New Roman" size=2>Total</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="2%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>558,519</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>1,141,236</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>483,875</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD></TR>
  <TR>
    <TD width="99%" bgColor=#ffffff colSpan=18>&nbsp;&nbsp; </TD>
    <TD width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Severance</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>566,037</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>663,629</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Continued</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Healthcare</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Benefits</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>32,880</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>41,100</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Option</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Vesting</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>729,938</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>729,938</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Total</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>598,917</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1,434,667</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>729,938</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD width="99%" bgColor=#cceeff colSpan=18>&nbsp; </TD>
    <TD width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#ffffff colSpan=2><FONT face="Times New Roman" size=2>Stephen N. Rosenfield, J.D.</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Severance</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>465,972</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>546,312</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="2%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#ffffff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Continued</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="2%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="2%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#ffffff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Healthcare</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="2%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="2%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#ffffff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Benefits</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>1,872</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>2,340</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="2%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#ffffff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Option</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="2%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="2%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#ffffff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Vesting</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>612,506</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>612,506</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#ffffff colSpan=2><FONT face="Times New Roman" size=2>Total</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="2%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>467,844</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>1,161,158</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#ffffff><FONT face="Times New Roman" size=2>612,506</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD></TR></TABLE><DIV>____________________</DIV><BR>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD vAlign=top align=left width="100%">
      <P align=justify><FONT face="Times New Roman" size=2>Amounts represent
      lump-sum severance payments, target annual incentive bonus or accrued
      annual incentive bonus and continued healthcare benefits that could be
      paid to the Named Executive Officer upon a Covered Termination, not in
      connection with a change in control transaction on December 31, 2015,
      under such Named Executive Officer&#146;s employment agreement as of December
      31, 2015, as applicable. Descriptions of the severance payments in the
      event of the Covered Termination provided for under such Named Executive
      Officer&#146;s employment agreement are included under the section entitled
      &#147;Compensation Discussion and Analysis &#150; Severance and Change in Control
      Benefits&#148;. Any payments made under the Named Executive Officer&#146;s
      employment agreement would be deducted from payments due under the Amended
      Severance Plan.</FONT></P></TD></TR>
  <TR>
    <TD vAlign=top colSpan=2>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD vAlign=top align=left width="100%">
      <P align=justify><FONT face="Times New Roman" size=2>Amounts represent
      lump-sum severance payments, target annual incentive bonus or accrued
      annual incentive bonus, continued healthcare benefits and the intrinsic
      value of acceleration of unvested stock options, based on a market value
      of $4.84 per share of Common Stock as of December 31, 2015, as applicable,
      that could be paid to the Named Executive Officer under such Named
      Executive Officer&#146;s employment agreement and/or our Amended Severance Plan
      in the event of the Covered Termination or Change in Control Triggering
      Event on December 31, 2015, as applicable. Any payments made under the
      Named Executive Officer&#146;s employment agreement would be deducted from
      payments due under the Amended Severance Plan.</FONT></P></TD></TR>
  <TR>
    <TD vAlign=top colSpan=2>&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD vAlign=top align=left width="100%">
      <P align=justify><FONT face="Times New Roman" size=2>Amounts represent or
      include, as applicable, the intrinsic value of unvested stock options that
      would become fully vested and exercisable upon a change in control
      regardless of termination, based on a market value of $4.84 per share of
      Common Stock as of December 31, 2015.</FONT></P></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>47</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="EquityCompensationPlans"></A>EQUITY COMPENSATION
PLANS</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following table
summarizes information with respect to equity awards under Geron&#146;s equity
compensation plans at December 31, 2015:</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Number
      of<BR><B><FONT face="Times New Roman" size=1>securities to be</FONT></B><BR><B><FONT face="Times New Roman" size=1>issued upon exercise</FONT></B><BR><B><FONT face="Times New Roman" size=1>of outstanding</FONT></B><BR><B><FONT face="Times New Roman" size=1>options,
      warrants<BR></FONT></B>and rights<SUP>(1)</SUP></FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=4><B><FONT face="Times New Roman" size=1>Weighted-<BR><B><FONT face="Times New Roman" size=1>average</FONT></B><BR><B><FONT face="Times New Roman" size=1>exercise
      price</FONT></B><BR><B><FONT face="Times New Roman" size=1>of
      outstanding</FONT></B><BR><B><FONT face="Times New Roman" size=1>options,
      warrants<BR></FONT></B>and rights</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Number of
      securities<BR><B><FONT face="Times New Roman" size=1>remaining available
      for</FONT></B><BR><B><FONT face="Times New Roman" size=1>future issuance
      under</FONT></B><BR><B><FONT face="Times New Roman" size=1>equity
      compensation</FONT></B><BR><B><FONT face="Times New Roman" size=1>plans (excluding
      securities<BR></FONT></B>reflected in column
    (a))<SUP>(1)</SUP></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap style="text-align: center" width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>(a)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=4><B><FONT face="Times New Roman" size=1>(b)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap style="text-align: center" width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>(c)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Equity compensation plans approved by</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp; &nbsp;&nbsp;&nbsp; &nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; security
    holders</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>17,205,683</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><SUP>(2)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3.29</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>12,997,281</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><SUP>(3)</SUP></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT face="Times New Roman" size=2>Equity compensation plans not approved by</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; security
    holders</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%"></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>17,205,683</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD NOWRAP STYLE="text-align: right; width: 1%; background-color: #cceeff"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD NOWRAP STYLE="text-align: center; width: 1%; background-color: #cceeff"><FONT face="Times New Roman" size=2>3.29</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>12,997,281</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR></TABLE><DIV>____________________</DIV><BR>
<TABLE cellSpacing=0 cellPadding=0 border=0 style="text-align: justify">

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>The table does not include information
      regarding Geron&#146;s 401(k) Plan. The Geron 401(k) Plan permits us to make
      matching contributions on behalf of plan participants, which matching
      contributions can be made in Common Stock that vests ratably over four
      years for each year of service completed by the employee, commencing from
      the date of hire, until it is fully vested when the employee has completed
      four years of service. As of December 31, 2015, there were approximately
      734,049 shares of Common Stock held in this plan.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 1,047,991 shares to be issued
      upon exercise of outstanding options under the 2002 Equity Incentive Plan,
      15,041,067 shares under the 2011 Incentive Award Plan, 5,000 shares under
      the 1996 Directors&#146; Stock Option Plan and 1,111,625 shares under the 2006
      Directors&#146; Plan.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 942,365 shares of Common Stock
      available for issuance under the 2014 Employee Stock Purchase Plan and
      12,054,916 shares of Common Stock available for issuance under the 2011
      Incentive Award Plan.</FONT></TD></TR></TABLE>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="proposal3"></A>PROPOSAL 3</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>RATIFICATION OF SELECTION
OF<BR></FONT></B><B><FONT face="Times New Roman" size=2>INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Audit Committee of the
Board has selected Ernst &amp; Young LLP as our independent registered public
accounting firm for the fiscal year ending December 31, 2016, and has further
directed that management submit the selection of the independent registered
public accounting firm for ratification by our stockholders at the Annual
Meeting. Ernst &amp; Young LLP has served as our independent registered public
accounting firm since 1992. Representatives of Ernst &amp; Young LLP are
expected to be present at the Annual Meeting, will have an opportunity to make a
statement if they so desire, and will be available to respond to appropriate
questions from stockholders.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We have been informed by
Ernst &amp; Young LLP that, to the best of their knowledge, neither the firm nor
any of its members or their associates has any direct financial interest or
material indirect financial interest in Geron or our affiliates.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Stockholder ratification of
the selection of Ernst &amp; Young LLP as our independent registered public
accounting firm is not required by our Bylaws or otherwise. However, the Board
is submitting the selection of Ernst &amp; Young LLP to our stockholders for
ratification as a matter of good corporate practice. If our stockholders fail to
ratify the selection, the Audit Committee and the Board will reconsider whether
or not to retain that firm. Even if the selection is ratified, the Audit
Committee and the Board in their discretion may direct the appointment of a
different independent registered public accounting firm at any time during the
year if they determine that such a change would be in the best interests of
Geron and our stockholders.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>48</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><B><FONT face="Times New Roman" size=2>Vote Required and Board
Recommendation</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Stockholder ratification of
the selection of Ernst &amp; Young LLP as our independent registered public
accounting firm requires the affirmative vote of the holders of a majority of
the shares present in person or represented by proxy at this meeting.
Abstentions will have the same effect as a vote against this proposal, and
broker non-votes will have no effect on the outcome of this proposal.</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>The Board of Directors
Unanimously Recommends That<BR>Stockholders Vote <U>FOR</U> Proposal
3</FONT></B></P>
<P align=center><A NAME="PrincipalAccountantFees"></A><B><FONT face="Times New Roman" size=2>PRINCIPAL ACCOUNTANT FEES
AND SERVICES</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Audit Committee
maintains policies and procedures for the pre-approval of work performed by the
independent registered public accounting firm. Under the Audit Committee&#146;s
charter, all engagements of the independent registered public accounting firm
must be approved in advance by the Audit Committee. Management recommendations
will be considered in connection with such engagements, but management will have
no authority to approve engagements. For each quarterly Audit Committee meeting,
management prepares a schedule of all fees paid to Ernst &amp; Young LLP during
the previous quarter and estimated fees for projects contemplated in the
following quarter. The Chairperson of the Audit Committee must be notified at
any time the fees for a specific project exceed 20% of the approved budget for
authorization to continue the project.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Upon recommendation by the
Audit Committee, the Board selected Ernst &amp; Young LLP to act in the same
capacity for the fiscal year ending December 31, 2016. We have been informed by
Ernst &amp; Young LLP, to the best of their knowledge, that neither the firm nor
any of its members or their associates has any financial interest, direct or
indirect in Geron or our affiliates.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Audit Fees and All Other
Fees</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Audit Committee
approved 100% of all audit and other services provided by Ernst &amp; Young LLP
in 2015 and 2014. The total fees paid to Ernst &amp; Young LLP for the last two
fiscal years are as follows: </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Fiscal Year
      Ended<BR>December 31, 2015</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><B><FONT face="Times New Roman" size=1>Fiscal Year
      Ended<BR>December 31, 2014</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Audit Fees<SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>530,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>615,679</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>Audit Related Fees</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Tax
      Fees</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>All
      Other Fees<SUP>(2)</SUP></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>940</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>1,995</FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR></TABLE><DIV>____________________</DIV><BR>
<TABLE cellSpacing=0 cellPadding=0 border=0 style="text-align: justify">

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Audit Fees include
      the integrated audit of annual financial statements and internal control
      over financial reporting, reviews of quarterly financial statements
      included in Quarterly Reports on Forms 10-Q, consultations on matters
      addressed during the audit or quarterly reviews, and services provided in
      connection with SEC filings, including consents and comment and comfort
      letters.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Amounts represent
      fees for access to Ernst &amp; Young&#146;s technical research
  portal.</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>49</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="AuditCommitteeReport"></A>AUDIT COMMITTEE
REPORT</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Audit Committee of
Geron Corporation&#146;s Board of Directors is comprised of three independent
directors as required by the listing standards of NASDAQ. The Audit Committee
operates pursuant to a written charter adopted and amended by the Board in May
2015. A copy of the Audit Committee&#146;s amended and restated charter is available
on our website at www.geron.com.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The members of the Audit
Committee are Ms. Eastham (Chairperson), Dr. Lawlis and Mr. Bradbury. The Board
has determined that all members of the Audit Committee are financially literate
as required by NASDAQ. The Board has also determined that Ms. Eastham and Mr.
Bradbury are audit committee financial experts as defined by NASDAQ.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The function of the Audit
Committee is to assist the Board in fulfilling its oversight responsibilities
regarding: (i) the quality and integrity of our financial statements, (ii) our
compliance with legal and regulatory requirements, (iii) the qualifications and
independence of the independent registered public accounting firm serving as our
auditors and (iv) the performance of the independent registered public
accounting firm.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Management is responsible
for Geron&#146;s internal controls and financial reporting. The independent
registered public accounting firm is responsible for performing an independent
audit of Geron&#146;s financial statements in accordance with generally accepted
auditing standards and to issue a report thereon. The Audit Committee&#146;s
responsibility is to monitor and oversee these processes.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In this context, the Audit
Committee hereby reports as follows:</FONT></P>
<TABLE cellSpacing=0 cellPadding=0 border=0 style="text-align: justify">

  <TR>
    <TD vAlign=top noWrap>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>1)</FONT></TD>
    <TD noWrap>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>The Audit Committee has reviewed and
      discussed the audited financial statements of the Company as of and for
      the fiscal year ended December 31, 2015 with management and the
      independent registered public accounting firm serving as the Company&#146;s
      independent auditors.</FONT></TD></TR>
  <TR>
    <TD noWrap></TD>
    <TD width="100%" colSpan=3>&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>2)</FONT></TD>
    <TD noWrap></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>The Audit Committee has discussed with the
      independent auditors the matters required to be discussed by Auditing
      Standard No. 16 (Communication with Audit Committees) as adopted by the
      Public Company Accounting Oversight Board, other professional standards,
      membership provisions of the SEC Practice Session, and other SEC rules, as
      currently in effect.</FONT></TD></TR>
  <TR>
    <TD noWrap></TD>
    <TD width="100%" colSpan=3>&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>3)</FONT></TD>
    <TD noWrap>&nbsp;</TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>The Audit Committee has received the written
      disclosures and the letter from the independent auditors required by
      applicable requirements of the Public Company Accounting Oversight Board
      regarding the independent auditor&#146;s communications with the Audit
      Committee concerning independence, and has discussed with the independent
      auditors the independent auditor&#146;s independence.</FONT></TD></TR>
  <TR>
    <TD noWrap></TD>
    <TD width="100%" colSpan=3>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>4)</FONT></TD>
    <TD noWrap></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>The Audit Committee has considered whether
      the independent auditor&#146;s provision of non-audit services to the Company
      is compatible with maintaining the independent auditor&#146;s
      independence.</FONT></TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Based on the reports and
discussions described above, the Audit Committee recommended to the Board that
the audited financial statements be included in Geron&#146;s Annual Report on Form
10-K for the year ended December 31, 2015, for filing with the SEC.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Submitted on March 3, 2016
by the members of the Audit Committee of Geron&#146;s Board of Directors.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%"><FONT face="Times New Roman" size=2>Karin Eastham (Chairperson)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%"><FONT face="Times New Roman" size=2>Daniel M. Bradbury</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%"><FONT face="Times New Roman" size=2>V.
      Bryan Lawlis, Ph.D.</FONT></TD></TR></TABLE><BR>
<P align=justify><I><FONT face="Times New Roman" size=2>____________________<BR><BR>This
Section is not &#147;soliciting material,&#148; is not deemed &#147; filed&#148; with the SEC and is
not to be incorporated by reference in any filing of the Company under the
Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as
amended, whether made before or after the date hereof and irrespective of any
general incorporation language in any such filing.</FONT></I></P>
<P align=center><FONT face="Times New Roman" size=2>50</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="SecurityOwnershipofCertain"></A>SECURITY OWNERSHIP OF
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following table sets
forth the amount and percentage of the outstanding shares of Common Stock,
which, according to the information supplied to us, are beneficially owned by:
(i) each person, or group of affiliated persons, who is known by us to be a
beneficial owner of more than 5% of our outstanding Common Stock, (ii) each of
our directors and nominees for director, (iii) each of our Named Executive
Officers and (iv) all current directors and executive officers as a group.
Unless otherwise indicated, the address for each of the stockholders in the
table below is c/o Geron Corporation, 149 Commonwealth Drive, Suite 2070, Menlo
Park, CA 94025. Except for information based on Schedules 13G, as indicated in
the footnotes, beneficial ownership is stated as of February 11, 2016.
</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="9%" colSpan=7><B><FONT face="Times New Roman" size=1>Beneficial
      Ownership<SUP>(1)</SUP></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%"><B><FONT face="Times New Roman" size=1>Beneficial
      Owner</FONT></B></TD>
    <TD noWrap align=left width="88%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Number
      of<BR>Shares</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Percent
      of<BR>Total</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff colSpan=2><B><FONT face="Times New Roman" size=2>Directors/Nominees and Named Executive
      Officers:</FONT></B></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" colSpan=2><FONT face="Times New Roman" size=2>Daniel M. Bradbury<SUP>(2)</SUP></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>293,638</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Karin Eastham<SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>254,547</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" colSpan=2><FONT face="Times New Roman" size=2>Hoyoung Huh, M.D., Ph.D.<SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>416,619</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>V. Bryan Lawlis,
    Ph.D.<SUP>(5)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>175,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" colSpan=2><FONT face="Times New Roman" size=2>Susan M. Molineaux, Ph.D.<SUP>(6)</SUP></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>175,109</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Robert J. Spiegel, M.D.,
      FACP<SUP>(7)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>223,739</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" colSpan=2><FONT face="Times New Roman" size=2>Melissa A. Kelly Behrs<SUP>(8)</SUP></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>1,274,447</FONT></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Olivia K. Bloom<SUP>(9)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1,110,209</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" colSpan=2><FONT face="Times New Roman" size=2>Andrew J. Grethlein, Ph.D.<SUP>(10)</SUP></FONT></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>1,036,433</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Stephen N. Rosenfield,
      J.D.<SUP>(11)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1,271,957</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" colSpan=2><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.<SUP>(12)</SUP></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>3,542,710</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>2.18</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>All directors and executive officers as a
      group (11 persons)<SUP>(13)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>9,774,408</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>5.82</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" colSpan=2><B><FONT face="Times New Roman" size=2>5% Beneficial Holders:</FONT></B></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>FMR LLC<SUP>(14)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>23,721,325</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>14.93</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 245
      Summer Street, Boston, MA 02210</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" colSpan=2><FONT face="Times New Roman" size=2>BlackRock, Inc.<SUP>(15)</SUP></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>10,687,314</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>6.73</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 55 East 52<SUP>nd
      </SUP>Street, New York, NY 10055</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD></TR></TABLE>

<DIV align=justify>____________________</DIV><BR>

<TABLE cellSpacing=0 cellPadding=0 border=0 style="text-align: justify">

  <TR>
    <TD vAlign=top noWrap align=right><FONT size=2 face="Times New Roman">*</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD width="100%"><FONT size=2 face="Times New Roman">Represents beneficial
      ownership of less than 1% of Common Stock.</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap></TD>
    <TD width="100%">&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)</FONT></TD>
    <TD vAlign=top noWrap><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD align=left width="100%">
      <P align=justify><FONT face="Times New Roman" size=2>Beneficial ownership
      is determined in accordance with the rules of the SEC. In computing the
      number of shares beneficially owned by a person and the percentage of
      ownership of that person, shares of Common Stock exercisable pursuant to
      the exercise of options held by that person that are currently exercisable
      or exercisable within 60 days of February 11, 2016 are deemed outstanding.
      Such shares, however, are not deemed outstanding for the purpose of
      computing the percentage ownership of each other person. Applicable
      percentages are based on 158,916,775 shares outstanding on February 11,
      2016, adjusted as required by rules promulgated by the SEC. The persons
      named in this table, to the best of our knowledge, have sole voting and
      investment power with respect to all shares of Common Stock shown as
      beneficially owned by them, subject to community property laws where
      applicable and except as indicated in the other footnotes to this
      table.</FONT></P></TD></TR>
  <TR>
    <TD width="100%" colSpan=3>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 142,776
      shares held directly by Daniel M. Bradbury, 10,862 shares held by The
      Bradbury Family Trust and 140,000 shares issuable upon the exercise of
      outstanding options held by Mr. Bradbury exercisable within 60 days of
      February 11, 2016.</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=3>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 39,047
      shares held directly by Karin Eastham and 215,500 shares issuable upon the
      exercise of outstanding options held by Ms. Eastham exercisable within 60
      days of February 11, 2016.</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=3>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(4)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 119,119
      shares held by Hoyoung Huh and 297,500 shares issuable upon the exercise
      of outstanding options held by Dr. Huh exercisable within 60 days of
      February 11, 2016.</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>51</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<TABLE cellSpacing=0 cellPadding=0 border=0 style="text-align: justify">

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(5)</FONT></TD>
    <TD vAlign=top noWrap><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 175,000
      shares issuable upon the exercise of outstanding options held by V. Bryan
      Lawlis exercisable within 60 days of February 11, 2016.</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=3>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(6)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 35,109
      shares held by the Molineaux Family Trust and 140,000 shares issuable upon
      the exercise of outstanding options held by Dr. Molineaux exercisable
      within 60 days of February 11, 2016.</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=3>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(7)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 48,739
      shares held directly by Robert J. Spiegel and 175,000 shares issuable upon
      exercise of outstanding options held by Dr. Spiegel exercisable within 60
      days of February 11, 2016.</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=3>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(8)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 123,614
      shares held directly by Melissa A. Kelly Behrs and 1,150,833 shares
      issuable upon exercise of outstanding options held by Ms. Behrs
      exercisable within 60 days of February 11, 2016.</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=3>&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(9)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 115,839
      shares held directly by Olivia K. Bloom and 994,370 shares issuable upon
      the exercise of outstanding options held by Ms. Bloom exercisable within
      60 days of February 11, 2016.</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=3>&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(10)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 2,267
      shares held directly by Andrew J. Grethlein and 1,034,166 shares issuable
      upon the exercise of outstanding options held by Dr. Grethlein exercisable
      within 60 days of February 11, 2016.</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=3>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(11)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 17,624
      shares held directly by Stephen N. Rosenfield and 1,254,333 shares
      issuable upon the exercise of outstanding options held by Mr. Rosenfield
      exercisable within 60 days of February 11, 2016.</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=3>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(12)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 125,000
      shares held by the John A. Scarlett III 1999 Trust and 3,417,710 shares
      issuable upon exercise of outstanding options held by Dr. Scarlett
      exercisable within 60 days of February 11, 2016.</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=3>&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(13)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of shares
      beneficially owned by our current directors and executive officers as
      described in footnotes (2) through (12).</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=3>&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(14)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>The indicated
      ownership is based solely on a Schedule 13G/A filed with the SEC by FMR
      LLC (&#147;FMR&#148;) on February 12, 2016, reporting beneficial ownership as of
      December 31, 2015. The Schedule 13G/A filed by the reporting person
      provides information only as of December 31, 2015, and, consequently, the
      beneficial ownership of the above-mentioned reporting person may have
      changed between December 31, 2015 and February 11, 2016. FMR has sole
      voting power with respect to 500 shares and sole dispositive power with
      respect to all of the shares. FMR is the beneficial owner of 23,721,325
      shares. Members of the Johnson family, including Abigail P. Johnson, are
      the predominant owners, directly or through trusts, of Series B voting
      common shares of FMR, representing 49% of the voting power of FMR. The
      Johnson family group and all other Series B shareholders have entered into
      a shareholders&#146; voting agreement under which all Series B voting common
      shares will be voted in accordance with the majority vote of Series B
      voting common shares. Accordingly, through their ownership of voting
      common shares and the execution of the shareholders&#146; voting agreement,
      members of the Johnson family may be deemed, under the Investment Company
      Act of 1940, to form a controlling group with respect to FMR. Neither FMR
      nor Abigail P. Johnson has the sole power to vote or direct the voting of
      the shares owned directly by the various investment companies registered
      under the Investment Company Act (&#147;Fidelity Funds&#148;) advised by Fidelity
      Management &amp; Research Company, a wholly owned subsidiary of FMR, which
      power resides with the Fidelity Funds&#146; Boards of Trustees. Fidelity
      Management &amp; Research Company carries out the voting of the shares
      under written guidelines established by the Fidelity Funds&#146; Boards of
      Trustees.</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=3>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(15)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>The indicated
      ownership is based solely on a Schedule 13G/A filed with the SEC by
      BlackRock, Inc. (&#147;BlackRock&#148;) on January 26, 2016, reporting beneficial
      ownership as of December 31, 2015. The Schedule 13G/A filed by the
      reporting person provides information only as of December 31, 2015, and,
      consequently, the beneficial ownership of the above-mentioned reporting
      person may have changed between December 31, 2015 and February 11, 2016.
      BlackRock has sole voting power with respect to 10,391,795 shares and sole
      dispositive power with respect to all of the shares. BlackRock is the
      beneficial owner of 10,687,314 shares.</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>52</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="CertainTransactions"></A>CERTAIN
TRANSACTIONS</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>There has not been, nor is
there currently proposed, any transaction or series of similar transactions to
which the Company was or is to be a party in which the amount involved exceeds
$120,000 and in which any current director, executive officer, holder of more
than 5% of our Common Stock or any immediate family member of any of the
foregoing persons had or will have a direct or indirect material interest other
than with respect to compensation arrangements described under the sections
entitled &#147;Executive Compensation Tables&#148; and &#147;Compensation of Directors,&#148; and
the indemnification agreements described below.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Certain Transactions
With or Involving Related Persons</FONT></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Indemnity
Agreements</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We have entered into
indemnity agreements with all of our executive officers and directors which
provide, among other things, that we will indemnify such executive officer or
director, under the circumstances and to the extent provided for therein, for
expenses, damages, judgments, fines, settlements he or she may be required to
pay in actions or proceedings which he or she is or may be made a party by
reason for his or her position as a director, executive officer or other agent
of the Company, and otherwise to the full extent permitted under Delaware law
and our Bylaws.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Policies and
Procedures</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our Audit Committee is
responsible for reviewing and approving all related party transactions, which
would include a transaction, arrangement or relationship (or any series of
similar transactions, arrangements or relationships) in which we and any
&#147;related person&#148; are participants involving an amount that exceeds $120,000, not
including transactions involving compensation for services provided to Geron as
an employee, director, consultant or similar capacity by a related person.
Related parties include any of our directors or executive officers, certain of
our stockholders and their immediate family members. This obligation is set
forth in writing in the Audit Committee charter. A copy of the Audit Committee
charter is available on the Corporate Governance page under the Investor
Relations section of our website at www.geron.com.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Where a transaction has
been identified as a related-person transaction, management would present
information regarding the proposed related-person transaction to the Audit
Committee (or, where Audit Committee approval would be inappropriate, to another
independent body of the Board) for consideration and approval or ratification.
The presentation would include a description of, among other things, the
material facts, the interests, direct and indirect, of the related persons, the
benefits to Geron of the transaction and whether any alternative transactions
were available. To identify related-person transactions in advance, the Audit
Committee relies on information supplied by Geron&#146;s executive officers and
directors. In considering related-person transactions, the Audit Committee takes
into account the relevant available facts and circumstances including, but not
limited to: (a) the risks, costs and benefits to Geron, (b) the impact on a
director&#146;s independence in the event the related person is a director, immediate
family member of a director or an entity with which a director is affiliated,
(c) the terms of the transaction, (d) the availability of other sources for
comparable services or products and (e) the terms available to or from, as the
case may be, unrelated third parties or to or from employees generally. In the
event a director has an interest in the proposed transaction, the director must
recuse himself or herself from the deliberations and approval. In determining
whether to approve, ratify or reject a related-person transaction, the Audit
Committee considers, in light of known circumstances, whether the transaction is
in, or is not inconsistent with, the best interests of Geron and our
stockholders, as the Audit Committee determines in the good faith exercise of
its discretion.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>53</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="OtherMatters"></A>OTHER
MATTERS</FONT></B></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Section 16(a) Beneficial
Ownership Reporting Compliance</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Section 16(a) of the
Exchange Act requires our directors and executive officers, and persons who
beneficially own more than 10% of a registered class of our equity securities
(collectively, &#147;Reporting Persons&#148;), to file with the SEC initial reports of
ownership and reports of changes in ownership of Geron Common Stock and other
equity securities. Reporting Persons are required by SEC regulations to furnish
us with copies of all Section 16(a) forms they file.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>To our knowledge, based
solely upon a review of the copies of such reports furnished to us and written
representations from such directors, executive officers and stockholders that no
other reports were required, we believe that during fiscal year ended December
31, 2015, all Reporting Persons complied with the applicable Section 16(a)
reporting requirements.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Stockholder Nominations
and Proposals for 2017 Annual Meeting</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We expect to hold our 2017
Annual Meeting of Stockholders in May 2017. All proposals or director
nominations by stockholders intended to be presented at the 2017 Annual Meeting
of Stockholders must be directed to the attention of our Corporate Secretary, at
the address set forth on the first page of this Proxy Statement.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>To be considered for
inclusion in next year&#146;s proxy materials, your proposal must be submitted in
writing by December 5, 2016, to our Corporate Secretary at Geron Corporation,
149 Commonwealth Drive, Suite 2070, Menlo Park, California, 94025, and must
comply with all applicable requirements of Rule 14a-8 promulgated under the
Exchange Act. However, if our 2017 Annual Meeting of Stockholders is not held
between April 17, 2017 and June 16, 2017, then the deadline will be a reasonable
time prior to the time we begin to print and send our proxy
materials.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>If you wish to bring a
proposal before the stockholders or nominate a director at the 2017 Annual
Meeting of Stockholders, but you are not requesting that your proposal or
nomination be included in next year&#146;s proxy materials, you must notify our
Corporate Secretary, in writing, not earlier than the close of business on
January 17, 2017 and not later than the close of business on February 16, 2017.
However, if the 2017 Annual Meeting of Stockholders is not held between April
17, 2017 and July 16, 2017, the notice must be delivered no later than the 90th
day prior to the 2017 Annual Meeting of Stockholders or, if later, the 10th day
following the day on which public disclosure of the date of the 2017 Annual
Meeting of Stockholders is made. In addition, our Bylaws provide that the
stockholder&#146;s notice must include certain information for the person making the
proposal or the nomination for director, including:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">name and address;<BR>&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><FONT face="Times New Roman" size=2>the class
      and number of shares of the Company, owned of record or beneficially
      owned;<BR>&nbsp;&nbsp; </FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><FONT face="Times New Roman" size=2>any
      derivative, swap or other transaction which gives economic risk similar to
      ownership of shares of the Company;<BR>&nbsp; </FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">any proxy, agreement, arrangement,
      understanding or relationship that confers a right to vote any shares of
      the Company;<BR>&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">any agreement, arrangement, understanding or
      relationship, engaged in to increase or decrease the level of risk related
      to, the voting power with respect to, and certain other arrangements or
      agreements with respect to, shares of the Company;</TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>54</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">any performance-related fees that the
      proposing/nominating person is entitled, based on any increase or decrease
      in the value of any shares of the Company; and&nbsp;<BR>&nbsp;&nbsp;&nbsp;
    </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">any other information required by the SEC to be
      disclosed in a proxy statement or certain other
filings.</TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The stockholder&#146;s notice
must also include information for each proposed director nominee,
including:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">the same information as for the nominating
      person set forth above;&nbsp;<BR>&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">all information required to be disclosed in a
      proxy statement in connection with election of directors;
      and&nbsp;<BR>&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">financial or other relationships between the
      nominating person and the nominee during the past three
  years.</TD></TR></TABLE>
<P ALIGN="JUSTIFY"><FONT face="Times New Roman" size=2>Copies of our Bylaws may be
obtained from our Corporate Secretary.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Director Nominees
Recommended by Stockholders</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Nominating and
Corporate Governance Committee, to date, has not adopted a formal policy with
regard to the consideration of director candidates recommended by stockholders
and will consider director candidates recommended by stockholders on a
case-by-case basis, as appropriate. Stockholders who wish to recommend
individuals for consideration by the Nominating and Corporate Governance
Committee should send written notice to the Nominating and Corporate Governance
Committee Chairman, Geron Corporation, 149 Commonwealth Drive, Suite 2070, Menlo
Park, CA 94025, within the time periods set forth above. Such notification
should set forth all information relating to such nominee as is required to be
disclosed in solicitations of proxies for elections of directors pursuant to
Regulation 14A under the Exchange Act, including such person&#146;s written consent
to being named in a proxy statement as a nominee and to serving as a director if
elected, the name and address of such stockholder or beneficial owner on whose
behalf the nomination is being made, the class and number of shares of the
Company owned beneficially and of record by such stockholder or beneficial
owner, and all information regarding the nominee that would be required to be
included in the Company&#146;s proxy statement by the rules of the SEC, including the
nominee&#146;s age, business experience for the past five years and any directorships
held by the nominee during the past five years. The Nominating and Corporate
Governance Committee does not intend to alter the manner in which it evaluates
candidates based on whether the candidate was recommended by a stockholder or
not.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Director
Qualifications</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Nominating and
Corporate Governance Committee believes that nominees for election to the Board
must possess certain minimum qualifications and attributes. The nominee: 1) must
meet the objective independence requirements set forth by the SEC and NASDAQ, 2)
must exhibit strong personal integrity, character and ethics, and a commitment
to ethical business and accounting practices, 3) must not be involved in
on-going litigation with the Company or be employed by an entity which is
engaged in such litigation and 4) must not be the subject of any on-going
criminal investigations, including investigations for fraud or financial
misconduct. In addition, the Nominating and Corporate Governance Committee may
consider the following criteria, among others:</FONT></P>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD VALIGN="TOP" NOWRAP STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD VALIGN="TOP" NOWRAP STYLE="text-align: justify"><FONT face="Times New Roman" size=2>(i)</FONT></TD>
    <TD VALIGN="TOP" WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>experience
      in corporate management, such as serving as an officer or former officer
      of a publicly held company, and a general understanding of marketing,
      finance and other elements relevant to the success of a publicly traded
      company in today&#146;s business environment;</FONT></TD></TR>
  <TR>
    <TD NOWRAP STYLE="text-align: justify"></TD>
    <TD VALIGN="TOP" WIDTH="100%" COLSPAN="2" STYLE="text-align: justify">&nbsp; </TD></TR>
  <TR>
    <TD VALIGN="TOP" NOWRAP STYLE="text-align: justify"></TD>
    <TD VALIGN="TOP" NOWRAP STYLE="text-align: justify"><FONT face="Times New Roman" size=2>(ii)</FONT></TD>
    <TD VALIGN="TOP" WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>experience
      in our industry and with relevant social policy concerns;</FONT></TD></TR>
  <TR>
    <TD NOWRAP STYLE="text-align: justify"></TD>
    <TD VALIGN="TOP" WIDTH="100%" COLSPAN="2" STYLE="text-align: justify">&nbsp; </TD></TR>
  <TR>
    <TD VALIGN="TOP" NOWRAP STYLE="text-align: justify"></TD>
    <TD VALIGN="TOP" NOWRAP STYLE="text-align: justify"><FONT face="Times New Roman" size=2>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD VALIGN="TOP" WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>experience
      as a board member of other publicly held companies;</FONT></TD></TR>
  <TR>
    <TD NOWRAP STYLE="text-align: justify"></TD>
    <TD VALIGN="TOP" WIDTH="100%" COLSPAN="2" STYLE="text-align: justify">&nbsp; </TD></TR>
  <TR>
    <TD VALIGN="TOP" NOWRAP STYLE="text-align: justify"></TD>
    <TD VALIGN="TOP" NOWRAP STYLE="text-align: justify"><FONT face="Times New Roman" size=2>(iv)</FONT></TD>
    <TD VALIGN="TOP" WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>expertise
      in an area of our operations; and</FONT></TD></TR>
  <TR>
    <TD NOWRAP STYLE="text-align: justify"></TD>
    <TD VALIGN="TOP" WIDTH="100%" COLSPAN="2" STYLE="text-align: justify">&nbsp; </TD></TR>
  <TR>
    <TD VALIGN="TOP" NOWRAP STYLE="text-align: justify"></TD>
    <TD VALIGN="TOP" NOWRAP STYLE="text-align: justify"><FONT face="Times New Roman" size=2>(v)</FONT></TD>
    <TD VALIGN="TOP" WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>practical
      and mature business judgment, including the ability to make independent
      analytical inquiries.</FONT></TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Nominating and
Corporate Governance Committee does not specifically consider diversity in
identifying nominees for election as a director. However, specific experience or
expertise that could assist Geron in developing our clinical product opportunity
provides added value and insight to the Board. In general, the Nominating and
Corporate Governance Committee aspires the Board to be comprised of individuals
that represent a diversity</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>55</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<p align=left><font face="Times New Roman" size="2"><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><FONT face="Times New Roman" size=2>of professional experiences
and perspectives and who portray characteristics of diligence, commitment,
mutual respect and professionalism with an emphasis on consensus building. The
Board does not follow any ratio or formula to determine the appropriate mix.
Rather, it uses its judgment to identify nominees whose backgrounds, attributes
and experiences, taken as a whole, will contribute to the high standards of
board service at Geron.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Directors are expected to
rigorously prepare for, attend and participate in Board meetings and meetings of
the Committees of the Board on which they serve, to ask direct questions and
require straight answers, and to spend the time needed and meet as frequently as
necessary to properly discharge their responsibilities and duties as directors.
Each Board member is expected to ensure that other existing and planned future
commitments do not materially interfere with the member&#146;s service as an
outstanding director.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>General</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Your proxy is solicited on
behalf of our Board of Directors. Unless otherwise directed, proxies will be
voted at the Annual Meeting (or an adjournment or postponement thereof), &#147;FOR&#148;
all of the nominees listed in Proposal 1 and &#147;FOR&#148; Proposals 2 and 3. If any
matter other than those described in this Proxy Statement were to be properly
submitted for a vote at the Annual Meeting, or with respect to any adjournment
or postponement thereof, the proxy holders appointed by the Board will have the
discretion to vote on those matters for you as they see fit.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%"><FONT face="Times New Roman" size=2>By Order of the Board of
      Directors,</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%"><IMG src="geron_def14a5x12x1.jpg" border=0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%"><FONT face="Times New Roman" size=2>Stephen N. Rosenfield</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%"><I><FONT face="Times New Roman" size=2>Executive Vice President,
      General Counsel</FONT></I></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%"><I><FONT face="Times New Roman" size=2>and Corporate
      Secretary</FONT></I></TD></TR></TABLE><BR>
<P align=justify><FONT face="Times New Roman" size=2>April 1, 2016</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>56</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<P align=left><FONT face="Times New Roman" size=2><A href="#toc"><B>Table of
Contents</B></A></FONT></P>
<DIV style="PADDING-LEFT: 0.25in; PADDING-BOTTOM: 5%">
<TABLE style="FONT-SIZE: 10pt; FLOAT: left; FONT-FAMILY: Times New Roman; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="20%" border=0>

  <TR>
    <TD width="100%"><IMG src="proxyx1x1.jpg" border=0></TD></TR>
  <TR>
    <TD noWrap width="100%">
      <P align=left><B><I><FONT face="Times New Roman" size=2>GERON
      CORPORATION<BR>C/O COMPUTERSHARE<BR>8742 LUCENT BLVD., SUITE
      225<BR>HIGHLANDS RANCH, CO 80129</FONT></I></B></P></TD></TR></TABLE>
<TABLE style="FONT-SIZE: 8pt; FLOAT: right; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="55%" border=0>

  <TR vAlign=bottom>
    <TD style="WIDTH: 100%; TEXT-ALIGN: justify">
      <P style="TEXT-ALIGN: justify"><B><FONT face="Times New Roman">VOTE BY
      INTERNET - www.proxyvote.com<BR></FONT></B><FONT face="Times New Roman">Use the Internet to transmit your voting
      instructions and for electronic delivery of information up until 11:59
      P.M. Eastern Time the day before the cut-off date or meeting date. Have
      your proxy card in hand when you access the web site and follow the
      instructions to obtain your records and to create an electronic voting
      instruction form.</FONT></P></TD></TR>
  <TR>
    <TD style="WIDTH: 100%; TEXT-ALIGN: justify">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD style="WIDTH: 100%; TEXT-ALIGN: justify">
      <P style="TEXT-ALIGN: justify"><B><FONT face="Times New Roman">VOTE BY
      PHONE - 1-800-690-6903<BR></FONT></B><FONT face="Times New Roman" size=1>Use any touch-tone telephone to transmit your voting instructions
      up until 11:59 P.M. Eastern Time the day before the cut-off date or
      meeting date. Have your proxy card in hand when you call and then follow
      the instructions.</FONT></P></TD></TR>
  <TR>
    <TD style="WIDTH: 100%; TEXT-ALIGN: justify">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD style="WIDTH: 100%; TEXT-ALIGN: justify">
      <P style="TEXT-ALIGN: justify"><B><FONT face="Times New Roman">VOTE BY
      MAIL<BR></FONT></B><FONT face="Times New Roman" size=1>Mark, sign and date
      your proxy card and return it in the postage-paid envelope we have
      provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way,
      Edgewood, NY 11717.</FONT></P></TD></TR>
  <TR>
    <TD style="WIDTH: 100%; TEXT-ALIGN: justify">&nbsp;</TD></TR>
  <TR>
    <TD style="WIDTH: 100%; TEXT-ALIGN: justify">&nbsp;</TD></TR>
  <TR>
    <TD style="WIDTH: 100%; TEXT-ALIGN: justify">&nbsp;</TD></TR>
  <TR>
    <TD style="WIDTH: 100%; TEXT-ALIGN: justify">&nbsp;</TD></TR>
  <TR>
    <TD style="WIDTH: 100%; TEXT-ALIGN: justify">&nbsp;</TD></TR></TABLE></DIV><BR clear=all>&nbsp;<BR><BR><BR><BR><BR><BR>
<DIV>
<TABLE style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt dashed" noWrap align=left width="71%">TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS
      FOLLOWS:&nbsp;&#9746;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt dashed" noWrap align=left width="1%">E04475-P74112</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt dashed" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt dashed" noWrap align=right width="26%">KEEP THIS PORTION FOR YOUR RECORDS</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=3>&nbsp;</TD>
    <TD noWrap align=right width="26%">DETACH AND RETURN THIS PORTION
  ONLY</TD></TR>
  <TR>
    <TD style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center" noWrap width="99%" colSpan=4><FONT style="DISPLAY: inline; FONT-WEIGHT: bold">THIS PROXY CARD IS VALID ONLY
      WHEN SIGNED AND DATED</FONT></TD></TR></TABLE></DIV>
<DIV style="BORDER-RIGHT: #000000 2.25pt solid; PADDING-RIGHT: 4pt; BORDER-TOP: #000000 2.25pt solid; PADDING-LEFT: 4pt; FONT-SIZE: 8pt; PADDING-BOTTOM: 4pt; BORDER-LEFT: #000000 2.25pt solid; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 2.25pt solid; FONT-FAMILY: Times New Roman; TEXT-ALIGN: justify">
<TABLE style="FONT-SIZE: 8pt; FLOAT: left; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="53%" border=0>

  <TR>
    <TD vAlign=top width="88%" colSpan=4><STRONG>GERON CORPORATION</STRONG></TD>
    <TD vAlign=top noWrap width="1%"></TD>
    <TD vAlign=top noWrap align=center width="3%"></TD>
    <TD vAlign=top noWrap align=center width="4%"></TD>
    <TD vAlign=top noWrap align=center width="4%"></TD></TR>
  <TR>
    <TD vAlign=top width="88%" colSpan=4></TD>
    <TD vAlign=top noWrap width="1%"><STRONG>&nbsp;</STRONG></TD>
    <TD vAlign=top noWrap align=center width="3%"></TD>
    <TD vAlign=top noWrap align=center width="4%"></TD>
    <TD vAlign=top noWrap align=center width="4%"></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="87%" colSpan=3>
      <P align=left><B><FONT face="Times New Roman">The Board of Directors
      recommends you vote FOR the following:</FONT></B></P></TD>
    <TD vAlign=top noWrap width="1%"></TD>
    <TD vAlign=top noWrap align=center width="3%"><STRONG>For<BR>All</STRONG></TD>
    <TD vAlign=top noWrap align=center width="4%"><STRONG>Withhold<BR>All</STRONG></TD>
    <TD vAlign=top noWrap align=center width="4%"><STRONG>For
      All<BR>Except</STRONG></TD></TR>
  <TR>
    <TD style="TEXT-ALIGN: center" vAlign=top width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top width="87%" colSpan=3>&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="3%"><FONT style="DISPLAY: inline; FONT-WEIGHT: bold"></FONT></TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="4%"><FONT style="DISPLAY: inline; FONT-WEIGHT: bold"></FONT></TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="4%"><FONT style="DISPLAY: inline; FONT-WEIGHT: bold"></FONT></TD></TR>
  <TR>
    <TD vAlign=top width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top width="1%">1.&nbsp;&nbsp;&nbsp;</TD>
    <TD style="TEXT-ALIGN: justify" vAlign=top width="86%" colSpan=2>To elect
      the two nominees for director named in the accompanying proxy statement,
      or the Proxy Statement, to hold office as Class II members of the Board of
      Directors until the 2019 annual meeting of stockholders.</TD>
    <TD vAlign=top width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=bottom width="3%">&#9744;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=bottom width="4%">&#9744;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=bottom width="4%">&#9744;</TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="86%" colSpan=2></TD>
    <TD vAlign=top width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD vAlign=top width="3%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </TD>
    <TD vAlign=top width="4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </TD>
    <TD vAlign=top width="4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD noWrap width="1%">&nbsp;</TD>
    <TD noWrap width="98%" colSpan=6><FONT style="DISPLAY: inline; FONT-WEIGHT: bold">Nominees:</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap width="1%"></TD>
    <TD noWrap width="1%"></TD>
    <TD noWrap width="98%" colSpan=6>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">01)&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap width="97%" colSpan=5>Hoyoung Huh, M.D., Ph.D.</TD></TR>
  <TR>
    <TD vAlign=top noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">02)</TD>
    <TD noWrap width="97%" colSpan=5>Daniel M. Bradbury</TD></TR></TABLE>
<TABLE style="FONT-SIZE: 8pt; FLOAT: right; WIDTH: 45%; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD vAlign=top width="64%" rowSpan=2>&nbsp;<BR>&nbsp;<BR>To withhold
      authority to vote for any individual nominee(s), mark &#147;For All Except&#148; and
      write the number(s) of the nominee(s) on the line below.</TD>
    <TD vAlign=top noWrap width="20%"></TD>
    <TD vAlign=top noWrap width="15%"></TD></TR>
  <TR>
    <TD vAlign=top noWrap width="20%"></TD>
    <TD vAlign=top noWrap align=right width="15%" rowSpan=2>
      <DIV style="BORDER-RIGHT: #000000 2.25pt solid; BORDER-TOP: #000000 2.25pt solid; WIDTH: 0.4in; HEIGHT: 0.4in" align=right>&nbsp;&nbsp;</DIV></TD>
    <TD vAlign=top noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: justify" vAlign=top width="64%" rowSpan=2></TD>
    <TD vAlign=top noWrap width="20%">&nbsp;</TD>
    <TD vAlign=top noWrap width="1%" rowSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap align=right width="20%">&nbsp;</TD>
    <TD vAlign=top noWrap align=right width="15%"></TD></TR></TABLE>
<TABLE style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: justify" width="99%" colSpan=6>&nbsp;</TD></TR>
  <TR>
    <TD noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: justify" vAlign=top width="93%" colSpan=2>
      <P style="TEXT-ALIGN: justify"><B><FONT face="Times New Roman">The Board
      of Directors recommends you vote FOR proposals 2 and 3.</FONT></B></P></TD>
    <TD style="TEXT-ALIGN: justify" noWrap width="3%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; TEXT-ALIGN: center" noWrap width="1%"><FONT style="DISPLAY: inline; FONT-WEIGHT: bold">For</FONT></TD>
    <TD style="PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; TEXT-ALIGN: center" noWrap width="1%"><FONT style="DISPLAY: inline; FONT-WEIGHT: bold">Against</FONT></TD>
    <TD style="PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; TEXT-ALIGN: center" noWrap width="1%"><FONT style="DISPLAY: inline; FONT-WEIGHT: bold">Abstain</FONT></TD></TR>
  <TR>
    <TD noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: justify" vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: justify" vAlign=top width="92%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: justify" vAlign=top noWrap width="3%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="TEXT-ALIGN: justify" vAlign=top noWrap width="1%">2.&nbsp;&nbsp;&nbsp;</TD>
    <TD style="TEXT-ALIGN: justify" vAlign=top width="92%">To approve, on an
      advisory basis, the compensation of the Company's named executive
      officers, as disclosed in the accompanying Proxy Statement.</TD>
    <TD style="TEXT-ALIGN: justify" vAlign=top noWrap width="3%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&#9744;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&#9744;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&#9744;</TD></TR>
  <TR>
    <TD noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: justify" vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: justify" vAlign=top width="92%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: justify" vAlign=top noWrap width="3%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&nbsp;</TD></TR>
  <TR>
    <TD noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: justify" vAlign=top noWrap width="1%">3.</TD>
    <TD style="TEXT-ALIGN: justify" vAlign=top width="92%">To ratify the
      selection of Ernst &amp; Young LLP as the Company's independent registered
      public accounting firm for the fiscal year ending December 31, 2016.</TD>
    <TD style="TEXT-ALIGN: justify" vAlign=top noWrap width="3%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&#9744;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&#9744;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&#9744;</TD></TR>
  <TR>
    <TD noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: justify" vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: justify" vAlign=top width="92%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: justify" vAlign=top noWrap width="3%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&nbsp;</TD></TR></TABLE>
<TABLE style="FONT-SIZE: 8pt; FONT-FAMILY: Times new roman; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR>
    <TD width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top width="1%">
      <P style="TEXT-ALIGN: justify"><FONT style="FONT-SIZE: 8pt" face="Times New Roman"><STRONG>NOTE:&nbsp;</STRONG></FONT></P></TD>
    <TD vAlign=top align=left width="98%">
      <P style="TEXT-ALIGN: justify" align=justify><FONT style="FONT-SIZE: 8pt" face="Times New Roman">In their discretion, the proxies are authorized to
      vote on such other matters as may come before the meeting and any
      adjournment(s) or postponement(s) thereof.</FONT></P></TD></TR>
  <TR>
    <TD width="1%"></TD>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="98%">&nbsp;</TD></TR>
  <TR>
    <TD width="1%"></TD>
    <TD vAlign=top width="1%">
      <P style="TEXT-ALIGN: justify"><FONT style="FONT-SIZE: 8pt" face="Times New Roman"><STRONG>NOTE:</STRONG></FONT></P></TD>
    <TD vAlign=top align=left width="98%">
      <P style="TEXT-ALIGN: justify" align=justify><FONT style="FONT-SIZE: 8pt" face="Times New Roman">This proxy should be marked, dated and signed by
      the stockholder(s) exactly as his or her name appear(s) hereon, and
      returned in the enclosed
envelope.</FONT></P></TD></TR></TABLE><BR><BR><BR><BR><BR><BR><BR><BR>
<TABLE style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="48%" border=0>

  <TR>
    <TD noWrap align=left width="2%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="PADDING-RIGHT: 8pt; TEXT-ALIGN: justify" vAlign=top align=JUSTIFY width="97%">Please sign exactly as your name(s) appear(s) hereon. When
      signing as attorney, executor, administrator, or other fiduciary, please
      give full title as such. Joint owners should each sign personally. All
      holders must sign. If a corporation or partnership, please sign in full
      corporate or partnership name by an authorized
officer.</TD></TR></TABLE>
<TABLE style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="48%" colSpan=3>&nbsp;</TD>
    <TD noWrap width="1%">&nbsp;</TD>
    <TD width="49%" colSpan=3>&nbsp;</TD></TR>
  <TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="48%" colSpan=3>&nbsp;&nbsp;</TD>
    <TD noWrap width="1%">&nbsp;</TD>
    <TD width="49%" colSpan=3>&nbsp;</TD></TR>
  <TR style="HEIGHT: 20pt">
    <TD width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 2.5in; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1.25pt solid" width="1%"><BR></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 0.5in; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1.25pt solid" width="1%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
    <TD style="PADDING-LEFT: 2%" noWrap width="1%">&nbsp;</TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 2.5in; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1.25pt solid" width="1%">&nbsp;</TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 0.5in; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1.25pt solid" width="1%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD></TR>
  <TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">Signature [PLEASE SIGN WITHIN BOX]</TD>
    <TD width="1%">Date</TD>
    <TD width="46%">&nbsp;</TD>
    <TD noWrap width="1%">&nbsp;</TD>
    <TD width="1%">Signature (Joint Owners)</TD>
    <TD width="1%">Date</TD>
    <TD width="47%">&nbsp;</TD></TR></TABLE></DIV>&nbsp;
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A href="#toc"><B>Table of
Contents</B></A></FONT></P><BR><BR><BR><BR><BR><BR><BR><BR>
<P style="TEXT-ALIGN: center"><B><FONT face="Times New Roman" size=2>Important
Notice Regarding the Availability of Proxy Materials for the Annual Meeting:
</FONT></B><BR><FONT face="Times New Roman" size=2>Letter to Stockholders,
Notice and 2016 Proxy Statement, and 2015 Annual Report<BR>are available at
www.proxyvote.com.</FONT></P><BR><BR><BR><BR><BR><BR><BR><BR>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-TOP: #000000 1pt dashed" noWrap align=right width="100%"><FONT face="Times New Roman" size=1>E04476-P74112&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;
  </FONT></TD></TR></TABLE>
<DIV style="BORDER-RIGHT: black 2pt solid; PADDING-RIGHT: 15pt; BORDER-TOP: black 2pt solid; PADDING-LEFT: 15pt; BORDER-LEFT: black 2pt solid; BORDER-BOTTOM: black 2pt solid"><BR><BR>
<P align=center><B><FONT face="Times New Roman" size=2>THIS PROXY IS SOLICITED
ON BEHALF OF THE BOARD OF DIRECTORS</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>GERON
CORPORATION<BR></FONT></B><B><FONT face="Times New Roman" size=2>2016 ANNUAL
MEETING OF STOCKHOLDERS<BR>TO BE HELD ON MAY 17, 2016</FONT></B></P>
<P style="TEXT-ALIGN: justify"><FONT face="Times New Roman" size=2>The
undersigned stockholder of Geron Corporation, a Delaware corporation (the
"Company"), hereby acknowledges receipt of the Notice of Annual Meeting of
Stockholders and Proxy Statement, each dated April 1, 2016, and hereby appoints
John A. Scarlett, M.D., and Stephen N. Rosenfield, or either of them, as proxies
and attorneys-in-fact with full power to each of substitution, on behalf and in
the name of the undersigned to represent the undersigned at the 2016 Annual
Meeting of Stockholders of Geron Corporation to be held on May 17, 2016, at 4:00
p.m. Pacific Daylight Time at the Westin San Francisco Airport, One Old Bayshore
Highway, Millbrae, California 94030 and at any adjournment(s) or postponement(s)
thereof, and to vote all shares of Common Stock that the undersigned would be
entitled to vote if then and there personally present, on the matters set forth
on the reverse side, and in their discretion, upon such other matter or matters
that may properly come before the meeting and any adjournment(s) or
postponement(s) thereof.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><STRONG>This proxy will be
voted as directed or, if no contrary direction is indicated, will be voted as
follows:</STRONG></FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><B><FONT face="Times New Roman" size=2>"FOR" the election of
      the two nominees for director named in the accompanying Proxy Statement to
      hold office as Class II members of the Board of Directors until the 2019
      annual meeting of stockholders;</FONT></B></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><B><FONT face="Times New Roman" size=2>"FOR" proposal 2, to
      approve, on an advisory basis, the compensation of the Company's named
      executive officers, as disclosed in the accompanying Proxy
      Statement;</FONT></B></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><B><FONT face="Times New Roman" size=2>"FOR" proposal 3, to
      ratify the selection by the Audit Committee of the Board of Directors of
      Ernst &amp; Young LLP as the Company's independent registered public
      accounting firm for the fiscal year ending December 31,
      2016;</FONT></B></P></TD></TR></TABLE>
<P align=justify><FONT face="Times New Roman" size=2><B>and as said proxies deem
advisable on such other matters as may come before the meeting and any
adjournment(s) or postponement(s) thereof.</B></FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2></FONT></B>&nbsp;</P>
<P align=center><B><FONT face="Times New Roman" size=2>(CONTINUED AND TO BE
SIGNED ON REVERSE SIDE)<BR></FONT>&nbsp;</B></P></DIV><BR>
<HR align=center width="100%" noShade SIZE=2>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>geron_def14a1x1x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron_def14a1x1x1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  R &0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^E#_@MG_P
M5#\7?\$UO@C\+U^#'@G1/B+^TG^T5X^N?AY\'/"WB6TU/4-!@&F6ED_B/Q->
MZ9H^HZ3J&N7.F7^O^$=$TG0;?4K'^T-6\3V4T\[6=E<VUQ^'OQ8_;E_X.4_^
M";GA/2?VM/VTO#?P7^+O[.^H:_X?TOQG\.SI'P?MI/AW_P )/=+!IVEW.K_!
MW3_#OB[0+Z\N)$T;3=?U'5OB-X?L=9EL;35H[N>\MH+SZ)_X.3 #^VO_ ,$(
M0>0?VH_'N01D$?\ "V?V,0<C.#P2.?4U^D?_  <; '_@CA^U[D XB^"C#(S@
MC]H3X4C(ST(R2#U_6MHQ2C3;C%\[FKZMI)I::JV_F::)0]U/FO>ZU^)Q5G=6
MMOL[]3]1?V8/VB/ 7[6?[/OPC_:0^&#:@/ OQA\&:9XQT*VUB!+;5]-2]62'
M4-%U6&*2>"/5="U6VO\ 1]1%M/<6IO+&=K6XGMS%,_\ -C^VI_P5._X*<_M#
M?M_?%C_@G3_P2,\"^"+35/@5;):?%7XX^*M&\.ZK>:+K=K!IT/B>]>Y^(IO/
MA_X;\-^&=>U:+PK;PWWA/Q3K_B/7K&\FTFVFL0MNWZB?\$""?^'0/[$>>?\
MB@/& S[#XL_$''<\#I_]:ORP_P""+X'_  _!_P""YK8^8?$S7@#@9 /QL\8D
M@'&<$J"1TX&<XI**4JJLGR*=KW^S.*OI97L]?*_J0M%)V3Y4FD]KN26NU[)_
M.VII_L8?\%3/^"EW[-7[=WPM_P"">G_!8/P+X5U#5_VA(;+3?@C\=?!.F>#M
M-;5/$U_/<6&A2W\GP[-CX'\0^&O$^LV__"+RQZ=X9\+^)O"OB2ZTV35=,DTF
M]9K7^F+X]_'+X<?LT_!KXE?'OXNZS)X?^&WPH\)ZIXR\7:I;V5SJ5Y#I6EQ!
MC!I^G6B/<ZAJ=_<O!I^F6,"[[S4+JVMPR>877^87_@N$2O\ P66_X(3LN58?
M&G1RK E67;\<OA.5P1@@J<D<Y].]?JY_P7M)'_!(;]MX@D$_#CPT,C(X;XH>
M! 1QV*D@]B"1WQ4M)N#V4DFTK[.376_;1^7WEKJ/1R3;[?$XZ:NVVVMC\._A
M]_P6C_X+A?\ !1+6O'?BK_@F?^PU\)V^ WA+Q=JWAVQ\6>/C9W.KRFW$=_I^
MGZWXM\<?%SX<>"KKQ,="N]*O]8T#PIHVH2:1+J<"2WLUO+;7<_[)_P#!37_@
MJ/XI_P""8_[ WPN^,7Q&\&^&_$?[6WQ-T3P+X.T3X7WMY/:^%?\ A;=SX4T_
M5_BCJFIS>'+C4Q)X1\!7(U.:6TTG6576;RXT'0['Q!:Q:L-9MNW_ ."#FDZ7
MH_\ P2/_ &)8]*TZRTY+[X8ZGJUXEE;16RW>J:GXZ\67>H:C<B%%\Z]O;F1Y
MKJYDW33.V9'; Q^*'_!W6?\ B2_\$XE/W6^,'Q>++V)%I\(@"1T) 9@,]B1W
MIJTIQ2C%15W9+1V3W=[V=EI?36VX7C>/NV2DD[7O)-JU[Z7TU:7?0\W\?_M<
M?\'1_P"R[\*I?VY/C=X6^$?B7X#Z;8Z?XJ\:? NX\$_"&XN_ 7@J_-O=-K?B
M#2_ $6F?%?1].MK26--3F?XB^(M3\*1W#WOBK2K*'3]0DM/ZNOV'/VO/AW^W
M;^RW\)?VHOABEU:>'OB5H,DVH:'?I(FH>%?%VB7UUH/C3PE>/+%!]JD\.>*-
M-U32X=2BC6UU>S@MM6LLVE] 3B?\%&55O^"?7[<BLH9?^&1/VCLJP# X^$'B
M\@$-D'D#K7Y??\&P9)_X)$_!X$\#XE_'+'L#\2M;X_/)_$TVE*'/9)J5K+16
M>NW_  1_$I.T4TXW<59-2YDE:[U5M_70^=/^"F'_  5V_;@N?V\;;_@EM_P2
MN^&_A/Q%\?++1])NOB/\4O%.FV6O-X3U;6?#D/BZ[M-'L?$DD'@+0=#\&^$]
M4T'6_$WC'Q?%XDLY]2U(^&;'08M2L4&L> ?#C_@JS_P5?_X)J_M5_ OX!_\
M!9W2OAMXO^#'[1&IR:5X;_:!\,6/@/2[KPT+:]L](O\ Q#:W7PCTC0O#FJ:1
MX7U?7_#B>-?#VO>!]$\0V&AZE;:_IU[+ 8H-4U?V& &_X.JO^"CY8 E/@;X@
MV%ADI_H7[,"_*>=IVDKQ_"2.AKS#_@\B53\/?V"&P-P\9?M"J&P-P4Z)\(B0
M#V!*J2.A*C/2FK)Q@XIJ2C=_:]Y='TL_RLRE!7C%I/FC%\S7O)M/6_-:RVM:
MS7K<_M2HI%Z#Z#^5%8F5EV7W'\C_ /P<F?\ )Z__  0A_P"SH_'O_JV?V,:_
M23_@XV_Y0X?M??\ 7+X*?^M"?"JOS8_X.4I([;]L[_@A1>W#K#9VG[4'C^2Z
MN92(X+>-?BM^QK*SS3.1'$HBAED)=E 2*1R=L;$?I-_P<;?\H</VO2>/W7P5
M&/\ NX3X4X_S[UM?W*&VDJGYQ?J6W;V6G5?^EO\ X<[O_@@1_P H@?V(_P#L
M0/&'_JVOB#7Y*_\ !(75+S1/^"S?_!>W6=-TV36-0TCQCXSU.PTB+S1+JE[8
M?%SQS=6NFQ>1#<3>9>SQ1VL?DV\\NZ4>7#*^U&_6K_@@1_RB!_8C_P"Q \8?
M^K:^(-?EA_P1?(_X?@?\%S.G_)3->/8Y ^-GC'/'?&>3VR!BANT\1MM4^?OK
M3Y_\ 2^&=^T=O^OD?ZN?GE\1?V@?V_/^"E?_  4Z_P""77Q=^*/_  30_:&_
M9I\,?L[_ !^\ P:SK5UX ^+^N^&SH6N?%3P1KNI^(/$&O:]\+O"-CX<T_0X-
M#=[JZNI);-;:62YN;BV2!B_],?\ P7N_Y1"_MO?]DY\,_P#JT? =>_?M/?\
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M/Q&L]2O;?X,QPRZ[HESX4LM#M+,-\/M;#RV?B;4)E$VGD0OY\_V;C?\ @O\
M_P#!*?\ :._X*B^%OV8=#_9Z\0_"GP_=?!O7_BKJWBJ7XH^(O$>@07,'C73O
M EGI$>C'P]X1\6/=2QR>&]0:^%U'8K"C6IA>X,LBQ?T/44<SNGU227R5E^ <
MTKIIV<4DFDME^;?5@. !Z4445%G_ #-?)""BBBF 4444 %%%% !1110 4444
+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>geron_def14a1x1x2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron_def14a1x1x2.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !' ,<# 2(  A$! Q$!_\0
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M;*V\1^/?&%T;GQ'XY\0-:ED76?$>J:C<Q0R-;V;V]GY=NG\E/@[_ (*RWO\
MP<%^-;S_ ()7_M%?L'^+?V;OV>/VWOA3\1O&?[.GQ]G\2:WXB\7:3JGP9T[4
MO'_A?XH:5::QX+\*>$_%NG:;XA\%2Z9=S>'-:@T>/695\)7VK:C9:G=RO] _
ML[?\%A?VA_\ @D-\2/ ?_!.G_@M%\.]?LOAKX;>?X??L\?\ !2+PSIVK:GX
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M!M/EL=:T><^)_B-J7B[3KCQ#/!>7]_H7A[0DL&DD\3W=T/Z-/^"P/[?WA_\
M80_X)8>.?$/Q7^*W@GP#^W3\4OV4_P#A7OPVTC3[FTM/B/X@^+OBOPOI/AWQ
M;J_@;2(XI-=AT3P7XCUK4_%<NI2QVVCZ/+IEOYUW#J3VD4IY=K7Z[6?YVWU_
M!A>]TW;EY>;[KK7?L[[]>MS^+7]FO]G?_@D5I7_!:']G+_@G9\+O@1XH_;C^
M%S_$?Q#\)?CE\?OC3\2_%%E#XZ^)>D^%]?-]XA^"W@SX-:_X!\+Z9\+O!_BC
M2)KS4?\ A/1\1F\7:7;ZB^GW']CVND>(=<_TNOV>OV3_ -F;]DSPI)X'_9G^
M _PJ^!GA:XN?MM[I/PS\%:'X535+XQK$;_6;K3+.&^UK4&B18VO]6N;R[9%"
MM,1Q7^8U_P $3OA=K_\ P3,^(7P+_P""R?[=G[.WQEC_ &/+G0/B9X5^!WQ7
M\,Z5:Z_:^&O'GBOPK/H/AOQ[XO\ "WVN3Q+8^!O&UKK?BOP?X#\11:8EAJ7B
MC6[G6FE33]-M9KW]VO\ @WH_:6_X*$?\%8_^"F_[2W_!2'XM_%'Q9X1_9;^'
M'@S6?@YH7P2TC5=1'PM6_P#%]];Z[X'^%^AZ"\T6E:A<_#S1$;QKXK\:7EG/
MXGO-=U70WFGAL_$(MK$3\GK;;T3U>G]+Y)1?E9R>R3T72[TT5M'U]3^XVBBB
MF6%%%% 'EWQC^-WP>_9Y\!:Q\4OCM\3_  )\(/AQH B_MCQM\1?%&D>$O#5@
M]Q((K:&;5M:N[.T-S=2LL5K:I(]S<RD1P12.=M?S2_M7_P#!W/\ \$Y?@OXA
M_P"$"_9J\*?%[]M[Q[/-]CT]OA5HR^#_ (<7>J?:#;+I$/C+QE;KXGU6]GE'
M^AS>$OAQXITN]0HUMJ4@D0MS'[=_["NF?\%0O^"\WA/]FS]MCQQXNL?V/_@9
M^QUX9_: ^!/P%T?Q+<^&=$^/_B5_'[>&?BM+)<Z;J5MJ2/I-_J5CI_CC4-!D
ML/&</AW2_"MCIE]I.DWEWJ=Q_01^SC_P3P_88_9%M[*']FW]D_X$_"*[L((+
M>'Q%X6^'/AQ/&TRV]O\ 9$EU+Q_J%E?>.-9NGM_W<]YK'B&^NI_G>:5Y)9GD
M6OW/[]MOZZ?<M7>UE9]=>B>VG?O]Y_,E=_MY_P#!S7_P4E6Q\&_LG_L$>&_^
M":_PN\9#SI/CY\>FOY?&GAW0?+(:X@N?B5HVCWKKJ:2*+:3PQ^S_ *KKJ$I/
MINIV"(U^G\X&K_\ !-/PC:?"O_@LI^V'_P %#?VD?C7\=/B7^PU^T5#\&=7T
MKP;J=UIMA^TG^T!XJN[/PWHGB#Q=XQ\:Z7K7BRR\/:=XOU^Q?4$M]%TC6E\'
M6MY%I^IZ2T]O9+_J[5_,1_P3N_9M^%GQP_:5_P"#C;]D/]H;P1IOC/P#\1_V
MU_"?BCQEX$UV-IDO/"7QC^&Y\;^#?$%O=C$MIJ#M96OB+PYJEI*FI:)K&F6F
MHVTT-[:034:=;O3_ "=WII^'X(5MKW;MHWW[NRLON7SLC^1Z3X&_\$CO^">?
M_!,&XT?]I_0/!?[;W_!43]K7PGH_C#P3\,?AWXYUV*3]D2S\6>')XO -GXI\
M2_#S69;'2-;\-7.L+KOCCPG?+=:QXR\2FT\#OX<30-!&MS_L]^W5JO[27_!*
M[]C/_@W;_;0_:.\(ZK\=?&_[#=W\:?"'Q=\':SK%U8:M9>._C]\&)I/AMX1\
M0>(;^V\0SVNJ?#33_"M[X9U;4KK?_IW@YHK*VMKN6W:W_H#_ &%?^#>O_@E]
M^P'XB'CSX9_ [_A9_P 4+;5I-6T/XG?M 7ME\4?%/A!]D*6=OX+M+O2M-\)>
M&&TXQS36NMZ=X87Q:9[N<S>(Y(%@MX?V.\8>!O!/Q#T8^'/'_@_PMXY\/->V
M.HMH/C#P_I/B;1CJ&F7"7>FWYTO6K2]L3>Z?=1I<V-T8//M+A$F@DCD4,&M.
M_3K?56UV5WI]VFS=VE;;3;\+.[T5W>_RTZN_^7=\#?VHO^"K/_!-'_AH3_@H
MGX__ &7O&/C6;_@M3\)_'Z?#[XB:)J'BO1(OAI\6?'GQ \5O\.O%;Z-;^&O$
MNMIKEE#JTGBOX6^!]3N-,O/%7@SQ#X9GTKQ$;U=4L[7[1_X)<?\ !PQ^SI_P
M2[_X)4^(?A)XR\0?'+]H;]O76?C#\<O%D7P@\:>'/$5KX?\ A[XM\1ZE;Z1H
M4/BSX@>*=0M=_A&ZO=$C\=>+=/T:[OO&-QXN\3>+;"YTS3-0FNM:K_1=FT^R
MGMX;26TM9+6WDM9(+=[:"2"%[*6.:T:*&2-XHFMY(HV@9$5X&1'@:.1$9?DN
M[_X)\?L(ZA\7IOC]?_L:_LP7WQNN-7'B&X^*UY\#/AM=>/9O$ $>-?E\33^'
M)-5DUQ6B29=7:Y.HK<+]I%R+@F4JS[W_ #_R_#_@JSO>^RLDUT=KZJRZ:*VG
M<_ ?_@EE_P %G/\ @KM^TY\7O@3\%/VL/^"1/Q%\%>%?B/;IJ?BO]K'1_#OQ
M7^$WPS\-^$-1T"_\1Z#XTG\+^/?!'B+2)K;4K6+3K*WL8/B5:SZE=:A:O9PP
M-<Q6H_ G_@M!^U7\0A_P< :UIO[6'[(?Q*_;!\&_L\Z?X0T+]AO]C+37O;/X
M;_%J/6O#^B>(H/&/B/1U\#^.KWXF:)XD\8OKFO\ B?1/"_A>^N/%FI>%/#OP
M\\1:G'H'@2:SE_TKJYC7+/P9I4MQX_\ $=IX:T^X\+Z)J$USXTUFVTNVN/#_
M (=M(I=1U627Q#>HDNEZ-;PQ37U^6NX+**..2XGPJLX/GU7YK_+\6.S[O=/5
M)[6TV[KS\[H_@2\5?LV?\'%/QH^.G[-7_!7CXG_LN:-$G[*GQ,\+P_ 3_@FI
M\/O&>G_"KQ)X=^"^K6US;>(K/2/#T+ZLOA71=1M]/T+PUX]T_P 775U\1-9L
M9HV?P3;>#])@T_3_ ++_ &W_ /@X%^&7[1WP7\,?L1:;_P $UM)_:H_;\^-E
MSXJ\%>*?V(O&&L>'?CM\._@9XX\/ZQ=Z0EGX]\3^#["U?Q)X\@M;.[\0VGA[
MP(^@Z]X#6SU!?&_C/X=ZOI,T,T_QV_;^_;Z_X+R_'/Q1^R%_P2 U?7/@'^PM
M\/O%VE^&/VB?^"AWGZ[X.\1:N\?FZAJ>C?#N]T_5]&\3Q:#JNG0V]UH7AWPI
M_9OC/QG%-I=SXGU_P#X-U:::?^@7_@G'_P $C?V-?^"9G@33-)^!_P /-,UW
MXO76EF#XD?M)>-M/M-;^-/Q,UJ])FUK4M2\4WJW=YX;T?4;EF:/P=X4GTOPW
M#"D#WEIJ>JK<ZO=FMWVZW^6UK>EW?RV%9]-G?5[Z6V[WU5W?;YG^?[^TC_P:
M^?M\_LU?L4:;^V;K%QX2^)WQ)\$>*4\?^.?V'OA]H7B#Q]!\./AGJ$]MJ^OS
M0ZY!K]S%XLNO"]S;Q67Q*\*>%]/O;:'PQ;W&IVGCK7_[+NIV_47X>_\ !ZM\
M._#?P:T#PWKO_!."VT[XF>%;:RTW1?#/@'XNZ+X6^"=B-/L!!:7FBI>?#74O
M$7@JWM)S+!;>&;30M<33K7%O%XGF#&>O[^J^7_C9^Q-^R#^T=X,OOA]\<_V9
M_@=\3_"-^TLLFE>+/AGX1U)K2ZF!634M'U!]*&IZ!K.UF$.NZ%>Z=K5HS&6S
MO[>8+(K_ *_KY7]=!I6V>]EKKV7RT3V6K\C_ "R/'_[$/_!:3_@N5^W%\0?C
M+XK_ &:_BK8:S\1/$>CO/XO^)6F:OX ^ _P4^&>IO%>>!_#GAGQCXNCTO1M8
M\&>%?"FI6UUH]EX*7Q-XF\66DUUXFM=*UO7->N[R\^F_V3/^"*W_  6Q\ _$
M_P".?[$WP0^ ^M?LT:EXJ\43^ _CE_P4#U#5?%O@WPKXI^!6E7<%W'X(^%WQ
M)MA:OJOPQ\<W3Z/XN\5^&_AKIVK>,O&NH:1X:T/Q?<Z%I'A[7M&?^AWXG_\
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MOC/1;2YTWP-'I_A;4K?4+C5/]2*BG^']+3M;3H/E7I;KOMLM;V^1_G8^)O\
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MMV=[-;_)?TF;5%%%,84444 ?G1_P4'_X)[>'OVVM(^%GCGPK\1O%'P!_:O\
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EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>geron_def14a1x2x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron_def14a1x2x1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  R &$# 2(  A$! Q$!_\0
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M8@G\:OHFH7_A_P +>&O =QK&EZ')%<ZYJ$3N+N+^H?\ 8>_Y,K_9!]3^R[\
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M_!-+_@L'X4\#:?\ $3XMZ9IMQ\&_C7X7M/#6FOXAUOQ'/<Z?X'LKZ'X<Q_\
M"!ZYX>\>:QHNN>&M)U33-'\*ZIH?C.&/1-<TYEGE72?,_P#@VV53^WG_ ,%M
M7(!?_AH'3QO(!;#?&7]I%F&[K@L 2,X) )Y%>7_\%R%4?\'!/_!&)@ &/C']
MD$%L?,0/VV-3(!;J0"S$ G +$CJ:K2_)RJW+?FM[U^1RW5KZ]&G8M15W%K[%
MT[NZER<UWK9W:^'SW=KG]J=%%%8F6O=?<_\ ,_D>_;X_Y6I?^"6__9KFD?\
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M5_S_ (57_+F/_7V?XP@/H_5?DS\*O^#;7_D_'_@MK_V<%IO_ *N3]I*O+_\
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<HAU%%%, HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>geron_def14a1x2x2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron_def14a1x2x2.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  V .T# 2(  A$! Q$!_\0
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M:CK</@_P)HM]?:=:S7,.D:1JFMZ_KVLZAI'A+P;X;TS5?%/C#7M#\/:9?:E
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M>+F31M!N==>VN+/PSX5T#2+#6/&/C?Q3JIM=,T7POH&HM)>0WMQ8)* ?'_\
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M1J?@?Q-KMCX>M]-\4ZQ<6G_"S-6M[SPO>>*6\!:K]AL+O6O"FIWBO,?KZB@
MHHHH **** "J5UING7L]A=7MA97=UI5S)>:7<W5K!<3Z;=RVL]E+=6$TL;R6
M=S)975S:23V[1RO:W$]NS&*:1&** +M%%% !1110 4444 %%%% !1110 444
D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>geron_def14a5x12x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron_def14a5x12x1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ^ 0$# 2(  A$! Q$!_\0
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ML:I=>"-'\>^'_ T/]!= !1137=(T>21UCCC5GDD=@B(B LSNS$*JJH)9B0
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MII_QX\07'C6_;6/$/@+7OC/J?B;4_"NE?%C4)W^)'Q!^*6J:K=V7BV;Q9?\
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M/$>HW<$>N#P]863:=[U^TY^UG>_M5?&GX@?\$N_V*_'WC70?C38Z;HJ?M?\
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MJU+6O&GC;Q#=9O/$'BS7M9UJ\9KJ_F8G]?UN'W?U;UWU9V_Q+\6ZCX ^''Q
M\=Z1X*\4?$G5O!7@GQ7XMTOX=>!X;"X\:>/M1\-Z%?ZS9>"O"%OJM]IFF3^*
M/%-S91:'H$.I:EI]A+JU_:)>7UI;M)/'^$/P4_8:^+GQ.T3X_P#[9W_!83QS
MH7P^T/XH&_\ BK\2?V5_A[XRU3PK\-?AM\$_A;I.K3?#SX;?M/\ QG\*^(["
M^^-GP]^"W@2'6/$LWPJTV?PW\!W\>^-?B[X[^(?A_P"+.N>)M*U'PG_0I7A?
M[2/[.?PK_:Q^$'B+X#_&W2=1\1_"OQCJ?@^]\9^%K#6]3T&#Q=IO@[QGH'C>
M'PIX@N](N+6^O?"'B+4/#EGI/C'0%N8K7Q-X8NM5\/:B7T[4[N*0#U/S,_X(
MD_"/PSIOP4^.W[6WACX):%^SMX=_;L^/NL?&CX2_!SPWX%TSX7:3X%_9?\#^
M%O#?P5_9AM8_AWH.DZ#H'ANZ\:_##X?VGQDOO[/TBVGU&Y^*;W>H2W%P08_O
M[]L?P/\ M0_$[X+:A\-?V3OB9X$^"GC[Q_JUOX0\5?&CQA8^(=9UWX2_#'7-
M+UBR\7>/OA#X;T)8+7Q)\:-$>32S\/\ 3?%6M^&O"=K?3W&NZMK#OH]IH^K?
M4T<<<,<<44:111(L<44:JD<<:*%2.-% 5$10%55 55     I]']?UN']:',>
M"?"MEX$\&>$?!&G:AK>K:?X-\,:!X5L-5\3:K<:[XCU*R\/:5::1:ZAX@UN[
M_P!*UC6[R"S2YU75;G_2-0OY+B[F_>3-7XR_\%W?VP?B;\!_V7_"7[,7[+.J
MW2?MS?\ !0?QY8_LP?LQZ7H4U['XJT2W\27.F67Q>^+MA+IJ_;]$TWX8>"=9
M"S^-K>>U_P"$#\0^*O"WBN6XCMM+G=/W!KY(\9?L4? WQ_\ ME_!C]NKQ7I^
MNZK\</@!\)_B+\(_A8LVI6G_  B'AO3/B?=VK^)_%4.C?V9_:+>-3HHUGPE9
M:HNMQZ;'X9\5>(K.ZT:\O)].U#30#\HOBOI.O_"#]H/]C?\ 9&^$_P#P3P_:
MK_:'_9G_ ."=GP:\(>-_A@WPI\,?#[P1\)O%_P"U-!X6/P]^"UUJWQ#_ &@_
MBS\(OA]JFA_ [X?CQGXL\1:IIWB+XFZQ%\6_BGX0\32VL/B[X3:G+J'WFG@S
M_@HK^T8UV/B-\1/ G[!'POOH;ZR7P9^SY/HOQ\_:AU&S>YM!;7^I?'7XG>"X
MO@E\+;RZM;6^MM1\/>$/@;\7-1L[+61/X=^+FC:_IMIJMM^D-% ?U_77^K[Z
MG\PO[?W_  0U^+7[6GQE_93^#'P7^(^@_L[?L1?!OQ=IO[5/Q[^,&KZUJ7QJ
M_:Q_:2_:XL=8O?#NA^(/&]W\3M,\3/\ $'Q/X+^&]C]@\._$KXN^+?%.DZ+I
M_CJ]\)6?@'5?"7A/1O"\?]%/PI^"_P -/@E\)_"GP0^&'A>T\*?#7P9X<'AC
M0] T^:Z$BV4HGDU+4-1U5YFU;5O$GB#4+O4->\3^*M2O;KQ'XE\2ZIJOB76]
M3OM=U.]OY_4:* /@CX1_!7]F/_@E!^Q]HGPB^ 'PZU32_AWX&N)[#P+\/O#_
M )GB3XF_&+XK^.M7<Z5HJZC=[+SQ9\1/B!XEO+72_P"W==N;;2/#VCPQ7FMZ
MEX9^'OA*XN]#^4/A_P#\$=?AE\27_:"^+W[=FO\ B;XU_M'_ +8'C+PGXI^-
MMYX$^(OQ'^%O@?P9\,/ D=_;?#7]D'X>OX \2>$M;U;X ^ ]!U2;0?&']O26
M]Y\?==AE\>_$328;PZ#H?AGCO^"=\O[5'[7/[87[57[9W[3GP:\8?!/X-> ?
MB7K?PG_8>\(>/AXB\/\ B/QAX"\(Q^*?!.G?%Z_^'6HW%I9>&X+?P[KWQ U/
MPMXJDTV^UKQQ>?M*?%71KS7=4\"?#7X/)I/[KT!IT_R_#\GVVL?.ND_LC_LR
MZ!\2?A/\7= ^!WPXT+XA_ CX7:C\%?@OX@T7PW9:4/A7\*]6^R+?>"O 6D6"
M6^A^%](EMK*+3HAI&F6MU:Z1)>Z+:7$&DZCJ%E=?15%% !7YN?\ !5_P;\;?
M''['TEC^S]\)M6^.?Q$\+_M*?L2?%>/X3:!KGACPWKWC?P[\$/VRO@3\9?$^
MD:1KWC+4M'\,:3=_V-X#NKE[_6=4LK*TL[>ZN)I72,P2_I'10!XU\"=>^./B
MCP*?$/Q_\ >#?A7XUU?7M9N],^'/@[Q?/X_;PAX-\](?#&F^+O&?]G:1I&N^
M/)[.)]3\5?\ "*Z>/">C7]__ ,(WH6K>*[31AXP\0>RT44 %%%% !1110 5Y
MY\7=%^('B7X3_$_P[\)O%NF> ?BIK_P\\:Z+\,_'6M:._B'1O!7Q U7PWJ=C
MX,\6ZMH$5S92:YIGASQ'/INL7^CQWEH^IVMG+9)<P-.)4]#HH ^$?^"=/[ W
MPQ_X)T?LWZ+\"_ FK7WCOQ=JFLZM\0OCG\;_ !'9FW\=_'[XU^+9EO?''Q6\
M;RSZCK5\VI:W>!+;2].O-<UJ30O#]EI>C'5M4ELY]3O?MK7-&L/$>B:QX>U5
M;IM,UW2]0T;45L=1U'1[UK#5+2:QO%L]7T>[L-7TNZ-O/(+?4=+OK+4;&8I<
MV-W;W,44R:E% 'S_ /LP_LK_ +/O[&/P:\,?L_?LQ?##0?A'\(O"#ZA/HGA'
M0IM6U#_3=6O)+_5-5UC7O$6HZSXF\2ZYJ-U*7OM=\2ZUJ^LW21V\$]\\%K;1
M1?0%%% !2$ D$@$J<J2 2IP5R/0[69<CG!(Z$TM% !1110 4444 %%%% !11
I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>proxyx1x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 proxyx1x1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !- )0# 2(  A$! Q$!_\0
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MC!\!O_5]_#>OFG_@U)_Y1J>._P#L[;XG_P#JMO@M7TM_P<@?\H@_VE?^Q@^
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M_P!@_P"-?_K2'QAK\Z/^#MW_ ),E_9P_[.GL?_52_$VOT7_X-Z_^4/7['/\
MV#_C7_ZTA\8: /V>K_.DLO\ E:1?_L_^_P#_ $9<U_HMU_G267_*TB__ &?_
M '__ *,N: /]%NO\\?\ X)Q_\K1?CC_L[S_@HW_ZBG[3%?Z'%?YX_P#P3C_Y
M6B_''_9WG_!1O_U%/VEZ3V^:_-">WS7YH_T.*_SL/^"3W_*R=X@_[.#_ &]_
M_45^/-?Z)]?YV'_!)[_E9.\0?]G!_M[_ /J*_'FA[?-?F@>WS7YH_P!$^O\
M/P_X-8?^4I'[2?\ V:9\8O\ UHC]GJO] ^O\_#_@UA_Y2D?M)_\ 9IGQB_\
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MQYXB\+7UO(9;;4?#.DV6D>'/ VA:U9R[);+Q'IOA"W\1V#QHUEJ\!,F_]@Z
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)113 **** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
